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ABSTRACT
Established chemotherapeutic agents often produce dose limiting toxicities in 
normal tissues due to lack of selectivity for tumour cells. Identification of 
abnormalities in the control of signal transduction in tumour cells may suggest more 
specific targets. Phosphatidate phosphohydrolase (PAP) is involved in the generation 
of diradylglycerol (DRG) from phosphatidylcholine (PC) in response to a mitogenic 
signal. The aims of the present studies were firstly to determine whether the activity 
of PAP is altered in transformed cell lines and in human tumours and secondly to 
determine whether PAP is a target for anticancer drug development.
An assay was established and characterised to measure PAP activity. Two 
activities are present in rat liver. PAP1 is mainly cytosolic and is involved in 
glycerolipid synthesis. It requires Mg2+ and is inhibited by the thiol-blocking reagent 
n-ethylmaleimide (NEM). PAP2 is associated with the plasma membrane and is 
thought to be involved in mitogenic signal transduction. PAP activity can be 
measured in tissue homogenates and the two activities distinguished by their 
differential sensitivity to NEM. PAP activity was shown to be present in a range of 
mouse tissues The highest activities were present in the brain and the lowest in 
muscle tissue.
Transformation of mouse fibroblast cell lines by a mutant ras oncogene results 
in an increase in DRG mass. This DRG could be derived from the breakdown of 
either phosphatidylinositol (PI) by a phospholipase C activity or PC by the sequential 
activity of phospholipase D and PAP. PAP2 activity was shown to be decreased in the 
transformed cells and clearly could not account for the increased DRG mass. 
However, the level of phosphatidate was also increased and this was consistent with 
the decreased activity of PAP2. The association of a mutant ras oncogene and 
decreased activity of PAP2 was also observed in human colon tumour cell lines. Cell 
lines DLD-1 and LoVo contain a mutant Ki-ras oncogene and were shown to have 
lower PAP2 activities than HT29 and Colo320DM which express wild type Ki-ras. 
The phosphatidate and DRG mass were also higher in the cell lines with a mutant ras 
oncogene. Thus, in both cell models a decrease in PAP2 activity is associated with 
increased levels of phosphatidate, a second messenger with potent mitogenic activity.
PAP activity was measured in human colon tumours and in adjacent 
pathologically normal colonic mucosa. Two activities, with properties representative 
of PAP1 and PAP2, were identified. A wide range of activities were observed in the 
normal colon tissue. Both activities were significantly increased in the majority of 
tumours. Furthermore, the phosphatidate and DRG mass were decreased in the 
tumour tissue. An increase in PAP activity is consistent with the decreased 
phosphatidate mass but does not account for the decreased DRG mass. These changes
are in contrast to those observed in the ras transformed cell lines and it is probable 
that they are unrelated to ras since only 50% of the tumours contained a mutation in 
the Ki-ras oncogene. However, the tumours with a ras mutation tended to have the 
highest activities of PAP2. *
In an attempt to account for the decreased levels of DRG in the colon tumours 
two enzymes that are responsible for the metabolism of DRG were measured. A wide 
range of activities of both DRG kinase and DRG lipase were observed in the normal 
colonic mucosa. A DRG kinase activity was increased in the tumour tissue but the 
substrate specificity of this activity suggests that it metabolises DRG derived from PI 
rather than PC. In contrast, a DRG lipase activity was also increased in the tumour 
tissue and the substrate specificity of this activity indicated a preference for PC 
derived DRG. Thus there is evidence for a general increase in DRG turnover in colon 
tumours.
Studies of PAP activity in intact cell would be aided by a specific inhibitor. A 
number of cationic amphiphilic agents, including propranalol and sphingosine, were 
shown to inhibit PAP activity in rat liver homogenates and to inhibit proliferation of 
normal and ras transformed mouse fibroblast cell lines. These agents are known to 
inhibit other enzymes such as protein kinase C and thus lack specificity for PAP. 
Sphingosine was identified as the lead compound for future development of a more 
specific inhibitor of PAP.
The role of PAP in the control of proliferation in transformed cells remains 
unclear. However, the consistent increase in activity observed in colon tumours 
suggests that this may be a target for anticancer drug development.
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CHAPTER 1
GENERAL INTRODUCTION
In Britain, approximately 20% of deaths in any year are due to malignant 
disease. This is the second main cause of mortality in this country with heart disease 
being the biggest killer. Amongst the major forms of cancer arising include lung, 
colon and prostate in males and breast, lung and colon in females. Cancer patients 
generally die as a result of metastatic spread and therefore systemic therapy is 
essential to treat the disseminated disease.
Chemotherapy has an important role in cancer treatment. It can be used as a 
major curative modality for some malignancies, as adjuvant treatment before and after 
surgery or in combination with other modalities such as radiotherapy. Chemotherapy 
has had relatively major success in the treatment of a small number of malignancies 
including Hodgkin’s disease, testicular cancer and lymphocytic leukaemia (DeVita, 
1989). However, its impact on advanced solid tumours such as lung, colon and breast, 
is relatively limited. Since the main characteristic of tumours is their uncontrolled 
proliferation, many conventional chemotherapeutic agents were selected for their 
ability to inhibit DNA synthesis. However, many normal tissues such as the bone 
marrow, intestinal epithelium, skin and hair follicles demonstrate significant rates of 
cell renewal. As a result, these tissues are damaged by cytotoxic drugs and dose- 
limiting toxicities such as neutropenia and diarrhoea are associated with 
chemotherapy. A further complication is the development of resistance to cytotoxic 
drugs. Patients who show an initial response to treatment often relapse with a tumour 
that is resistant not only to the initial chemotherapeutic regimen but also to many 
other agents to which the tumour has not yet been exposed. In addition, some tumour 
types such as non-small cell lung and colon cancers frequently demonstrate 'intrinsic' 
resistance such that the patient fails to respond to treatment with cytotoxic drugs. 
Clearly, there is a need for more effective chemotherapeutic agents.
1
1.1 Colorectal Cancer
Colorectal cancer is the second most prevalent cancer in the United States and 
Europe preceeded only by lung cancer. Its etiology, like that of most human 
neoplasms, is probably multifactorial. Hereditory factors certainly play a predominant 
role in the development of familial polyposis coli and familial nonpolyposis colon 
cancer (Bussey, 1970). However, in the majority of colon cancer patients, dietary 
factors probably provide the overriding cause for tumour development and there is a 
positive association among dietary lipid intake, faecal bile acid secretion and 
increased risk of colon cancer (Doll & Peto, 1981; Nair, 1988; Reddy et a l , 1992).
The cure rate for colorectal cancer has remained relatively unchanged over the 
last 10-20 years. The most effective treatment is surgical resection of the tumour and 
the 5 year survival is high for patients who present early with a localised tumour 
(Cohen et a l, 1989). However, once the tumour has metastasised, surgery has limited 
success and additional chemotherapy is required. The most effective agent is 5- 
fluorouracil but 5 year survival rates are very low at only 10% (Vaughn & Haller, 
1992). New chemotherapeutic drugs are required for treatment of this cancer. A better 
understanding of the biochemical changes involved in colon carcinogenesis may 
identify potential therapeutic targets for development of more selective agents.
There is already a lot known about colon cancer in terms of the genetic 
alterations which occur in its progression from adenoma to carcinoma. It is known 
that colorectal tumours arise as a result of mutational activation of oncogenes coupled 
with the mutational inactivation of tumour suppressor genes; the latter stages of 
which predominate (Fearon & Jones, 1992) (Figure 1.1). Mutations in at least four or 
five genes are required before development of the full malignant phenotype. In 
patients with familial adenomatous polyposis coli (FAP), a mutation on chromosome 
5q is inherited. This may be responsible for the hyperproliferative epithelium present 
in these patients (Groden et a l,  1991). In tumours arising in patients without
2
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Figure 1.1 A genetic model for colorectal tumourigenesis
Abbreviations used: APC, adenomatous polyposis coli; DCC, deleted in colorectal 
cancer; LOH, loss of heterozygosity.
polyposis, the same region has also been shown to be altered at an early stage of 
tumourigenesis in a number of cases (Groden et a l , 1991). The early, intermediate 
and late stages of adenoma, represent stages of increasing size, dysplasia and villous 
content (Fearon & Vogelstein, 1990). It is thought that the ras gene mutations may be 
an initiating event in a subset of colorectal tumours and adenomas with the ras 
mutation are more likely to progress than adenomas without the ras gene mutation 
(Vogelstein et al, 1988). The chromosomes most frequently deleted include 17p and 
18q and these contain p53, a common tumour suppressor found in human cancers 
(Vogelstein & Kinzler, 1992), and deletion in colorectal cancer (DCC) genes, 
respectively (Thomas, 1991). These occur in later stages of tumourigenesis than 
deletions of chromosome 5q or ras mutations. Although these genetic alterations 
often occur according to a preferred sequence, the total accumulation of changes, 
rather than their order of occurrence, appear to be responsible for the tumour arising 
(Fearon & Vogelstein, 1990). Although the exact function of all these genetic 
alterations is not known, transformation of some genes, such as p53, is associated 
with development of more invasive and metastatic tumours. Another group of genes 
appear to promote the expansion of the adenoma, for example, DCC encodes a cell 
surface molecule that is homologous to N-CAM, a transmembrane cell-cell adhesion 
protein. A defect in this gene could produce the irregular cell packing that is 
characteristic of adenoma growth (Chuong et a l , 1994).
1.2 Signal Transduction
As a result of an increase in understanding the control of cell proliferation and 
differentiation, a number of new approaches to cancer treatment have been proposed. 
The stimulation of cell proliferation by growth factors involves a series of 
biochemical events whose regulation is controlled by the generation of intracellular 
messages in response to the binding of the mitogen to its cell surface receptor. Signals 
implicated in the onset of mitogenesis are tyrosine kinase activity and changes in the
3
levels of second messengers cyclic AMP, s/z-1,2-diradylglycerol (DRG) and inositol 
1,4,5-trisphosphate. Most oncogene products are components of signal transduction 
pathways (Figure 1.2) and transfection of cells with a number of oncogenes has been 
shown to subvert the regulation of pathways controlling second messenger 
concentration. If the key sites of regulation of these pathways can be identified, they 
might serve as targets for novel anticancer agents. For example, the ras genes appear 
to play an intermediary role in signal transduction pathways and this may provide a 
range of potential therapeutic targets upstream or downstream of ras (Bums & 
Balmain, 1992).
1.3 Protein Kinase C
Activation of protein kinase C (PKC) appears to be critical for mitosis. 
Chronic treatment of cells with the tumour promoting phorbol esters leads to down- 
regulation of PKC activity (Nishizuka, 1989). As a result cells are unable to enter 
mitosis in response to growth factor treatment (Gescher, 1985). PKC is therefore an 
obvious target for anticancer drug development. However, this has proved to be a 
very complex target. At least twelve subspecies of PKC exist which can be divided 
into three main groups (Dekker & Parker, 1994). The conventional PKCs, PKCa, pi, 
pn and y, are Ca2+-dependent, the novel PKCs, PKC6, e, 0, r\ and p are Ca2+- 
independent whilst the atypical PKCs, PKC£, X and i, are not activated by DRG or 
phorbol esters. These subspecies have distinct tissue distributions implying different 
roles in these cell types. For example, some isoforms such as PKCa, 6 and £ are 
widespread, whereas others are restricted to one of a few tissues, such as PKCy which 
is found only in a neuronal cell line (Hug & Sarre, 1993). Furthermore, PKC activity 
is also associated with expression of the differentiated phenotype in some cell lines in 
vitro. For example, differentiation of the HL-60 promyelocytic leukaemia cell line 
towards a macrophage-like phenotype is induced in response to phorbol ester 
(Vandenbark et a l , 1984; Vandenbark & Niedel, 1984).
4
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Figure 1.2 An overview of signal transduction and examples of oncogenes 
involved in the process
A number of inhibitors of PKC have been developed. Staurosporine is often 
used as the lead compound and the majority of inhibitors act at the ATP binding site 
of PKC (Grunicke & Uberall, 1992). This site is common to all PKC isoforms and 
shares sequence homology with the ATP binding site of other cellular kinases. This is 
clearly not the ideal site for development of selective inhibitors but attempts to target 
other sites on the protein have been largely unsuccessful. Bryostatins are a group of 
natural compounds which activate PKC but still show antitumour activity bothm vitro 
and in vivo (Homung et a l , 1992). They activate PKC at the same site on the 
regulatory domain as phorbol esters, however, these compounds can antagonise 
certain effects of the phorbol esters including tumour promotion in mouse skin 
(Hennings et a l, 1987). Bryostatin 1 exhibits activity against a number of tumours in 
vivo and is currently undergoing clinical trial as a chemotherapeutic drug (Prendiville 
e ta l, 1993).
An alternative approach to direct targetting of PKC is to prevent formation or 
to increase degradation of the stimulatory regulator of PKC.
1.4 Generation of DRG
Protein kinase C is activated physiologically by DRG. Stimulation of cells by 
several hormones and neurotransmitters (Berridge & Irvine, 1989) as well as 
mitogenic growth factors such as platelet-derived growth factor (PDGF) and 
bombesin (Berridge, 1987; Exton, 1990), result in the generation of DRG (Figure
1.3). Originally, it was thought that the sole source of agonist-stimulated DRG was 
the phospholipase C catalysed breakdown of phosphatidylinositol 4,5-bisphosphate 
(PI-PLC) (Wakelam et a l, 1986). PI-PLC is stimulated through either a G protein 
coupled reaction (PLC(3) (Plevin et a l , 1990) or phosphorylation by an activated 
receptor tyrosine kinase (PLCy) (Nishibe et a l , 1990) (Figure 1.3). Hydrolysis of 
phosphatidylinositol 4,5-bisphosphate yields two second messengers, inositol 
trisphosphate and DRG (Berridge & Irvine, 1989). Inositol trisphosphate translocates
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from the plasma membrane to specific receptors on the endoplasmic reticulum, 
resulting in the release of Ca2+. An increase in intracellular Ca2+ modulates the 
activity of certain regulatory proteins such as PKC (Berridge, 1993). The PI-PLC 
pathway, however, is rapidly desensitised, within 90s, following stimulation and it is 
clear that it represents only a minor component of the elevation of DRG observed in 
response to mitogens (Cook et a l , 1990). A more sustained source of DRG is thought 
to arise from phosphatidylcholine.
Phosphatidylcholine (PC) can be hydrolysed directly by a PC-specific PLC to 
yield DRG and phosphocholine (Pcho) or by a coupled pathway where phospholipase 
D (PLD; EC 3.1.4.4) activity gives rise to phosphatidate and choline (cho). These 
pathways were identified from studies of the rates of formation of [3H]cho and 
[3H]Pcho in stimulated cells, representative of PLC and PLD activity, respectively 
(Figure 1.4) (Cook & Wakelam, 1991a). However, activation of PLD was also 
demonstrated in whole cells in a transphosphatidylationreaction (Yang, 1967). In this 
reaction the PC pool is labelled specifically with [3H]palmitate and a primary alcohol 
is used to substitute for water in the phosphatidyltransferase reaction of PLD. PLD 
activity is determined from the rate of production of radiolabelled 
phosphatidylalcohol which can be measured.
Phosphatidate, produced by the action of PLD, is dephosphorylated by 
phosphatidate phosphohydrolase (PAP; EC 3.1.3.4) to generate DRG. This DRG can 
activate PKC but is also metabolised by both kinase and lipase activities to yield 
phosphatidate and monoacylglycerols respectively (Bishop & Bell, 1988) (Figure
1.4). Exogenous phosphatidate and particularly its lyso-derivative, lyso- 
phosphatidate, are mitogenic in a number of cell systems (Moolenaar, 1994; van 
Corven et a l ,1991; van Corven al , 1992). This lipid has been shown to stimulate 
phosphatidylinositol hydrolysis (van Corven et a l, 1989), to activate PLD in a PKC 
dependent manner (van der Bend et a l , 1992) and to modulate the amount of GTPase 
activating protein (GAP).and hence increase the amount of activated Ras protein (Tsai 
et a l , 1989; Van Corven et a l , 1993).
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Figure 1.4 Generation of DRG from phosphatidylcholine
PC can be converted directly to DRG by the action of PLC. Alternatively, DRG can 
be generated from PC by the activity of PLD and PAP. DRG can then activate PKC 
and can be metabolised by kinase or lipase action which generate phosphatidate and 
free fatty acids, respectively. Abbreviations used: cho, choline; DRG, diradylglycerol; 
DGK, diacylglycerol kinase; DGL, diacylglycerol lipase; FA, fatty acid; MG, 
monoacylglycerol; PA, phosphatidate; PAP, phosphatidate phosphohydrolase; PC, 
phosphatidylcholine; pcho, phosphocholine; PKC, protein kinase C; PLC, 
phospholipase C; PLD, phospholipase D.
The two candidate enzymes for PC hydrolysis, PLC and PLD, have been 
reported in a number of cell systems but it is difficult to assess which activity 
predominates (Billah et a l, 1989; Cook & Wakelam, 1992; Cuadrado et a l,  1993). 
Pcho levels are increased in growth factor stimulated cells (Exton, 1990) and as a 
result of transformation by oncogenes (Lacal et a l, 1987), an indication of PC-PLC 
action. This hypothesis, however, has been questioned (Lacal, 1990; Plevin et a l, 
1991; Song et a l,  1991) since Pcho can also be generated by phosphorylation of 
choline by choline kinase, the choline resulting from PLD activation. The fact that 
choline kinase activity is increased in ras transformed cells (Teegarden et a l, 1990) 
provides support for this explanation. In addition, Cuadrado and coworkers have also 
demonstrated that both Pcho and DRG are generated by sequential action of PLD, 
choline kinase and PAP in serum-stimulated and oncogene transformed cells 
(Cuadrado et a l , 1993). It may be that sustained DRG levels are a composite of PLC 
and PLD/PAP pathways, however, DRG synthesis de novo can also not be ruled out 
(Chiarugi et a l , 1989).
The role of PLD and PAP in the generation of DRG from PC was identified 
mainly from studies with 3T3 fibroblasts, both Swiss and NIH, and neutrophils. These 
two systems have proved invaluable in studies of cell signalling. In particular, the 
effects of oncogenes on signalling have been studied in fibroblast cells. For example, 
one of the responses to transformation by the ras oncogene is the generation of 
several lipids such as phosphatidate and DRG and these were found to be derived 
from PC (Lacal et a l ,  1987). However, it is far from clear if results from such 
systems can be extrapolated to other cell types such as epithelial cells and, in 
particular, to tumour cells. Although bombesin stimulates breakdown of PC by PLD 
in Swiss 3T3 fibroblasts it is itself only a weak mitogen in these cells (Rozengurt & 
Sinnett-Smith, 1983). A much greater mitogenic response is obtained with bombesin 
and insulin as co-mitogens. This may be explained by the stimulation of a second 
signalling pathway by insulin which acts in a synergistic manner with the products of 
the breakdown of PC by PLD/PAP. In the neutrophil, the chemotactic peptide formyl-
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methionyl-leucyl-phenylalanine (fmet-leu-phe) stimulates the breakdown of PC by 
PLD and the resultant production of phosphatidate is essential for the response to the 
peptide (Bonser et a l, 1989; Perry et a l, 1992). However, the response is secretion 
not mitogenesis suggesting that PLD could be involved in control of the secretory 
pathway. This suggestion is supported by the observation that PLD activation in 
neutrophils requires a small molecular weight cytosolic protein ADP ribosylation 
factor (ARF). ARF is a GTP binding protein involved in the control of vesicle 
formation in the golgi. It has been proposed that PLD is involved in transmission of 
the secretory signal from the cell surface receptor to the golgi through association 
with ARF (Donaldson & Klausner, 1994; Kahn et a l, 1993). Thus, there is evidence 
for the involvement of PLD mediated breakdown of PC in both mitogenic signalling 
as well as in membrane trafficking. The relative importance of the pathways of PLD 
activation is not clear and may be cell type specific. Furthermore, mitogenesis 
requires synthesis and modification of new proteins such that effects on trafficking 
through the golgi may not be distinct from mitogenic signalling.
There is little information available on the metabolism of PC in tumour cells. 
In view of the generation of two important lipid second messengers, phosphatidate 
and DRG, by the sequential action of PLD and PAP on PC, both these enzymes could 
be regarded as potential targets for anticancer drug development. Whilst inhibition of 
PLD would prevent production of both mitogenic lipids, it is also apparent that this 
will result in effects on membrane trafficking in normal cells such as neutrophils.
1.5 Phosphatidate Phosphohydrolase
It is only in recent years that PAP has been shown to play a role in mitogenic 
signal transduction (Billah & Anthes, 1990; Billah et a l , 1989; Bocckino et a l , 1987) 
and, in comparison to some other signalling enzymes, very little information is 
available concerning its regulation and function. The established function of this 
enzyme is as an intermediate in glycerolipid synthesis and it has been studied in great
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detail particularly in the liver (Brindley, 1987). Subsequent studies have revealed two 
distinct activities based on differential sensitivity to N-ethylmaleimide (NEM) (Jamal 
et a l , 1992; Jamal et al., 1991). PAP1 is stimulated by Mg2+ and is inhibited by NEM 
(Brindley, 1987). The other form of PAP, PAP2, is an integral plasma membrane 
protein which does not require Mg2+ for its activity and is not inhibited by thiol- 
blocking reagents (Jamal et a l, 1991).
1.5.1 PAP1
PAP1 plays a role in glycerolipid metabolism, controlling the direction of de 
novo glycerolipid biosynthesis from phosphatidate either to diglycerides and 
triglycerides, or to the zwitterionic phospholipids, PC and phosphatidylethanolamine. 
Phosphatidate is derived from stepwise acylation via dihydroxyacetone phosphate and 
glycerol 3-phosphate in the endoplasmic reticulum. The cytosol acts as a reservoir of 
PAP1 activity which associates with the endoplasmic reticulum when active (Martin 
et a l , 1986). Translocation occurs as a result of accumulation of fatty acids, acyl Co A 
esters or phosphatidate within the membranes (Butterwith et a l , 1984; Martin et a l , 
1987). This promotes the production of triacylglycerol and increased secretion of very 
low density lipoproteins which occurs during gluconeogenesis (Brindley, 1987). In 
addition, PAP1 activity is increased in the long term by glucagon, cyclic AMP, 
glucacorticoids and growth hormone (Brindley, 1987; Pittner et a l , 1985), whereas 
insulin antagonises these effects (Pittner et a l,  1986). Thus, PAP1 activity is 
increased, for example, in diabetes and the increase in enzyme activity is reversed by 
insulin (Woods et a l, 1981). It has also been suggested that this form of PAP could 
play a role in signal transduction (Gomez-Munoz et a l, 1992) either by an association 
with the internal surface of the plasma membrane or by regulation of the balance 
between phosphatidate and DRG formed de novo in the cell (Farese et a l , 1987; 
Rossi et a l ,1991). This may be particularly important in cells where PAP2 activity
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is absent but agonist-stimulated PLD activation results in DRG generation (Truett et 
al, 1992).
1.5.2 PAP2
An NEM-insensitive PAP enzyme has been described (Brindley, 1987; 
Cascales et a l , 1984; Martin et al. , 1987) but the role of this enzyme has only 
recently been elucidated. Billah and Anthes first proposed that phosphatidate, formed 
in response to agonist stimulation, is converted to DRG by PAP activity (Billah and 
Anthes, 1990). This form of the enzyme, PAP2, is located in the plasma membrane, 
an ideal position for carrying out a signalling role. The degradation of PC by PLD 
coupled to the activation of PAP is now recognised as an important route of DRG 
formation (Billah & Anthes, 1990; Exton, 1990; Exton, 1992). The action of PAP is, 
therefore, closely linked to the release and control of lipid second messengers as has 
been shown in the fibroblast system (Martin et a l , 1993) and in neutrophils (Taylor et 
al., 1993).
Unlike PAP1 which is known to be under complex, long term regulation, the 
factors which control PAP2 activity are unknown. Cultured vascular smooth muscle 
cells incubated with phorbol ester to deplete the cells of PKC, have been shown to 
generate more phosphatidate and less DRG than untreated cells in response to 
stimulation with angiotensin II (Lassegue et al. , 1993). This observation suggests that 
PAP may be regulated by PKC. Like PAP1, PAP2 activity may also be associated 
with physiological and pathological processes. An increase in an NEM-insensitive, 
plasma membrane PAP activity was associated with the inflammatory response in 
cyrrotic liver (Day et a l , 1993).
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1.5.3 Purification of Phosphatidate Phosphohydrolase
To date, PAP has not been purified to homogeneity from mammalian tissue 
although a number of partially purified preparations have been described (Butterwith 
et a l, 1984; Day & Yeaman, 1992; Hosaka et al.t 1975; Ide & Nakazawa, 1989). A 
membrane-associated PAP, however, has been purified from the yeast Saccharomyces 
cerevisiae (Lin & Carman, 1989; Morlock et al, 1991).
In yeast, two forms of PAP have been identified with molecular weights of 
45- and 104-kDa, located in mitochondrial and microsomal yeast fractions, 
respectively. These enzymes are regulated by certain nutritional requirements and 
growth conditions of the cell (Morlock e ta l, 1991). Levels of both forms increase as 
S.cerevisae progresses from exponential to stationary phase of growth. The 
expression of the two forms is regulated differentially by inositol and phosphorylation 
(Morlock et al., 1991; Quinlan et al., 1992). The levels of the 45 kDa form are 
induced in cells supplemented with inositol, whereas the other form is uneffected. 
Also, only the 45kDa form is phosphorylated by cAMP-dependent protein kinase in 
vitro and in vivo, resulting in activation of PAP activity (Quinlan et a l,  1992). The 
effects of growth phase, inositol and phosphorylation state on PAP activity correlates 
with changes in lipid synthesis (Morlock et al., 1988; Quinlan et al., 1992), implying 
a close involvement in their regulation of lipid synthesis.
Whilst investigating the molecular properties of diacylglycerol kinase, an 
enzyme which catalyses the conversion of DRG to phosphatidate, Kanoh and co­
workers purified not only this enzyme, but also PAP from the plasma membrane of 
porcine thymus (Kanoh et al., 1992). The properties of the purified 83kDa enzyme 
were clearly distinct from the yeast forms but were similar to those described for the 
PAP2 enzyme in hepatocytes (Jamal e ta l, 1991). Unfortunately, subsequent analysis 
of the 'pure* protein using silver staining techniques revealed that there were four 
bands on the gel. It is not clear which band is responsible for PAP2 activity. 
Purification studies by Professor D.N.Brindley's group have also identified a 83kDa
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protein that co-purifies with PAP2, but this protein has no activity under the 
conditions used to measure the PAP2 enzyme (Brindley, D.N., personal 
communication).
1.6 Aims of the Thesis
The main aims of these studies can be summarised as follows:
(i) to establish an assay for measuring PAP1 and PAP2 enzyme activities and 
determine their tissue distribution.
(ii) to determine whether PAP activity is altered in ras transformed fibroblasts.
(iii) to measure PAP activity in colorectal cancer and in adjacent normal tissue and 
to relate changes in PAP to levels of the second messengers phosphatidate and DRG.
(iv) to determine the effects of known PAP inhibitors on enzyme activity and cell 
proliferation.
(v) to establish whether PAP is a potential target for anticancer drug development.
1.7 Lay-out of Thesis
Each chapter begins with a self-contained introduction and hence full details 
of the rational behind the various individual stages of the work are not discussed here.
Chapter 2 describes the establishment and characterisation of an assay for the 
measurement of PAP activity in tissue samples. This was an essential requirement for 
the later studies and a well characterised assay in routine use in the laboratory of 
Professor D.N.Brindley was chosen. PAP1 and PAP2 differ in their sensitivity to the 
thiol-blocking reagent, NEM, and this property is used as the basis of an assay that 
allows estimation of the two activities without the need for subcellular fractionation 
to separate the two forms of PAP.
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Transformation of fibroblasts by a mutant ras oncogene has been shown to 
increase cellular levels of DRG and to increase PKC activity (Price et a l , 1989). This 
implies an increase in the activity of the enzymes involved in generation of DRG. If 
the breakdown of PC by PLD/PAP is an important source of DRG for PKC 
activation, then it would be expected that PLD and/or PAP activity might be 
increased in ras transformed fibroblasts. This possibility was examined in a study 
described in Chapter 3. Although levels of DRG were indeed higher in the ras 
transformed fibroblasts, the activity of PAP2 was decreased.
Surgical resection is the major form of treatment of colon cancer. Since large 
sections of the colon are removed, it is possible to obtain samples of both tumour and 
adjacent pathologically normal colon. As a result, this disease lends itself to 
comparative studies. In view of the poor prognosis of this form of cancer and of the 
importance of ras mutations in tumour progression, colon cancer was chosen as a 
model to study PAP activity in human tumours. Chapter 4 describes a study of PAP 
activity in human colon cancer samples and in the adjacent normal colon. It has 
already been reported that PKC activity and levels of DRG are decreased in colon 
tumours and it was suggested that the pathways for generation of DRG is down- 
regulated in this tumour type (Guillem et a l, 1987a; Phan et a l,  1991). In contrast, 
PAP1 and PAP2 activities were both shown to be elevated in the tumour tissue.
Not all colon cancers contain ras mutations and it is possible that the 
signalling pathways in the tumours will show different changes depending on the ras 
status of the tumour. Chapter 5 describes a study of Ki-ras mutations present in the 
human colon cancer samples. Mutations were observed in a proportion of the tumour 
samples and this tended to be the samples with the greatest increase in PAP activity.
An increase in PAP activity in the tumour tissue is apparently inconsistent 
with the observed decreased levels of DRG. Whilst this may be explained by a 
decrease in the generation of DRG from other sources, it is possible that the enzymes 
responsible for DRG metabolism are also affected by transformation. Chapter 6
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describes a study of the activity of two enzymes involved in DRG metabolism, DRG 
kinase and DRG lipase, in the colon tissue samples.
The observation that PAP activity is increased in tumour tissue lends support 
to the suggestion that this may be a target for anticancer drug development. In the 
absence of a purified form of PAP, direct design of inhibitors is not easy. A group of 
compounds, the cationic amphiphilic agents (CAAs), have been used in the past as 
inhibitors of PAP activity in whole cells (Mullmann et a l, 1991). However, these 
agents are not specific for this enzyme and can effect other signalling enzymes such 
as PKC (Sozzani et a l, 1992). These compounds may be a suitable basis for the 
development of specific inhibitors of PAP. Chapter 7 describes a study of the 
potential cytotoxicity of the CAAs as well as their effects on partially purified 
preparations of PAP1 and PAP2.
Finally, Chapter 8 is a general summary and discussion of the experimental 
evidence presented in this thesis. That PAP activity is altered in transformed cells 
suggests that it may play a role in the altered control of proliferation in these cells. 
Furthermore, the observation that PAP activity is increased in colon tumours lends 
support to the identification of this enzymes as a target for novel chemotherapies.
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CHAPTER 2
ESTABLISHMENT AND CHARACTERISATION OF AN ASSAY TO 
MEASURE PHOSPHATIDATE PHOSPHOHYDROLASE ACTIVITY IN
TISSUE EXTRACTS
2.1 Introduction
Much of the information available on the properties of PAP comes from the 
work of Professor D.N.Brindley (University of Alberta, Canada). An assay for 
measurement of PAP activity, routinely used in his laboratory (Jamal et al., 1991), 
was thus chosen for use in these studies. This chapter focuses on the characterisation 
of enzyme activites in plasma membrane and cytosolic fractions from animal tissues. 
Differential assays based on inhibition by N-ethylmaleimide (NEM) are used to 
distinguish between the plasma membrane PAP activity, which is not inhibited by 
NEM, and a cytosolic form which is sensitive to this compound. A well-established 
and reliable assay will enable further studies on the characterisation and functional 
properties of the PAP enzymes in cells lines and cancer tissues.
PAP has been shown to occur as two distinct activities within rat liver (Jamal 
et a l, 1992; Jamal et a l, 1991). The form of the enzyme involved in glycerolipid 
synthesis, PAP1, is present in the cytosol but can translocate to the endoplasmic 
reticulum to become metabolically functional (Brindley, 1984; Brindley, 1987). In 
contrast, PAP2 is an integral plasma membrane protein. To date, the two forms of 
PAP have not been purified and thus their properties are not yet clearly defined. Since 
the activities have been identified as present in distinct cellular compartments, 
preparations of subcellular fractions can be used as a source of each activity. Until the 
two activities are purified, it is not certain that they represent two separate isoforms of 
the enzyme. However, PAP1 is known to be highly sensitive to the thiol-blocking 
reagent, NEM, whilst the activity of PAP2 is unaffected by this agent. This is strong
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supporting evidence that the activities represent two separate enzymes and this 
property forms the basis of a differential assay. The assay allows estimation of PAP1 
and PAP2 in tissues without the need for subcellular fractionation (Jamal et al., 
1991). A disadvantage of enzyme assays based on pure or partially pure preparations 
is that they estimate total activity and do not reflect enzyme activity under 
physiological conditions where substrate and co-factor availability and feedback 
inhibition or activation controls are present. This problem can sometimes be 
overcome in studies with cell lines in vitro by estimation of activities in intact cells. 
An example of such an assay is used for measurement of PLD. This enzyme catalyses 
the hydrolysis of phosphatidylcholine (PC) to form phosphatidate and choline. If cells 
are incubated with primary alcohols, these can substitute for water in the 
phosphatidyltransferase reaction giving rise to the corresponding phosphatidylalcohol 
(Yang et a l , 1967). Moreover, since the phosphatidylalcohols are poor substrates for 
PAP (Metz & Dunlop, 1991), they accumulate in the cell and allow estimation of 
product formation. No such assay is yet available for measurement of PAP activity. 
Furthermore, an assay was required that could be used both for cell lines in culture 
and for biopsies of human colon tumours.
There are other methods available for measurement of PAP activity and these 
are based on the release of inorganic phosphate from a phosphatidate emulsion. Such 
methods are valid if there is no degradation of phosphatidate by phospholipase A 
(Figure 2.1). Release of inorganic phosphate in subsequent reactions would result in 
an overestimation of PAP activity (Sturton & Brindley, 1978). When rat liver was 
used as a source of PAP, activity measured by release of inorganic phosphate was 
shown to be 32% higher than that measured by other methods. This discrepancy was 
found to be due to deacylation of phosphatidate leading to the production of glycerol 
phosphate and glycerol (Sturton & Brindley, 1978). These problems can be overcome 
by the estimation of the product of PAP activity, DRG, as in the method chosen for 
these studies. In this method the substrate is radiolabelled and the DRG formed in the 
reaction is separated by addition of aluminium oxide which absorbs unreacted
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Figure 2.1 Possible routes for the degradation of phosphatidate 
phosphohydrolase assay
The reactions are catalysed as follows: (1) phosphatidate phosphohydrolase, (2) 
phospholipase A activity, (3) lysophospholipase, (4) diacylglycerol lipase, (5) 
monoacylglycerol lipase, (6) probably phophatidate phosphohydrolase, (7) acid or 
alkaline phosphatase.
phosphatidate (Martin et al., 1987). Significant hydrolysis of DRG by lipase action 
would interfere with this assay and this is particularly relevant in adipose tissue where 
lipase activity is high. This problem is avoided by addition of a lipase inhibitor (Ide & 
Nakazawa, 1989).
Phosphatidate is regarded as a relatively minor membrane constituent with 
less than 1% of total phospholipids being accounted for by this lipid in eukaryotic 
cells (Zachowski, 1993). This water-insoluble lipid is found only in membranes 
where it can act as a substrate for PAP activity. Since PAP2 is an integral plasma 
membrane protein the substrate is readily available for its action. However, PAP1, 
found mainly in the cytosol, has to translocate to endoplasmic reticulum to come in 
contact with the substrate and, hence, carry out its role in glycerolipid synthesis. A 
major problem in determining PAP activity is to present this substrate in a suitable 
form for measuring enzyme activity in aqueous solution. In the past, a membrane- 
bound substrate was used but this has the disadvantage that the substrate is relatively 
undefined in terms of lipid composition and phosphatidate concentration 
(Mangiapane et a l , 1973). Incorporation of phosphatidate into a mixed micelle with 
PC produces a substrate which closely resembles the natural one. This substrate has 
been used to measure PAP1 activity (Martin et a l, 1987). PAP2 has highest activity 
when a phosphatidate/Triton X-100 micelle is used as substrate (Jamal et a l , 1991).
This chapter describes the assay used to estimate PAP activity. Distinct 
activities were characterised in rat liver in terms of their dependence on Mg2+ and 
Triton X-100 and sensitivity to NEM. Once established, the assay was used to 
determine PAP activities in a variety of tissues in mice.
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2.2 Materials and Methods
2.2.1 Chemicals and Reagents
All general chemicals were of Analar grade and supplied by Merck 
(Thomliebank, Glasgow) or Sigma (Fancy Road, Poole, Dorset) unless otherwise 
stated. Tetrahydralipstatin was a kind gift from Dr.M.K.Meier (Hoffman-La-Roche 
Ltd., Basel, Switzerland). [3H]Phosphatidate was provided by Professor Brindley and 
co-workers (University of Alberta, Canada).
2.2.2 Preparation of Phosphatidate as Enzyme Substrate
[3H]Phosphatidate was synthesised enzymatically from [3H]palmitate and 
glycerol phosphate. Stock solutions of cold phosphatidate and PC were prepared in 
chloroform. Two substrates were required for this assay. For PAP1, a mixed micelle 
was prepared from [3H]phosphatidate, cold phosphatidate and PC to give a molar 
ratio of phosphatidate:PC of 3:2 and specific activity of 0.4Ci/mol (SturtoneJ al , 
1978). For PAP2, the plasma membrane form, a mix of [3H]phosphatidate and cold 
phosphatidate was used. The solvent was removed in a stream of N2 and the chelating 
reagents EDTA (5.56mM) and sodiumEGTA (5.56mM, adjusted to pH 7 with KOH) 
were added to give a concentration of phosphatidate in both cases of 3.33mM. The 
mixture was sonicated at 22kHz with an amplitude of 8pm peak for 30s at 22°C using 
an MSE probe sonicator (Fisons Instruments, Loughborough, Leicestershire). To 
every 9 volumes of this mixture, 1 volume of lOOmg/ml fatty acid free bovine serum 
albumin (BSA) was added to give a final concentration of phosphatidate of 3mM. The 
substrate for PAP2 was prepared in the same way except that PC was omitted. Both 
substrates were stored at -20°C.
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2.2.3 Crude Enzyme Preparations
Subcellular fractions from rat liver were used as a source of the enzymes for 
characterisation of the assay and enzyme kinetic analysis. Enzyme activity was also 
measured in a variety of homogenate preparations from tissues of nude mice.
Plasma membrane and cytosolic fractions were prepared as in Jamal et al 
(Jamal et a l , 1991). At all stages the tissues and fractions were kept cold at 4°C or on 
ice. Livers from male Wistar rats (120-200g) (Harlam Olac, Glasgow) were perfused 
with saline (NaCl; 0.15M) through the inferior vena cava, dissected out and minced 
with scissors in 4 volumes of ice-cold Tris/HCl (5mM, pH7.4) buffer containing 
sucrose (0.25M), MgCl2 (0.5mM) and dithiothreitol (DTT, 0.5mM) (buffered 
sucrose). Mouse tissues were dissected out and washed in saline. All tissues were 
homogenised with 3 strokes up and down in a homogeniser (Citeco Varilab, Citenco 
Ltd., Borhamwood, Herts.) with a loose fitting pestle. The homogenate was filtered 
through four layers of gauze presoaked in buffered sucrose and the homogenate was 
centrifuged in a Centaur 1 benchtop centrifuge (Fisons Instruments) at 280 x g for 
5min at 4°C. Mouse tissues were split into aliquots at this stage and stored at -70°C.
The supernatant was centrifuged at 1,500 x g for lOmin in a benchtop 
centrifuge. The supernatant was transferred to a clean tube and centrifuged at 18,000 
x g in a J2-21 Beckman centrifuge (Beckman Instruments, High Wycombe, Bucks.). 
These steps removed mitochondria, lysosomes and golgi from the preparation. The 
supernatant was then centrifuged at 100,000 x g in a Beckman L-60 ultracentrifuge 
using an SW 28 rotor for 60min to yield a cytosolic supernatant fraction. This was 
stored frozen in aliquots at -70°C.
The 280 x g pellet from rat liver was used to prepare plasma membrane 
fractions (for PAP2). The pellet was resuspended in buffered sucrose (l-2ml/g liver). 
The sucrose density of this homogenate was adjusted to 1.186g/ml using buffered 
sucrose solution prepared with 2M sucrose. Samples (35ml) were overlaid with 2 to 4 
ml 0.25M buffered sucrose and, after centrifuging for 60min at 82,000 x g in the
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Beckman L-60 ultracentrifuge using an SW 28 rotor and no brake, the interfacial 
layer was collected and resuspended with sufficient 0.25M buffered sucrose to obtain 
a sucrose density of 1.05g/ml. This was centrifuged at 280 x g for 5min as before and 
the supernatant discarded. The crude plasma membrane preparation was resuspended 
in a minimum volume of 0.25M buffered sucrose and layered over a self-forming 
gradient consisting of 3.5ml Percoll (Sigma), 16ml buffer A (Tris/HCl lOmM, pH7.4, 
sucrose 0.25M and sodiumEGTA 2mM) and 0.5ml buffer B (Tris/HCl 80mM, pH7.4, 
sucrose 2M and sodiumEGTA 8mM) for which the final density of sucrose was 
1.05g/ml. The mixture was centrifuged at 10,000 x g for 15min in the J2-21 Beckman 
centrifuge with a JA-20 fixed angle rotor to yield a plasma membrane fraction just 
below the surface. This was removed and washed in 10 volumes of sucrose (0.25M, 
adjusted to pH7.4 with KHCO3) containing DTT (0.5mM) and centrifuged at 10,000 
x g for 5 min as before. The pellet was resuspended in the same sucrose solution and 
stored frozen in aliquots at -70°C.
Protein concentration in the fractions was determined using the Bio-rad 
protein assay (Bio-rad Laboratories Ltd., Homesdale Road, Bromley, Kent) which is 
based on the method of Bradford (Bradford, 1976).
2.2.4 Estimation of Phosphatidate Phosphohydrolase Activity
Solutions:
PAP1 Incubation Solution: Tris/maleate 500mM, pH6.5 
5mMDTT
MgCl2 15mM
Tetrahydralipstatin ImM
PAP2 Incubation Solution: Tris/maleate 500mM, pH6.5
Tetrahydralipstatin ImM
NEM 21mM
Triton X-100 2.5%
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PAP activity was determined by measuring the amount of [3H]DRG formed 
from a [3H]phosphatidate substrate prepared as described. Assays for two distinct 
PAP activities were based on the differential effect of NEM; PAP1 is sensitive to this 
reagent, PAP2 is insensitive. Tetrahydralipstatin was added to prevent the degradation 
of DRG by lipase action (Jamal et al., 1991). PAP1 and PAP2 activities were 
measured using 20pg protein unless otherwise stated.
The reaction was carried out in polypropylene test tubes. The enzyme 
preparation was added in a volume of lOpl and was either rat liver cytosolic fraction 
for PAP1, plasma membrane fraction for PAP2 or crude tissue homogenate in which 
both enzymes were present. The incubation solution for PAP1 or PAP2 was added to 
to each tube in a volume of 20pl. The reaction volume in each tube was then made up 
to 80pl with water. The tubes were preincubated for lOmin at 37°C and the reaction 
started by addition of 20pl substrate, either a phosphatidate/PC micelle for PAP1 or 
phosphatidate alone for PAP2 activity. This gives a final concentration of reaction 
mixture in the tubes of Tris/maleate buffer lOOmM, DTT ImM, MgCl2 3mM, 
tetrahydralipstatin 200pM, NEM 4.2mM and Triton X-100 0.5%. The final 
concentration of substrate was 0.6mM [3H]phosphatidate for PAP1 and PAP2 and 
0.4mM PC for PAP1. Also, albumin (0.2mg), EDTA (ImM) and sodiumEGTA 
(ImM) were added along with the substrate. In the case where both forms of the 
enzyme were present, parallel incubations were performed for PAP1 with NEM 
(4.2mM) in the incubation solution. Control reactions contained no enzyme 
preparation.
The reaction was terminated after incubation for 60min at 37°C by addition of 
2.2ml chloroform/methanol (19:1, v/v) containing 0.08% olive oil as carrier. The 
[3H]DRG formed in the reaction was purified by adding lg  dry aluminium oxide (80- 
200 mesh from Merck). The tubes were capped, vortexed and then centrifuged for 
lOmin at 250 x g at 4°C. This pelleted the aluminium oxide to which unreacted 
phosphatidate was absorbed. The [3H]DRG formed in the reaction was in the top 
chloroform phase. One ml of this was removed and placed in scintillation vials. The
21
chloroform was evaporated by placing the tubes in a boiling waterbath and 3ml 
scintillation fluid (Ecoscint A; B.S&S. Scotland Ltd., Edinburgh) was then added to 
each vial and the radioactivity determined by scintillation counting using a 1600TR 
scintillation counter (Canberra Packard, Berkshire, UK). Samples were counted after 
24h to attain maximum counting efficiency. For both PAP1 and PAP2 enzymes, 
samples were assayed in triplicate and activities expressed as nmoles DRG formed / 
min / mg protein.
Kinetics of the PAP1 and PAP2 reactions were analysed by studying the 
reaction at increasing concentrations of substrate. In this case, a 9mM stock of 
[3H]phosphatidate was prepared and diluted to a range of substrate concentrations 
between 0.1 and 1.8 mM phosphatidate for PAP1 and between 0.01 and 1.8mM for 
PAP2. For the former enzyme, the ratio of the [3H]phosphatidate to PC was kept 
constant (3:2) as was the ratio of phosphatidate to Mg2+ (1:5). Enzyme kinetic data 
was analysed by use of the "Enzyme Kinetics" package of European Scientific 
Software (Britannia Centre, Point Pleasant, Wallsend).
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2.3 Results
2.3.1 Effect of Protein Concentration and Time on Reaction Rate
For both forms of the enzyme, DRG production was proportional to protein 
concentration at least up to lOOpg and to time up to 60min (Figure 2.2). For this 
reason, the majority of experiments were carried out for 60min using concentrations 
of protein on the linear portion of the graph, usually 20pg.
2.3.2 Effect of Mg2+, NEM and Triton X-100 on Enzyme Activity
PAP activity in the rat liver cytosol fractions is dependent on the presence of 
Mg2+ with optimum activity observed between 2 and 3mM (Figure 2.3). Mg2+ 
concentrations above 3mM appear to be inhibitory. All future assays contained 3mM 
Mg2+ for measurement of PAP1 activity. Addition of Mg2+ to the assay for PAP2 
made no difference to the activity of this form of the enzyme.
One of the main differences between the two forms of PAP is in the sensitivity 
to NEM as shown in Figure 2.4. In the presence of NEM (4.2mM), the PAP1 enzyme 
was almost completely inhibited whereas the PAP2 enzyme was insensitive to this 
reagent. NEM is added to all assays for PAP2 to inhibit any contaminating cytosolic 
enzyme activity.
When Triton X-100 was present for measurement of PAP2 activity, there was 
a substantial increase in the observed activity (Figure 2.5). The optimum activity 
occurred between 7.5 and 8mM which is equivalent to the concentration used for 
measurement of PAP2 in the assay. Addition of this detergent to the assay for PAP1 
severely inhibits this enzyme.
The effect of tetrahydralipstatin, an acylglycerol lipase inhibitor, was also 
determined. For the PAP preparation from rat liver, there was no significant
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Figure 2.2 Effect of enzyme concentration and incubation time on PAP1 and 
PAP2 activities.
DRG production was measured with various concentrations of rat liver cytosol 
(PAP1,0) and plasma membrane (PAP2, • )  as sources of the enzymes (A). DRG 
production was also determined after incubation of samples (20pg) for various times 
(B). Each point is a mean ± SE of triplicate determinations and is representative of 
three observations showing similar results.
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Figure 2.3 Effect of Mg2+ on PAP1 and PAP2 enzyme activities
PAP activity was measured in the presence of increasing concentrations of Mg2+ as 
indicated. Rat liver cytosol (PAP1) (O) and plasma membrane (PAP2) (•) fractions 
were used as sources of the enzymes using 20pg protein in the assay. Values are 
means ± SE of triplicate determinations and are representative of two observations 
showing similar results.
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Figure 2.4 Effect of N-ethylmaleimide on PAP1 and PAP2 enzyme activities 
PAP activity was measured with various concentrations of protein from rat liver 
cytosol (PAP1) (O, • )  and plasma membrane (PAP2) (□, I )  fractions. Activity was 
measured in the presence (open symbols) and absence (filled symbols) of NEM 
(4.2mM). Values are means ± SE of triplicate determinations and are representative of 
two independent observations showing similar results.
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Figure 2.5 Effect of Triton X-100 on PAP1 and PAP2 enzyme activities
PAP activity was measured in the presence of increasing concentrations of Triton X- 
100 as indicated. Rat liver cytosol (PAP1, O) and plasma membrane (PAP2, •) 
fractions were used as sources of the enzymes using 20pg protein in the assay. Values 
are means ± SE of triplicate determinations and are representative of two independent 
observations showing similar results.
degradation of DRG since PAP activity was not affected by addition of 
tetrahydralipstatin (Table 2.1).
2.3.3 Effect of Substrate Concentration on Enzyme Activity
The rate of DRG production by PAP1 and PAP2 enzymes was measured over 
a range of concentrations of phosphatidate as shown in Figure 2.6. For any given 
concentration of substrate, the rate of the reaction for PAP2 was higher than for 
PAP1. From the straightforward plots of initial velocity against substrate 
concentration, PAP2 appeared to obey Michaelis-Menton kinetics (Figure 2.6). The 
hyperbolic graph indicates that the rate of reaction is proportional to lower substrate 
concentrations, but at higher values a maximum velocity is reached (at 0.6mM 
phosphatidate). The results for PAP2 were linearised as a double reciprocal plot (1/v 
against 1/s, where v and s are the rate of reaction and substrate concentration, 
respectively). This Lineweaver-Burk plot shows that the points are widely scattered 
about the best fit line (Figure 2.7). The estimated Km and Vmax values for the PAP2 
enzyme were 0.09 and 6.4mM, respectively.
For PAP1, the graph of v against s is sigmoidal rather than hyperbolic (Figure 
2.6) which is typical of allosteric enzymes. Maximum velocity was reached but 
substrate concentrations higher than 1.2mM appeared to inhibit the enzyme.
2.3.4 Tissue Distribution of PAP1 and PAP2 Activities
Activities of both PAP1 and PAP2 were measured in a range of normal tissues 
from nude mice (Figure 2.8). Total PAP activity is highest in brain, lung and kidneys 
with lowest activity in the muscle (Figure 2.8A) as measured under the conditions of 
the assay used for the rat liver enzymes. PAP2 activity was generally higher than 
PAP1 and different patterns of activity of these two enzymes were observed in these 
tissues. For example, PAP1 activity was high in lung and liver (1.77 and 1.42 nmoles
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PAP Activity  
(nmoles DRG / min / mg protein)
+ THL -THL
PAP1 4.6 ± 0.3 4.8 ± 0.3
PAP2 4.5 ± 0.4 4.5 ± 0.1
Table 2.1 Effect of tetrahydralipstatin on PAP1 and PAP2 enzyme activities
PAP activity was measured in the presence and absence of 200 pM tetrahydralipstatin 
(THL) as indicated. Rat liver cytosol (PAP1) and plasma membrane (PAP2) fractions 
were used as sources of the enzymes using 20pg protein in the assay. Values are 
means ± SE of triplicate determinations.
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Figure 2.6 Effect of substrate concentration on PAP1 and PAP2 enzyme
activities
PAP activity was measured in the presence of increasing concentrations of substrate as 
indicated. For PAP1, the molar ratio of 3phosphatidate:2PC and 5Mg2+:lphosphatidate 
was maintained at all levels of substrate used. Rat liver cytosol (PAP1,0 ) and plasma 
membrane (PAP2, •) fractions were used as a sources of the enzymes using 30pg 
protein in the assay. Values are means ± SE of triplicate determinations and are 
representative of three independent observations showing similar results.
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Figure 2.7 The double reciprocal plot of the PAP2 enzyme kinetics
The rate of DRG production of PAP2 enzyme is expressed as a Lineweaver-Burk plot. 
Rat liver plasma membrane (PAP2) fraction were used as a source of the enzyme using 
20pg protein in the assay. Each point is a mean of triplicate determinations and is 
representative of three observations showing similar results.
DRG formed / min / mg protein respectively) and low in muscle and small intestine 
(0.33 and 0.29 nmoles DRG formed / min /  mg protein respectively). Highest activity 
for the PAP2 enzyme was in the brain, small intestine and kidney (3.43, 2.89 and 2.76 
nmoles DRG formed / min / mg protein respectively) and lowest in muscle (0.34 
nmoles DRG formed / min / mg protein) (Figure 2.8B).
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Figure 2.8 PAP1 and PAP2 enzyme activities measured in a variety of tissues 
from nude mice
PAP activity was measured using 20pg of protein in the indicated tissues. The results 
are means ± SE of the enzyme activities of three different mice. Total PAP activity is 
shown in A and B shows PAP1 Oand PAP2 $1) activities.
2.4 Discussion
PAP is an enzyme which dephosphorylates phosphatidate to produce DRG 
and may control the regulation between these two second messengers in signal 
transduction. An assay to distinguish PAP1 and PAP2 activities has been established 
and characterised using subcellular fractions from rat liver as crude sources of these 
enzymes. The activity of PAP was shown to be dependent on both time and 
concentration of protein. The rate of reaction was linear with protein concentration up 
to lOOpg and the reaction rate for both PAP1 and PAP2 was linear with time up to 
60min. These observations were used to define the conditions used for the subsequent 
assays. Both PAP1 and PAP2 activities were shown to be present in a variety of 
tissues from mice.
Two activities of PAP were characterised based on their different sensitivity to 
the thiol-blocking reagent, NEM. PAP1, which is involved in glycerolipid synthesis 
(Brindley, 1987), was inhibited by this reagent, whilst the activity of PAP2, the 
signalling form of the enzyme (Jamal et a l, 1991), was insensitive to NEM. This 
work confirms the findings of Professor Brindley's group (Jamal et a l , 1991) and 
forms the basis for the differential assay. In this study an NEM concentration of 
4.2mM was chosen as it was previously found that PAP1 was almost completely 
inhibited at this concentration whilst PAP2 activity was unchanged (Jamal et a l, 
1991; Martin et a l , 1991). Since PAP1 is strongly inhibited by NEM, it would appear 
that this enzyme is dependent on functional thiol groups. NEM and other such thiol- 
blocking compounds, for example p-chlormercuribenzoate, have also been shown to 
inhibit PAP activity in rat liver (Butterwith et a l, 1984) and rat lung (Casola & 
Possamayer, 1981). Inhibition by the latter compound, however, may involve binding 
of the mercury to a metal-binding site on PAP since mercury chloride has also been 
shown to inhibit PAP activity from rat lung (Casola & Possmayer, 1981). Although 
the different sensitivity to NEM would appear to distinguish two separate enzymes, it 
could be argued that the functional properties of an enzyme may be critically affected
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by its environment. This raises the possibility that the activity of PAP in the plasma 
membrane and cytosol are due to the same enzyme with different properties due to 
their different locations (Bates & Saggerson, 1979; Ide & Nakazawa, 1985). Physical 
evidence obtained from gel filtration and anion exchange chromatography on partially 
purified enzyme preparations, clearly demonstrate that PAP1 and PAP2 have different 
size and charge characteristics which implies two different forms of PAP (Day & 
Yeaman, 1992).
Another main difference between the two enzymes is in their dependence on 
Mg2+. PAP1 was found to have an absolute requirement for Mg2+ whereas PAP2 
enzyme activity is not dependent on this metal ion for its activity, which confirms 
previous reports (Jamal et a l , 1991). Divalent cations have a profound effect on the 
packing arrangement and spacing of phosphatidate molecules in membranes (Cullis & 
DeKruijff, 1979) and this may explain the effects of Mg2+ on PAP activity. The 
optimal concentration of magnesium ions could thus create the appropriate physical 
conditions in the substrate such that PAP1 is able to interact with and insert itself into 
the prepared phosphatidate/PC micellar substrate, and then hydrolyse the 
phosphatidate. The effect of Mg2+ is known to be different from other polyvalent 
cations, such as calcium ions (Ca2+) (Ito & Ohnishi, 1974). Addition of Ca2+ to the 
incubations for the NEM-sensitive PAP resulted in a 5-fold increase in activity, but 
this increase was less than 10% of that produced by Mg2+ (Martin et a l, 1987). The 
PAP1 found in the cytosol has a higher requirement for Mg2+ than other cations, 
however, this dependency is lost when PAP attaches to endoplasmic reticulum 
(Martin et a l , 1987).
PAP2 activity is Mg2+ independent and NEM insensitive and has been 
identified as localised in the plasma membrane (Jamal et a l, 1991). However, other 
studies that have identified a Mg2+ independent and/or NEM insensitive PAP activity 
located in microsomal membranes and cytosol (Martin et a l ,  1987; Walton & 
Possmayer, 1985; Walton & Possmayer, 1989). It is possible that there is a Mg2+ 
independent/NEM insensitive PAP activity in the endoplasmic reticulum and/or
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cytosolic fractions as well as the plasma membrane. This possibility has been 
investigated and it was concluded that the NEM insensitive form was predominantly, 
if not exclusively, in the plasma membrane fraction (Jamal et a l, 1991). Alternative 
locations may be the result of contamination of these fractions with plasma 
membranes. The NEM-sensitive PAP was mainly found in the cytosolic fraction but 
can associate with the endoplasmic reticulum (Brindley, 1984) or with mitochondrial 
membranes (Freeman & Mangiapane, 1989). There is negligible activity found in the 
plasma membrane (Jamal et a l, 1991). The degree of contamination of microsomal 
membranes with plasma membranes is presumably dependent on the method of 
homogenising, with different methods fragmenting the plasma membrane to different 
extents leading to their appearence in different subcellular compartments. With the 
mild homogenisation procedures used in this study, which have been well 
characterised in the past (Jamal et a l, 1991), it is known that the fractions obtained 
are largely either plasma membrane or cytosol. Furthermore, PAP activities can be 
selectively measured using NEM which inhibits PAP1 in the cytosol and endoplasmic 
reticulum but does not effect PAP2 activity in the plasma membrane. Hence, PAP 
activities can be measured in a tissue sample without subcellular fractionation (Jamal 
e ta l, 1991; M artin i a l, 1991).
Membrane-bound enzyme activities are often measured in the presence of 
detergents as, for example, for DRG kinase (Ohanian & Heagerty, 1994). It was 
perhaps not surprising, therefore, that at least one of the PAP enzymes, PAP2, had 
elevated activity when Triton X-100 was used in the assay. This detergent ensures 
that the protein is present in a detergent micelle, dissociates it from other membrane 
components and allows it to act on the lipid substrate added to the reaction (Jamal et 
a l,  1991). PAP1 is present in an aqueous environment and the detergent was shown 
to inhibit this form of the enzyme. PAP1 activity is highest when the substrate is 
presented as a mixed micelle of the acidic phosphatidate and the zwitterionic lipid, 
PC. This may provide a substrate resembling the physiological one in the 
endoplasmic reticulum membrane with which PAP1 can interact.
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A potential problem with this assay is the degradation of DRG by lipase action 
which, if this enzyme is present in large enough amounts, would lead to a decrease in 
the estimation of PAP activity. However, inclusion of the acylglycerol lipase 
inhibitor, tetrahydralipstatin, in the assay overcomes this effect (Hadvary et a l , 1991;
Hermier et a l , 1991; Jamal et a l , 1991). In the liver fractions, no significant increase 
in DRG production was observed with tetrahydralipstatin (Table 2.1) suggesting that 
lipase activity in this tissue is not sufficient to invalidate the determination of the 
activity of PAP by the rate of DRG formation. However, this assay was required to 
determine the enzyme activity in other tissues where lipase action may present more 
of a problem. Thus, the inhibitor was routinely incorporated into the assay so that the 
enzymes were always measured under similar conditions.
PAP2 enzyme activity displayed Michaelis-Menton kinetics and the results
were similar to those achieved for a membrane-associated form found in neutrophils
(Taylor et a l, 1993). The Km of rat liver and neutrophil membrane forms were 88
nmoles DRG formed / min / mg protein 
and 65pM respectively and the Vmax of the former enzyme was 6.44. The Km
values of enzymes can range widely, for example, chymotrypsin which acts on acetyl-
L-tryptophanomide has a Km of 5000[xM whereas lysozyme, acting on Hexa-N-
acetylglucosamine has a Km of 6pM (Stryer, 1988). At Km half the active sites of the
enzyme are filled and it can be a measure of the strength of the enzyme-substrate
complex. A high Km indicates weak binding whereas a low Km indicates strong
binding as appeared to be the case with PAP2 enzyme.
Most allosteric or regulatory enzymes have atypical substrate-saturation 
curves, are very complex in nature and appear to be at variance with classic 
Michaelis-Menton behaviour. Homotropic regulatory enzymes, that is ones which are 
believed to contain two or more binding sites for the substrate at least one of which is 
catalytic, show a sigmoid dependence on substrate concentration. PAP1 showed 
sigmoidal kinetics and this may reflect a regulatory role for this form of the enzyme 
as has been suggested (Bell & Coleman, 1980). This sigmoid nature implies that the 
binding of the first substrate molecule to the enzyme enhances the binding of a
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second and thus enhances activity of the enzyme. It is also common for homotropic 
enzymes to be inhibited by excess substrate such that maximum velocity is obtained 
at a limited range of substrate concentrations. This was observed with PAP1 enzyme 
activity which was inhibited at concentrations of substrate above 1.2mM. This has not 
been shown previously probably due to the limited number of substrate 
concentrations used (Jamal et a l, 1991).
Once the PAP assay had been established it was used to determine enzyme 
activity in a variety of tissues from mice. PAP activity has already been identified in 
several tissues including lung (Walton & Possmayer, 1985), adipose tissue (Jamal et 
a l, 1992), heart (Jamal etal., 1992) and brain (McCaman et a l, 1965; Vaswanni & 
Ledeen, 1989). There was a marked variation in the activities of both PAP1 and PAP2 
in the various tissues analysed which suggests a difference in importance or function 
of the enzyme. One striking observation was the high PAP2 activity observed in brain 
tissue. Interestingly, mammalian brain is also one of the richest sources of PLD 
(Billah & Anthes, 1990). Signalling enzymes are often found to be highly active in 
brain, however, the exact functions of these are not fully understood (Farooqui & 
Hirashima, 1992). It has been postulated that, for example, one of the products of the 
PLD reaction, choline, is used for the synthesis of the neutotransmitter, acetylcholine 
(Wurtman et a l, 1985). PLD/PAP action may provide a long term increase in DRG, 
which could modulate the activity of numerous enzymes in the brain (Farooqui & 
Hirashima, 1992). In contrast, glycerolipid synthesis, which is particularly evident in 
the liver, does not occur in the brain which supports the lack of PAP1 activity. The 
range in activities suggests this is not just a constitutive enzyme but has a different 
role depending on the tissue. This supports the idea that the enzyme may be a suitable 
target for anticancer agents.
In summary, an assay has now been established and characterised for 
measuring PAP enzyme activities in rat liver. This can now be used routinely and 
reliably as a basis for future measurements involving the activity of PAP1 and PAP2.
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CHAPTER 3
EFFECT OF Ki-ras MUTATION ON PAP ACTIVITY AND LEVELS OF 
PHOSPHATIDATE AND DIRADYLGLYCEROLS IN NIH 3T3 MOUSE 
FIBROBLASTS AND HUMAN COLON CANCER EPITHELIAL CELLS
3.1 Introduction
An assay has been established and characterised for measuring PAP1 and 
PAP2 activities. Both enzymes were found to have a wide range of activities in 
normal tissue suggesting differential regulation depending on the cellular 
environment. If they play a role in the control of cell proliferation then it might be 
expected that activity of these enzymes would be altered as a result of cell 
transformation. The aim of the studies described in this chapter was to investigate the 
possible importance of PAP1 and PAP2 activities in proliferation by the use of an 
experimental model of increased proliferation.
The ras oncogene has attracted much attention since ras mutations are 
observed in about 30% of human cancers. Almost all pancreatic tumours contain ras 
mutations and about 50% of colorectal cancers express a mutant ras oncogene 
(Fearon & Jones, 1992; Rodenhuis, 1992). The ras gene is highly conserved 
throughout evolution such that the yeast gene can substitute for the human gene 
(DeFeo-Jones et a l, 1985). Three ras genes have been identified in mammals: Ha­
ras, N-ras and Ki-ras. These genes encode closely related 21kDa proteins that 
undergo post-translational modification and localise on the inner surface of the 
plasma membrane (Willingham et a l, 1983). Ras proteins have been implicated in 
both cellular proliferation and in terminal differentiation (Barbacid, 1987; Hall, 
1990). They are thus regarded as a key point in signal transduction and this is 
supported by the potent transforming ability of mutant ras genes, for example, in NIH 
3T3 cells (Stacey & Kung, 1984).
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Ras is a member of the guanosine triphosphate (GTP) binding protein family. 
These proteins act as molecular switches in signal transduction pathways and activity 
is determined by the phosphorylation status of the bound guanine nucleotide 
(Wittinghofer & Pai, 1991). In the GTP bound state, the protein is active. Ras has 
intrinsic GTPase activity and hydrolysis of GTP to GDP results in inactivation of the 
protein (Trahey & McCormick, 1987; Zhang et a l , 1992). Activation can be achieved 
by the activity of a guanine nucleotide exchange factor which dissociates GDP from 
the ras protein (Mizuno et al , 1991). Since GTP is present at much higher levels than 
GDP in cells, the nucleotide binding site is rapidly filled by GTP. The majority of 
transforming ras mutations are found in a limited number of positions, codons 12,13 
and 61, and these encode amino acids located in the guanine nucleotide binding site 
of the ras protein. These mutations result in either increased rates of GDP dissociation 
or decreased intrinsic GTPase activity, both of which increase the activity of ras 
(Barbacid, 1987; Vogel et a l, 1988). Substitution of Gly with Val at codon 12 is 
commonly observed in human tumours and this results in a 10-fold decrease in the 
rate of GTP hydrolysis by the ras protein (Hoshino et a l , 1988).
Mouse fibroblasts are readily transformed by transfection with oncogenic ras 
and this property of ras is exploited in the NIH 3T3 transfection assay used to detect 
ras mutations in human tumours. Fibroblasts have receptors for epidermal growth 
factor (EGF), PDGF and insulin and all are mitogenic (Burgering et al. ,1991; Gibbs 
et a l , 1990; Satoh e ta l , 1990). Stimulation of cells with these growth factors leads 
to activation of the tyrosine kinase activity of the receptors and an increased level of 
ras-GTP (Kaplan et a l , 1990). Transformation of the cells with mutant ras results in 
serum independent proliferation (Hoshino et a l , 1988). In addition to increased levels 
of ras-GTP, these transformed cells have also been shown to have increased levels of 
DRG, the physiological activator of PKC (Hancock et a l, 1988). The source of this 
DRG is not clear. Activation of the EGF receptor tyrosine kinase activity is known to 
activate PLCy which hydrolyses phosphatidylinositol 4,5-bisphosphate (Margolis et 
a l , 1989). Serum-stimulated NIH 3T3 cells have been shown to have increased levels
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of DRG and inositol phosphates which is consistent with activation of 
phosphatidylinositol-specific PLC (Wakelam e ta l, 1986). However, ras transformed 
NIH 3T3 cells do not have increased levels of inositol phosphates which indicates 
that, in this case at least, phosphatidylinositol is not the only source of increased DRG 
(Lacal et a l, 1987). Fibroblasts transformed with w-src also show increased levels of 
DRG and this DRG is derived from a pool of cellular lipids that label preferentially 
with myristate (Song et a l, 1991). This suggests that in v-src transformed cells, the 
increased levels of DRG is as a result of an increased breakdown of PC.
PC is the major phospholipid class in mammalian tissues and is known to be 
the source of DRG produced in response to hormonal stimulation (Exton, 1990; 
Martinson, 1989; Pelech & Vance, 1989). Furthermore, PC is thought to be the source 
of the sustained elevation of DRG observed in response to a number of mitogens 
(Besterman et a l, 1986a; Billah et a l, 1989; Exton, 1990). If PC is the source of 
increased levels of DRG in ras transformed cells then this would suggest that the 
activity of an important mitogenic pathway is stimulated in such cell lines. Thus, both 
ras and src transformed fibroblasts contain increased levels of DRG and the most 
likely source is from the breakdown of PC by the action of PLD and PAP. If this is 
the case, then it would be expected that the activity of PLD and/or PAP might be 
increased. It has been suggested that PAP is a regulatory point in the pathway for 
glycerolipid synthesis (Bell & Coleman, 1980; Brindley, 1987). Although it is 
thought to be PAP1 that is involved in glycerolipid synthesis, a regulatory role for 
PAP2 in the pathway for DRG production from PC could be postulated. This 
possibility is supported by the observation that when 1321N1 astrocytoma cells are 
stimulated via the muscarinic receptor with carbachol, there is a rapid and transient 
increase in PLD activity but a much slower increase in DRG levels (Martinson et al , 
1990). It was suggested that this discrepancy could be the result of a slow conversion 
to DRG by PAP. However, the kinetics of PLD and PAP derived from bovine 
endothelial cells suggest that PLD may be the rate-limiting enzyme in the pathway 
from PC to DRG (Martin, 1988).
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Therefore, PAP activity and levels of phosphatidate and DRG, were 
determined in NIH 3T3 fibroblasts and in fibroblasts transfected with a mutant Ki-ras 
oncogene. The Ki-ras oncogene was chosen since this is the most common ras 
mutation observed in colon cancers (Fearon & Vogelstein, 1990). However, one cell 
line with mutant Ha-ras was included for comparison. Fibroblast cell lines are easily 
transformed by a number of oncogenes and such cell lines are readily available. 
Furthermore, these cell lines have been widely used in studies of cell signalling 
pathways (Lowe & Skinner, 1994). However, colon tumours are derived from 
epithelial cells and the effects of transformation may be cell type specific. In spite of 
much effort, attempts to establish normal colonic epithelial cells in tissue culture have 
met with little success to date (Friedman et a l, 1981). In contrast, colon tumour- 
derived cell lines can be established in vitro and a number are available which have 
been characterised for ras mutations. The human colonic adenocarcinoma cell line, 
Caco-2, expresses wild-type Ha-ras (Delage eta l, 1993). When transfected with Ha­
ras containing a mutation at codon 12, cells were shown to have increased levels of 
DRG which is comparable to the effects of mutant ras on fibroblasts cells. However, 
in these cells the DRG appeared to be derived from both phosphatidylinositol and PC 
since both [3H]arachidonic acid and [3H]myristic acid were able to label the lipids 
from which the DRG was derived (Delage et a l , 1993). Four colon cancer cell lines 
were also included in this study. Although it is not possible to compare PAP activity 
in the tumour cell lines with that in normal colon cells, two of the cell lines did not 
contain a mutant ras oncogene. It was, therefore, possible to compare PAP activity in 
cells with and without a mutant ras oncogene. Clearly, the lines probably contain a 
number of mutations in other oncogenes of relevance to cell signalling.
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3.2 Materials and Methods
3.2.1 Chemicals and Reagents
Silica gel 60 thin layer chromatography plates were from Merck 
(Thomliebank, Glasgow) and the silica gel 150A plates with fluorescent indicator 
were purchased from Whatman (Maidestone, Kent). DRG kinase from E.coli was 
purchased from Calbiochem-Novabiochem (Nottinghamshire, U.K.); s/z-l-stearoyl-2- 
arachidonylglycerol (SAG) and adenosine-5’ -triphosphate disodium salt (ATP) were 
from Sigma (Poole, Dorset); phosphatidylserine was from Lipid Products (Crabhill 
Lane, Surrey) and [y-32P]ATP (specific activity 3 Ci/mmol) was from Amersham 
(Little Chalfont, Buckinghamshire). Tissue culture flasks were obtained from Bibby 
Sterilin (Stone, Staffordshire) and the 9cm2 petri dishes were from Falcon (Becton 
Dickinson Labware, Plymouth). All components of the tissue culture media were 
purchased from Life Technologies (Paisley, Scotland).
3.2.2 Cell Lines
The source, Ras status and doubling times of the cell lines used in the study 
are shown in Table 3.1. All epithelial lines were from the American Type Tissue 
Collection (ATCC). DLD-1 and LoVo contain a mutation in Ki-ras whereas HT 29 
and Colo 320DM do not (Benhatteref al , 1993; Finkelsteinef al , 1993). NIH 3T3 I 
and NIH 3T3 II are essentially the same cell line but were obtained from the 
respective laboratories as the parental line for the transfectants. The former was 
transformed by v-Ha-ras (HT3 I) and v-Ki-ras (KMSV I) and NIH 3T3 II was 
transformed by v-Ki-ras (Ki 858 II) with a different point mutation to that in KMSVI.
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I Cell lin e Ras Status Doubling 
Time (h)
Source Reference
NIH 3T3 I WT for ras 20 Dr. A. Balmain, 
Medical 
Oncology, 
Glasgow.
(Copeland & 
Cooper, 
1979; Ellis ef 
al., 1981; 
Fusco et al, 
1987)
HT3 I v-Ha-ras with Gly- 
Val mutation at 
codon 12
16 The transformed 
lines are derived 
from the
KMSVI v-Ki-ros with Gly- 
Val mutation at 
codon 12
18 NIH 3T3 line.
NIH 3T3 II WT for ras 21 Prof.M. Wakelam, 
Dept, of Cancer 
Studies,
Ki 858 II v-Ki-ras with 
Gly-Asp mutation 
at codon 12
17 Univ.of Bir'ham.
■
HT29 WT for ras 19 adenocarcinoma 
(ATCC HTB 38)
(Marshall et 
a l , 1977)
Colo320DM WT for ras 21 adenocarcinoma 
(ATCC CCL220)
(Quinn et a l , 
1979)
DLD-1 Ki-ras with Gly to 
Asp mutation at 
codon 13
21 adenocarcinoma 
(ATCC CCL221)
(Cexter et 
al, 1979)
LoVo Ki-ras with Gly to 
Asp mutation at 
codon 13
22 adenocarcinoma 
(ATCCCCL 229)
(Drewinko et 
a l, 1976; 
Drewinko et 
a l , 1978)
Table 3.1 Source and Ras status of the murine fibroblast and human colon 
cancer epithelial cell lines
The ras transformed fibroblasts are suffixed with I or II to show which parental NIH 
3T3 cell line they are derived from.
3.2.3 Routine Cell Maintenance
All fibroblast cell lines were grown in Dulbecco’s modified Eagle's Medium 
(DMEM) containing sodium bicarbonate (23mM), glutamine (2mM) and donor calf 
serum (10%, v/v). HT 29 and Colo 320DM were grown in a mixture of Ham's F10 
and DMEM (50:50) supplemented with sodium bicarbonate (23mM), glutamine 
(2mM) and foetal calf serum (10%, v/v). LoVo and DLD-1 were maintained in RPMI 
1640 (Northumbria Biologicals, Cranlington, Northumberland) supplemented as for 
the previous medium. The untransformed fibroblast and epithelial cell lines were 
passaged at weekly intervals, whereas the transformed lines required passaging twice 
weekly. They were seeded at an initial density of 106 cells per 75 cm2 flask and 
incubated at 37°C in an atmosphere of 2% CO2 in air. Cells were grown for a 
maximum of 10 passage from frozen stocks which had been stored in liquid nitrogen 
in growth medium containing DMSO (10%).
Cells were passaged by removal of all medium from the flask then adding 5ml 
of phosphate buffered saline (PBS) (Dulbeccos A) containing EDTA (ImM) and 
trypsin (0.25%) to the flask. This solution was removed almost immediately and the 
cells left for 30s to allow detachment from the surface of the flask. Cells were 
resuspended into 10ml of medium and counted using a Coulter Counter (Coulter 
Electronics Ltd., Luton, Bedfordshire) before dilution and plating into fresh tissue 
culture flasks.
3.2.4 Mycoplasma Testing
All cell lines were free of mycoplasma as confirmed by monthly screening. 
Cells were fixed with ice-cold glacial acetic acid (25%, v/v) in methanol and then 
stained with the fluorescent DNA stain Hoescht 3328 (Sigma, Poole, Dorset) at a 
concentration of lOOng/ml for 15min at room temperature (Chen, 1977). Plates were
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then examined under a fluorescent microscope (Polyvar Microscope, Reichert, Leica 
Ltd., Milton Keynes, England) for visual evidence of infection.
3.2.5 Estimation of Phosphatidate Phosphohydrolase Activity
Cells were plated out at a density of 106 cells / dish in 9cm2 tissue culture 
petri dishes and incubated at 37°C in an atmosphere of 2% CO2 in air for 3-4 days 
until the cells were confluent. They were washed four times with ice-cold PBS and 
scraped from the plates in 0.5ml of Tris buffer (20mM, adjusted to pH6.5 with 
maleate) containing sodium phosphate (5mM), DTT (ImM), NaCl (140mM), 
leupeptin (lpg/ml) and, forPAP2 measurements, sodium orthovanadate (400pM) and 
ZnCl2 (lpM) to inhibit activity of protein tyrosine phosphatase. The cells were 
sonicated four times for 2s then stored frozen at -70°C in aliquots. After thawing, 
samples were sonicated briefly and protein concentrations determined as described in 
section 2.2.3. The samples were diluted for use in the same harvesting medium.
Unless stated otherwise, PAP activity was determined at a protein 
concentration of 20pg/assay. Cells harvested in the absence of vanadate and Zn2+ 
were used for the assay of PAP1 activity. Assays of cells harvested with vanadate and 
Zn2+ all contained a final concentration of 240pM vanadate and 0.6pM Zn2+. The 
cells were used as sources of the enzymes and PAP activity was measured as 
described in section 2.2.4.
3.2.6 Cell Lipid Extraction
Lipid extraction was carried out essentially by the method of Bligh and Dyer 
(Bligh & Dyer, 1959). Confluent cultures of cells were washed twice with ice-cold 
PBS and scraped from the petri dish in 0.5ml methanol. This was transferred to a 
glass test tube and the residue collected with a further 0.5ml methanol. Chloroform 
(0.5ml) and water (0.4ml) were added and lipids were extracted by addition of a
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further 0.5ml chloroform and 0.5ml NaCl (1M) in water. The tubes were vortexed 
then centrifuged at 250 x g for lOmin to separate the phases. The lower chloroform 
phase from one tube was mixed with that of another to ensure sufficient mass of lipid 
for accurate determination. This lipid extraction mixture was then split into aliquots 
of 900pl for phosphatidate mass measurement, 400pl for measurement of DRG mass 
and 50pl for total phospholipid assay. The lipids were dried under a stream of 
nitrogen and stored at -70°C until ready for use. The lipids were assayed for DRG and 
phosphatidate within three days of extraction.
3.2.7 Measurement of Phosphatidate Mass
Phosphatidate was measured using a modification of the method Bocckino et 
al (Bocckino et al., 1987). Lipid extracts were redissolved in 50pl chloroform and 
applied in 0.5cm bands half way up a plastic thin layer chromatography silica gel 60 
plate that had been previously developed in petroleum ether / diethylether (1:1, v/v). 
Standards of phosphatidate (0.5,1, 2.5 and 5pg) prepared in chloroform were applied 
to each plate. They were developed to 95% of their length with chloroform : methanol 
: ammonium hydroxide (65:35:7.5, v/v/v), air dried and then cut 1.5cm above the 
origin which removes the neutral lipids and most of the zwitterionic phospholipids. 
Phosphatidate remained at the origin in this chromatographic system. The plates were 
then developed in the reverse direction to 95% of their remaining length using 
chloroform : methanol: acetic acid (9:1:1, v/v/v).
The dried plates were then stained for 1 hour with Coomassie Blue R250 
(0.03%) in methanol /  water (4:1, v/v) containing NaCl (lOOmM), destained for 10- 
15min using methanol / water (4:1, v/v) and dried overnight. The absorbancies of the 
phosphatidate bands were measured using an LKB 2202 Ultrascan Laser densitometer 
(Pharmacia LKB Biotechnology, St.Albans, Hertfordshire) in the reflectance mode at 
580nm. The output was channelled to an LKB analogue/digital converter and the thin 
layer chromatographic bands integrated using an LKB CD Plot system. A standard
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curve of phosphatidate was constructed from the peak areas for each plate. Triplicate 
samples from each cell line were analysed on separate plates and the average values 
calculated.
Figure 3.1 shows a typical standard curve obtained from densitometric 
analysis (peak areas) of phosphatidate at 0.5,1.0, 2.5, 5.0 and 10.0 nmoles lipid. This 
was linear up to 5nmoles of phosphatidate. This represents the mean curve from three 
t.l.c.plates. Provided staining and destaining of the lipids was carried out for 
approximately the same time and hence background was a similar intensity, variation 
between plates for the lipids was within 5%. It is important, however, to compare cell 
lipid extracts with the standard curve of that particular t.l.c. plate analysis.
3.2.8 Measurement of Diradylglycerol Mass
Solutions: 
Incubation Buffer:
Triton Solution:
ATP Buffer:
Imidazole/HCl
MgCl2
sodium EGTA 
Triton X-100 
Imidazole/HCl 
Imidazole/HCl
250mM, pH6.6
62.5mM
5mM
0.06%, w/v 
25mM, pH6.6 
lOOmM, pH6.6
It should be noted that many reports often refer to DRG as diacylglycerol 
(DAG). However, most methods for measuring this lipid cannot distinguish between 
the various DRGs, that is, sn-1,2-diacylglycerol, s/i-l-alkyl-2-acylglycerol and sn-1- 
alkenyl-2-acylglycerol. Hence, it is more accurate to use the term 'DRG1 unless 
referring to a particular class of the lipid.
Cell lipid extract previously dried under a stream of nitrogen in glass vials was 
used for measurement of DRG mass. A standard curve of DRG (25 - 500 pmoles), 
prepared in chloroform, was also set up. The standards were dried under a vacuum in
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Figure 3.1 Standard curve for the phosphatidate mass assay 
The standard curve was generated from three separate mass assays. Phosphatidate was 
separated from other lipids using thin-layer chromatography and then stained with 
Coomassie Blue. The area of the peak corresponding to phosphatidate was measured 
by a densitometric scan. Each point is a mean value ± SE.
a Gyrovap (V.A.Howe, Oxfordshire, England) and both cell extracts and standards 
were solubilised in 50pl of Triton X-100 (0.6%, w/v) /  phosphatidylserine (288pM) 
by brief vortexing followed by bath sonication for 30min at 4°C (KS100 bath 
sonicator, Kerry Ultrasonics Ltd., Kent). Following sonication, 10pl DTT solution 
(lOOmM) and 20pl incubation buffer were added to each tube. An E.coli DRG kinase 
solution was prepared by mixing 10pi of the purchased enzyme (lOOm-Units) with 
190pl of enzyme mix (885pl water, 17pl Triton solution and lOOpl ATP buffer). Ten 
pi of the final enzyme solution was added to each tube. An ATP stock solution was 
prepared in ATP buffer ensuring there was sufficient ATP and [y-32P]ATP (taking 
into account decay) to obtain a final concentration of ATP of 0.5mM and 1 pCi/assay. 
The final reaction mixture contained Triton X-100 (0.3%, w/v), phosphatidylserine 
(144pM), imidazole/HCl (50mM, pH6.6), NaCl (50mM), MgCl2 (12.5mM), 
sodiumEGTA (ImM), DTT (lOmM), ATP (0.5mM, lpCi of [y-32p]ATP) and E.coli 
DRG kinase (5m-Units) in a volume of lOOpl. The reaction was started by the 
addition of the ATP and samples were incubated at 30°C for 30min.
The reaction was terminated by the addition of 1ml chloroform : methanol : 
HC1 (5N) (150:300:2, v/v/v). The tubes were left to stand for lOmin at room 
temperature and the phases split by the addition of 300pl chloroform and 400pl water 
followed by centrifugation at 250 x g in a benchtop centrifuge (model CR411, Deva 
Medical Electronics Ltd., Runcorn, Cheshire) for lOmin. The top phase was discarded 
and the remaining organic phase mixed with 1ml of chloroform : methanol : water 
(1:1:0.9, v/v/v), centrifuged as before and the top phase discarded. The bottom phase 
was dried under vacuum. Radiolabelled products were reconstituted in 20pl 
chloroform and applied to a 5x20cm silica gel 60 t.l.c. plate. The plates were 
developed in chloroform : methanol : acetic acid (39:9:4.5, v/v/v). The 
[ 32P]phosphatidate was identified by autoradiography and the silica corresponding to 
the phosphatidate scraped, placed in scintillation vials with 3ml scintillation fluid and 
counted by liquid scintillation counting. DRG in the cell extracts was determined
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from a standard curve. Average values were calculated and expressed as pmoles 
DRG.
Figure 3.2 shows a typical standard curve obtained for conversion of 25-500 
pmole s/z-l-stearoyl-2-arachidonylglycerol to [32P]phosphatidate and indicates that 
100% efficiency of conversion of DRG to phosphatidate occured which is essential 
when mass analysis is used.
3.2.9 Measurement of Inorganic Phosphate
Inorganic phosphate was determined by the method of Van Veldhoven (Van 
Veldhoven & Mannaerts, 1987). The cell lipid extract for this assay was reconstituted 
into 50pl chloroform and then split in aliquots of 2xl0pl, 2x5pi and 2x2pl into pyrex 
test tubes. A standard curve of glycerol phosphate (l-100nmole) was prepared in 
water. All samples and standards were dried in a Techne Dri-block (Fisons 
Instruments, Loughborough, Leicestershire) at 180°C for 15min or until they were 
completely dry. Fifty pi of 70% perchlorate was added to each tube and they were 
then heated to 180°C for 30min, ensuring that the acid did not evaporate by placing a 
glass marble over each test tube. The tubes were removed and cooled.
To each assay was added 120pl water, 50pl ammonium heptamolybdate.4H20 
(2.5%) and 50pl ascorbic acid (10%). The solution was vortexed then heated to 90°C 
in a waterbath for 5min. The colour change was from pale yellow to blue in the 
presence of phosphate. An aliquot of 200pl was removed from each tube and placed 
in a well of a 96 well plate. Absorbance at 750nm was measured in a plate reader 
(Emax model, Alpha laboratories, Hampshire, England). Phospholipid content in the 
cell extract was calculated from a standard curve.
The mass levels of phosphatidate and DRG could then be standardised with 
reference to nmoles phospholipid in the cell lipid extract.
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Figure 3.2 Standard curve of conversion of s/i-l-stearoyl-2-arachidonyl- 
glycerol to phosphatidate
The result presented is a typical standard curve generated for conversion of 25-500 
pmole sn-1-stearoy 1-2-arachidonylglycerol to phosphatidate. The determination was 
performed in triplicate and values are expressed as means ± SE. The 
[32P]phosphatidate was identified by autoradiography and silica corresponding to 
phosphatidate scraped and counted by liquid scintillation counting.
3.2.10 Statistics
Student's unpaired t-test was used to compare results for the untransformed 
and transformed fibroblast cells and analysis of variance (ANOVA) was used to 
compare differences between the colon epithelial cells. "Staview 512+" statistical 
package for the Apple Macintosh system was used.
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3.3 Results
3.3.1 Activity of Phosphatidate Phosphohydrolase in Fibroblast and Epithelial Cells
The activity of PAP1 and PAP2 in control fibroblasts (NIH 3T3 I and II) and 
the ras transformed varients from these lines (KMSVI, HT3I and Ki 858II) as well as 
the colon cancer epithelial cell lines with (DLD-1 and LoVo) and without (HT 29 and 
Colo 320DM) a Ki-ras mutation, is shown in Table 3.2 and in Figures 3.3 and 3.4. 
The ras transformed cells HT3I and KMSVI have significantly higher PAP1 activity 
(p<0.0001 and p<0.02, respectively) than the parental line NIH 3T3 I. Similarly, Ki 
858II has significantly higher (p<0.0018) activity than its parental line NIH 3T3II 
(Figure 3.3A). The two parental cell lines had similar PAP1 activities. In contrast, the 
specific activity of PAP1 was significantly lower (p<0.0001) in the colon epithelial 
cell lines with the Ki-ras mutation (LoVo and DLD-1) compared to those without this 
mutation (Figure 3.4A). Activity of this enzyme was similar in the two cell lines with 
a Ki-ras mutation, but for the two lines with wild type Ki-ras, Colo 320DM had 
significantly higher PAP1 activity than HT 29 (p<0.0001).
Overall there was a decrease by approximately 2-fold in the specific activity 
of PAP2 in the ras transformed fibroblast cells. HT3I had a significant 2.1 fold 
decrease (P<0.005) in PAP2 activity, and KMSVI, a 2.4 fold decrease (p<0.004) in 
activity compared to control cells. The Ki 858II cell line had a significant 2.5 fold 
decrease (p<0.018) in PAP2 activity compared to NIH 3T3 II cells (Figure 3.3B). The 
activity of PAP2 was similar in the two parental cell lines. Specific activity of PAP2 
was significantly lower (p<0.0001) in the colon epithelial cell lines with a Ki-ras 
mutation compared to those without this mutation (Figure 3.4B).
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nmoles DRG formed / 
min / mg protein
pmoles lipid / nmole 
phospholipid
CELL LINE ras
mutation
status
PAP1 PAP2 phosphati­
date
DRG
NIH 3T3 I - 1.7 ± 0.1 3.5 ± 0.2 4.7 ± 0.3 1.8 ± 0.2
HT3 I + 6.4 ± 0.2 1.7 ± 0.0 23.0 ± 2.0 6.3 ± 0.1
KMSVI + 2.9 ± 0.3 1.4 ± 0.1 23.4 ±0.9 6.9 ± 0.5
NIH 3T3 II - 1.4 ± 0.1 3.2 ± 0.1 4.5 ± 0.7 1.7 ± 0.2
Ki 858 II + 2.5 ± 0.0 1.3 ± 0.1 27.1 ±0.9 4.6 ± 0.2
HT 29 - 3.4 ± 0.2 3.6 ± 0.2 5.4 ± 0.6 3.4 ± 0.4
Colo 320DM - 6.7 ± 0.3 3.3 ± 0.2 5.4 ± 0.4 3.7 ± 0.5
DLD-1 + 2.1 ± 0.2 1.9 ± 0.1 33.9 ±1.1 10.5 ±0.6
LoVo + 2.2 ± 0.2 2.0 ± 0.1 75.7 ± 3.5 16.4 ± 0.5
Table 3.2 Specific activities of PAP1 and PAP2 and mass levels of
diradylglycerol and phosphatidate in control and ras transformed 
fibroblasts and in human colon epithelial cells
The results for the PAP activities in all cell lines were calculated as specific activities 
relative to protein for each experiment. The mass levels of lipids were measured 
relative to total phospholipid. Results are means ± SE for three independent 
experiments performed in triplicate.
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Figure 3.3 Specific activities of PAP1 and PAP2 in control CD and ras 
transformed (p) fibroblast cells
The results are those from Table 3.2 but the graph shows the mean values from 
triplicate determinations of each of 3 independent observations. The overall mean is 
indicated by a bar.
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Figure 3.4 Specific activities of PAP1 and PAP2 in colon cancer epithelial cell 
lines without CD and with (p) Ki-ras mutations
The results are those from Table 3.2 but the graph shows the mean value from 
triplicate determinations of each of 3 independent observations. The overall mean is 
indicated by a bar.
3.3.2 Phosphatidate and DRG Mass Levels in Fibroblast and Epithelial Cells
Total phosphatidate and DRG mass levels in the cell lines is shown in Table
3.2 and Figures 3.5 and 3.6. In HT3I and KMSVI ras transformed cells, 
phosphatidate mass was significantly higher by about 4.8-fold compared to the NIH 
3T3 I fibroblast line (P<0.003 and p<0.0001, respectively). Similarly, Ki 858II had a 
significantly higher phosphatidate mass, by 6-fold (p<0.001), compared to NIH 3T3II 
(Figure 3.5A). DRG mass was also found to be higher in the ras transformed cells 
compared to the parental lines although the increase was not as marked as for 
phosphatidate (Figure 3.5B). HT3I had a 3.5-fold higher DRG mass than NIH 3T3 I 
(P<0.0004), KMSVI had a 3.9-fold increase (p<0.0023) and Ki 858II also had a 
significantly higher DRG mass by 2.8-fold (p<0.0023) than NIH 3T3 II cells.
The colon lines with mutant ras also had a much higher phosphatidate mass 
(p<0.0001) than those without the mutation (Figure 3.6A). Whilst phosphatidate mass 
was similar in the two colon lines with wild type ras, LoVo had significantly higher 
(p<0.0001) phosphatidate mass compared to DLD-1. DRG mass was also higher in 
the two epithelial cell lines with a Ki-ras mutation (p<0.0001) compared to those 
without (Figure 3.6B). Again, there was no significant variation in DRG mass 
between HT 29 and Colo 320DM, however, DRG mass was significantly higher 
(p<0.0001) in LoVo than DLD-1.
3.3.3 Relative Changes in Phosphatidate and DRG Mass
The ratio of total DRG relative to total phosphatidate within the cells is shown 
in Figures 3.7 and 3.8. This was calculated by dividing the mean mass of DRG by the 
mean phosphatidate mass from each experiment. The ratio of DRG to phosphatidate 
was significantly lower in the ras transformed fibroblasts compared to their parental 
lines (pcO.OOOl) (Figure 3.7). Also, in the epithelial cells there was a significant
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Figure 3.5 Second messenger mass levels in control CO and ras transformed 
(O) fibroblast cells
The results are those from Table 3.2 but the graph shows the mean value from 
triplicate determinations of three independent observations. The overall mean is 
indicated by a bar.
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Figure 3.6 Second messenger mass levels in colon cancer epithelial cell lines 
without <P) and with Ki-ros 0 ) mutations
The results are those from Table 3.2 but the graph shows the mean value from 
triplicate determinations of the three independent observations. The overall mean is 
indicated by a bar.
Figure 3.7 Mass of diradylglycerol relative to phosphatidate in control $1) 
and ras transformed (3) fibroblast cells
The results are the mean ± SE of three independent experiments. For each experiment 
the mean diradylglycerol mass was divided by the mean phosphatidate mass.
decreased level of DRG relative to phosphatidate (p<0.0001) in the cells with the Ki­
ras mutation (Figure 3.8).
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Figure 3.8 Mass of diradylglycerol relative to phosphatidate in colon cancer 
epithelial cell lines without 0*3) and with 0) Ki-rcs mutations
The results are the mean ± SE of three independent experiments. For each experiment 
the mean diradylglycerol mass was divided by the mean phosphatidate mass.
3.4 Discussion
PAP1 and PAP2 activities and second messenger levels were measured in two 
cell model systems. The specific activity of PAP1 was shown to be higher in ras 
transformed fibroblast cells whereas PAP2 activity was lower in these cells. Total 
levels of both the second messengers, phosphatidate and DRG, were higher in the 
transformed cells. However, the increase in phosphatidate mass was greater than that 
of DRG such that the ratio of DRG:phosphatidate was lower in the ras transformed 
cell lines. In contrast, both PAP1 and PAP2 activities were lower in the colon 
epithelial cell lines which contained a Ki -ras mutation than in those with wild type 
Ki-ras. Again, both phosphatidate and DRG mass levels were higher. As for the 
fibroblasts cells, the ratio of DRG:phosphatidate was lower in the lines containing a 
mutation in the Ki-ras gene.
Transformation of fibroblasts by mutant ras oncogene results in cells that 
show increased rates of proliferation, are able to form colonies in agar and produce 
tumours when injected into mice. Furthermore, the transformed cells do not show 
increased rates of proliferation in the presence of growth factors (Parries et a l , 1987). 
Since a number of growth factors are known to activate ras, substitution of ras with a 
mutant form that remains in the active state is thought to circumvent the requirement 
for growth factor activation. Consistent with the increased proliferation rates is the 
observation that the levels of the important second messenger, DRG, is increased in 
ras transformed fibroblasts (Perry et a l , 1992; Wolfman & Macara, 1987). All three 
ras transformed fibroblasts used in this study showed increased rates of proliferation 
(Table 3.1) and increased levels of DRG (Table 3.2). The two major sources of DRG 
in mitogen stimulated cells are from the breakdown of phosphatidylinositol 4,5- 
bisphosphate by PLC and from the breakdown of PC either by a PC-specific PLC or 
by a combined action of PLD and PAP (Cook & Wakelam, 1992). Since there is 
evidence to suggest that PC is the main source of the sustained levels of DRG 
observed in cells stimulated with certain mitogens (Cook & Wakelam, 1991a; Cook
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& Wakelam, 1991b) as well as the source of DRG in transformed fibroblasts (Lacal et 
a l , 1987), it was proposed that the activity of PLD and/or PAP might be increased.
All three ras transformed fibroblast cell lines had increased levels of PAP1 
activity (Table 3.2). However, this form of the enzyme is found in the cytosol and is 
thought to translocate to the endoplasmic reticulum where it becomes activated 
(Brindley, 1987). The main function of PAP1 is considered to be glycerolipid 
synthesis rather than as an intermediate in signal transduction. In contrast, activity of 
PAP2 was significantly decreased (p<0.004) in the transformed cell lines (Table 3.2). 
This form of PAP is thought to be involved in signal transduction and, certainly, its 
location in the plasma membrane, the source of PC, would support this role (Billah & 
Anthes, 1990). Although this result was unexpected, the results confirm a recent 
observation that PAP2 activity is decreased in Rati fibroblasts transformed with Ha­
ras (Martin et a l , 1993). They did not determine the steady state levels of DRG but 
did show an increased rate of formation of both phosphatidate and DRG from cellular 
lipids labelled with myristate. This would also exclude the possibility that elevated 
levels of DRG result from an increased breakdown of PC by a PC-specific PLC, 
although it has been reported that ras can activate such an enzyme (Diaz-Laviada et 
a l , 1990). DRG can also be derived from PC by the activity of PLD and PAP. 
Decreased activity of PAP would suggest that this is not the main pathway for 
generation of DRG. However, the level of phosphatidate, the intermediate in the 
PLD/PAP coupled reaction, is increased in the ras transformed fibroblasts. Although 
PLD activity was not measured in this study, previous work has suggested that 
activity of this enzyme is not increased in ras transformed cells (Fu et a l , 1992; 
Huang & Cabot, 1992). In addition, work using an anti-ras antibody has shown that 
ras is downstream from the phospholipases in 3T3 cells and it might be expected that 
an alteration in the ras gene would not effect enzymes such as PLD and possibly PAP 
(Yu et a l , 1988). An alternative explanation is that DRG is derived from another 
pathway. For example, some reports have suggested that ras causes an elevation of 
phosphatidylinositol 4,5-bisphosphate breakdown (Fleischman et a l , 1986; Hancock
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et al., 1988) leading to increased DRG levels. Phosphatidate may be generated in the 
transformed cells from an increased activity of DRG kinase which phosphorylates 
DRG to produce phosphatidate (Kanoh et a l , 1990).
Both phosphatidate and DRG may be important second messengers and it is 
unknown which has the predominant effect in transformed cells. It is possible that 
phosphatidate is the more important messenger and that the decreased PAP2 activity 
allows only a slow removal of phosphatidate. Furthermore, as the ratio of DRG to 
phosphatidate was found to be lower in the ras transformed cells, this would support 
the idea that phosphatidate is the more important second messenger. Certainly, in 
growth factor stimulated cells this would appear to be the case. It has been shown that 
the mitogenic response of 3T3 cells stimulated by PDGF correlates with the 
production of phosphatidate rather than DRG (Fukami & Takenawa, 1992). 
Phosphatidate has been shown to evoke various cellular responses and although the 
exact cellular functions are unclear, it may be involved in linking growth factor 
receptor signalling to Ras. Evidence for this comes from the ability of phosphatidate 
to increase the activity of the ras GTPase-inhibiting protein (Tsai et a l, 1990) and to 
inhibit the activity of ras GTPase-activating protein (GAP) (Tsai et a l, 1989), the 
effects of which would maintain Ras in its active GTP-bound form. As this lipid can 
also activate protein kinase C Z> in vitro (Berra et a l, 1993) and has several mitogenic 
effects such as increase in arachidonic acid (Murayama & Ui, 1987), phosphatidate 
may indeed play an important role in cell signalling.
Unlike PAP2, PAP1 activity was increased in the ras transformed fibroblasts. 
Although the activity of this enzyme was increased, it does not appear to be removing 
phosphatidate. As the ras transformed fibroblasts have an increased rate of 
proliferation compared to the control cells, these have a requirement for a higher rate 
of synthesis of membrane lipids. The increase in PAP1 activity could account for its 
involvement in this process. This increase in activity could also account, at least in 
part, for the observed increase in DRG levels found in the ras transformed cells. 
Interestingly, PAP1 activity was higher in the fibroblasts transformed with Ha-ras
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compared to Ki-ras. As the Ha-ras transformed cells also have a higher rate of 
proliferation, this would seem to corroborate the idea that PAP1 is involved in 
increased membrane synthesis in these cells.
One of the main differences between the two cell models used in this study 
was in the activity of PAP1. In the colon epithelial cell lines which contained the ras 
mutation, PAP1 activity was decreased. This suggests that the ras mutation itself does 
not alter PAP1 activity. Unlike the fibroblast cells, there is no difference in doubling 
time between these four colon lines and other genetic alterations which are probably 
present in these cells, such as a src mutation, may effect cell turnover rate. PAP2 
activity was lower in the colon lines with mutant ras which was consistent with the 
findings in the ras transformed fibroblasts cells. Likewise, similar results were 
observed with regards the levels of phosphatidate and DRG, in that presence of 
oncogenic ras was associated with an increased level of both second messengers. 
Although the results between the two cell models compared well, other mutations 
may also have been present in the epithelial cells and it cannot definitely be 
concluded that ras was responsible for the observed changes. It could also be argued 
that as the pairs of colon lines were grown in different media, this may have had an 
effect on signalling in these cells. However, no evidence has yet been presented that 
media has an effect on cell signalling. It is probably more likely that the serum, which 
contains the essential growth factors and fatty acids required to sustain growth of the 
cells, is the important component of the growth medium. As the same serum was used 
for all cell lines and the results were similar in the two cell models, then this would 
suggest that any changes are not due to the fact that different media was used.
The results presented would appear to argue against a role for the PLD/PAP 
pathway in the formation of increased DRG. It is not certain from this study the exact 
source of DRG in these cells. Other studies have compared DRG and PKC levels in 
colon tumours and compared with normal colon tissue. Both were found to be 
decreased in colon tumour tissue (Guillem et a l , 1987b; Phan et al., 1991) which is in 
contrast to what was observed in the ras transformed fibroblast cell model. Although
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signalling was also studied in colon tumour derived cell lines, there was not a ’normal' 
control and, hence, the previously reported colon tumour data cannot be directly 
compared with these results. However, in the colon tumour cells, mutant ras appeared 
to be having a similar effect on second messengers as in the fibroblast model.
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CHAPTER 4
ACTIVITY OF PHOSPHATIDATE PHOSPHOHYDROLASE AND MASS 
MEASUREMENT OF PHOSPHATIDATE AND DIRADYLGLYCEROL
SECOND MESSENGERS IN HUMAN COLORECTAL CANCER
4.1 Introduction
Protein kinase C is thought to play a central role in signal transduction since it 
is involved in the control of both proliferation and differentiation (Clemenses al., 
1992). As a result there has been much interest in the use of PKC as a target for anti­
tumour drug development (Gescher & Dale, 1989). However, there are multiple 
isoforms of PKC which show differential tissue distribution and are involved in 
diverse signalling pathways (Dekker & Parker, 1994). Furthermore, it has been 
proposed that certain isoforms may play a role as tumour suppressors. Overexpression 
of PKCa or PKCpl in rodent fibroblasts has been shown to stimulate cell 
proliferation (Borner et al., 1992; Finkenzeller et a l ,  1992). In contrast, 
overexpression of PKCJ31 in the human colon carcinoma cell line HT29 results in 
decreased rates of proliferation and decreased tumourigenicity in nude mice (Choi et 
al., 1990).
PKC activity has been shown to be decreased in human colon tumours when 
compared with the activity present in adjacent normal colon (Guillem et al., 1987a; 
Kopp et a l, 1991). Furthermore, PKC activity was shown to be lower in the normal 
colon of patients with colon tumours than in the colon of patients without cancer 
(Sakanoue et a l, 1991). Decreased activity of PKC was also detected in benign 
adenomas (Guillem et a l, 1987a). Weinstein and coworkers have suggested that this 
may indicate a role for PKC in the origin and growth of colon cancer (Weinstein, 
1990; Weinstein, 1992). Whereas a mutation in Ki-ras is observed in about 50% of 
colon tumours, nearly all tumours studied had decreased activities of PKC (Guillem et
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a l,  1987a; Guillem et a l, 1987b). Clearly, if PKC acts as a tumour suppressor then 
activators rather than inhibitors of PKC could have a role as chemotherapeutic agents.
Levels of the main physiological activator of PKC, DRG, have also been 
shown to be decreased in human colon tumours (Phan et a l, 1991; Sauter et a l,  
1990). During growth factor stimulation of cell proliferation, the two main sources of 
DRG are thought to be from the breakdown of phosphatidylinositol 4,5-bisphosphate 
by PLC and from the breakdown of PC by the combined activities PLD and PAP 
(Billah & Anthes, 1990; Wakelam et a l, 1991). Reduced activity of the enzymes 
involved in one or both of these pathways would result in reduced rates of production 
of DRG. A recent study has reported that expression of PLCy is increased in human 
colon tumours (Noh et a l , 1994). It is not known if this increased expression is 
associated with increased activity of PLCy. Nothing is known about the expression or 
activity of PLD or PAP in human colon tumours. However, in the previous chapter, 
PAP activity was shown to be decreased in ras transformed fibroblasts and in human 
colon carcinoma cell lines that express a mutant ras oncogene. This suggested that 
transformation is associated with reduced activity of PAP. Whilst this observation 
could be used to support the hypothesis that DRG levels are reduced in the human 
colon tumours due to decreased activity of PAP, it should be noted that the ras 
transformed fibroblasts had increased levels of DRG.
PAP activity was, therefore, determined in human colon cancers and in 
adjacent pathologically normal colon. There are a number of problems associated 
with such a study since neither tissue represents a homogenous cell population. The 
tumour tissue will contain some normal colonic epithelium as well as a proportion of 
inflammatory cells and connective tissue. The epithelial lining of normal colonic 
mucosa consists of a sheet of single-cell thickness organised into tubular 
invaginations or crypts with surface epithelium between the crypt orifices. The 
proliferative region of the large intestine occupies approximately the basal two-thirds 
of the crypts (Hamilton et a l , 1994). Cells migrate towards the surface of the colonic 
crypts and are extruded from the mucosal surface. This cell loss is thought to be
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caused by induction of apoptosis. Clearly, the process of proliferation and maturation 
is under tight control and regulated by the expression of specific signal transduction 
pathways. For instance, in the rat intestine immunofluorescence and western blot 
analysis has revealed that PKC a, (311, 5, e and £ are expressed in all intestinal 
epithelial cells in situ and exhibit distinct subcellular distribution patterns along the 
crypt-villus unit. Dramatic changes in membrane association and level of expression 
of these isoforms occur as the cells ceased division in the mid crypt region and begin 
differentiation (Black & Saxon, 1994). Signalling events such as increased levels of 
Ca2+ and modulation of PKC have been implicated in the apoptotic procedure (Dive 
et a l , 1992; Martin et a l , 1994) and these must be regulated in some way, although 
the biochemical events surrounding this are unknown. Perhaps altered PKC isoform 
expression in mature cells activate signal transduction pathways leading to 
transcription of genes which regulate programmed cell death (Martin et a l ,  1994). 
Thus, the normal colonic mucosa is composed of cells at different stages of 
maturation and at each stage it is probable that the activity of various signalling 
pathways will differ.
Most colorectal cancers develop from adenomas derived from normal colonic 
epithelium lining the intestine. Adenomas contain a high proportion of replicating 
cells found all along the crypt column and even at the luminal surface of the gut 
(Friedman^ al., 1981). As a tumour progresses through the adenoma-carcinoma 
sequence of events (Fearon & Jones, 1992), it invades underlying layers of tissue and 
can be staged according to how far it has penetrated the bowel wall and nodal status 
of the tumour. One of most commonly used staging systems is the Astler-Coller 
modification of the original Duke’s system (Astler & Coller, 1954). For example, a 
Stage A tumour involves the submucosa layer only, it is a small benign tubular type 
of adenoma or polyp which can increase in size and become more villous. This stage, 
Stage B, penetrates underlying layers of the bowel, is more aggressive and can 
contain patches of carcinoma tissue. These patches may grow out to form the third 
stage, Stage C, which is an invasive carcinoma typically with the development of
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pericolic or perirectal nodes. In the case of a Stage D tumour, distant metastases are 
present. Tumours normally remain undetected until the later stages of development. 
The relationship between biochemical events in signal transduction and invasivness 
of a tumour has not been reported.
A total of 35 colon tumours were studied. The tumours were obtained from 
various sites along the length of the colon and ranged from Stage A to Stage D. 
Normal colon was defined as macroscopically normal colon as judged by a 
pathologist. Activities of PAP1 and PAP2 were determined in all samples. Levels of 
the substrate and product of PAP activity, phosphatidate and DRG respectively, were 
also determined in 14 of the samples. These 14 were selected on the basis of tissue 
availability and included tumours with a range of activities of PAP.
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4.2 Materials and Methods
4.2.1 Preparation of Human Colon Tissue for Analysis
Surgically resected colorectal tumours were obtained from the Western 
Infirmary, Glasgow. Immediately following resection, the specimen was opened 
longitudinally along the antimesenteric border and rinsed thoroughly with saline 
solution to remove blood clot and debris. Samples of tumour tissue were taken, 
avoiding obvious areas of necrosis, rinsed again in ice-cold saline solution, placed in 
plastic sealed tubes and immediately frozen in liquid nitrogen. In addition, samples of 
macroscopically normal mucosa were taken as close to the resection margin as 
possible and treated in the same way. All samples were frozen within 10-15min of 
tumour resection and stored at -70°C until analysis. Detailed information on each 
patient including tumour site, histology and Duke's staging (Astler-Coller) were 
obtained.
Samples were prepared for analysis by firstly grinding the frozen tissue into 
small pieces using a pestle and mortar. The tissue, still frozen, was then ground to a 
fine powder using a Microdismembrator (Braun Ltd., Buckinghamshire). The 
powdered tissue was kept at -70°C until use. For measurement of enzyme activity, the 
tissue was hand homogenised in 3 volumes of ice-cold Tris buffer (20mM, adjusted to 
pH 6.5 with maleate) containing di-sodium phosphate (5mM), DTT (ImM), NaCl 
(140mM) and leupeptin (lpg/ml) at 4°C. This was divided into aliquots which could 
be stored at -70°C. Protein was determined as previously described (Section 2.2.4).
4.2.2 Estimation of PAP Activity in Colon Tissue
PAP1 and PAP2 activity was measured using the method of Jamal and co­
workers (Jamaica al, 1991) as described previously (Section 2.2.5). PAP1 and PAP2 
activities were determined in triplicate and at three concentrations of protein (10, 20
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and 30pg/assay). Values are expressed as nmoles DRG formed / min /  mg protein. 
The standard error of the triplicate samples was always less than 5%. Data was 
analysed using a Student's paired T-test of the Statview 512+ system for the Apple 
Macintosh.
4.2.3 Measurement of Phosphatidate and DRG Mass
A lipid extraction was carried out on about 500mg of the powdered tissue 
essentially using the method of Bligh and Dyer (Bligh & Dyer, 1959). The tissue was 
hand homogenised in 500pl methanol per lOOmg tissue and chloroform, 250pl per 
lOOmg tissue, was added. The tissue was allowed to extract for 15min. A volume of 
water equal to that of the chloroform was added to the extracted tissue samples and 
vortexed thoroughly. Samples were then centrifuged at 250 x g in a benchtop 
centrifuge (Model CR411, Deva Medical Electronics, Runcorn, Cheshire) for lOmin 
to separate the phases. The upper phase was discarded and a further 250pi chloroform 
and 250pl water were added and the mixture vortexed and centrifuged as before. The 
lower phase was divided into aliquots of 200pi, 400pl and 50pl for analysis of DRG, 
phosphatidate and total phospholipid respectively. The aliquots were dried under 
nitrogen and stored at -70°C.
All samples were analysed for the second messengers within three days of 
lipid extraction. Total phospholipid was measured as in section 3.2.9 and all results of 
DRG and phosphatidate mass were expressed per nmole phospholipid. Phosphatidate 
was measured as before (section 3.2.7) in triplicate measurements where sufficient 
tissue was available. Each replicate was analysed on a separate t.l.c. plate and the 
results presented as means ± SE. DRG mass was also measured essentially as 
described earlier (Section 3.2.8). The lipid extract aliquot for this assay (200pl) was 
split into 2 x 50pl, 2 x lOpl and 2 x 2pi aliquots and the mass from these was always 
within the range of the standard curve (25-500 pmoles s/z-l-stearoyl-2-arachidonyl- 
glycerol). Phosphatidate and DRG mass measurements were carried out on 14
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patients out of the 35 patient samples. Results were analysed as described in section 
4.2.2.
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4.3 Results
4.3.1 Characterisation of PAP1 and PAP2 in Colon Samples
A total of 35 colorectal carcinomas and paired normal mucosa samples were 
assayed for PAP1 and PAP2 activities. Clinical pathology reports on the tumour 
tissue of the 35 patients is given in Table 4.1.
PAP1 and PAP2 activities were characterised in human tissue to determine 
whether the human enzyme could be measured under similar conditions to those used 
for the rat liver enzymes. The reaction rates for both forms of the enzyme were 
proportional to the protein concentration up to 50pg and time up to 60min (Figure 
4.1). Hence, the majority of experiments were carried out using concentrations of 
protein from the linear portion of the curve for a reaction time of 60min.
Figure 4.2 shows that PAP1 activity has an absolute requirement for Mg2+ 
with optimum activity reached at around 3mM Mg2+. Presence of Mg2+ made no 
difference to the activity of PAP2. As with the rat liver enzymes, PAP1 activity was 
found to be sensitive to NEM (Figure 4.2) whereas the PAP2 signalling enzyme is 
insensitive to this reagent.
When Triton X-100 was present for the measurement of PAP2, there was a 
substantial increase in the activity of this enzyme (Figure 4.3) with optimum activity 
achieved at about 0.5% Triton X-100 in the assay. This is equivalent to 8mM used in 
the past to measure the rat liver enzyme. The addition of this detergent to the assay 
for PAP1 inhibited the activity of this enzyme at concentrations where PAP2 activity 
was stimulated.
4.3.2 PAP Activity in Human Colon Tumour and Adjacent Normal Mucosa
There was a wide range of activities of both PAP1 (0.1 - 2.3) and PAP2 (0.3 - 
4.6) in the normal colon samples (Figure 4.4). Similarly, a wide range of both PAP1
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Patient Age (Yr) Sex
(M/F)
Duke's
Staging
Location
1 62 F A rectal adenocarcinoma
2 85 F A rectal adenocarcinoma
3 35 F A rectosigmoid carcinoma
4 85 F A rectal adenocarcinoma
5 87 M Bi sigmoid carcinoma
6 71 M Bi rectal adenocarcinoma
7 63 M B2 rectal adenocarcinoma
8 75 M b2 adenocarcinoma
9 79 M b 2 adenocarcinoma
10 75 M b 2 adenocarcinoma
11 77 M b 2 rectal carcinoma
12 75 M b2 adenocarcinoma
13 93 F Ci rectosigmoid carcinoma
14 67 F Cl sigmoid carcinoma
15 58 M Cl adenocarcinoma
16 60 M Cl adenocarcinoma
17 52 M Cl adenocarcinoma
18 74 M Cl caecal carcinoma
19 58 F c2 caecal carcinoma
20 49 M c2 rectosigmoid carcinoma
21 46 M c2 rectal carcinoma
22 75 F c2 ascending colon
23 54 M c2 caecal carcinoma
24 51 F C2 caecal carcinoma
25 83 F C2 caecal carcinoma
26 69 M C2 rectal carcinoma
27 68 M C2 ascending colon
28 70 M C2 rectal carcinoma
29 60 M C2 rectal carcinoma
30 64 F C2 rectal carcinoma
31 65 F D ascending colon
32 56 F D sigmoid carcinoma
33 83 M D caecal carcinoma
34 71 M D caecal carcinoma
35 79 M D rectosigmoid carcinoma
Table 4.1 Clinical pathology of individual colon samples
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Figure 4.1 Effect of enzyme concentration and incubation time on PAP1 and 
PAP2 activities in colon tissue
DRG production was measured with various concentrations of normal human colon 
tissue as a source of PAP1 (O) and PAP2 (•) (A). DRG production was also 
determined after incubation of samples (20pg) for various times (B). Each point is a 
mean ± SE of triplicate determinations and is representative of two experiments 
showing similar results.
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Figure 4.2 Effect of Mg2+ and NEM on PAP1 and PAP2 enzyme activities 
in normal colon tissue
PAP activity was measured in the presence of increasing concentrations of Mg2+ as 
indicated either in the presence (closed symbols) or absence (open symbols) of 
4.2mM NEM. Normal human colon tissue was used as a source of the enzyme (20pg) 
for measuring PAP1 (O, • )  and PAP2 (□, ■) activities. Each point is a mean ± SE of 
triplicate determinations and is representative of two independent observations 
showing similar results.
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Figure 4.3 Effect of Triton X-100 on PAP1 and PAP2 enzyme activities in 
normal colon tissue
PAP activity was measured in the presence of increasing concentrations of Triton X- 
100 as indicated. PAP1 (O) and PAP2 (•) activities were measured in normal human 
colon tissue using 20pg protein in the assay. Each point is a mean ± SE of triplicate 
determinations and is representative of two independent observations showing similar 
results.
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(0.2 - 4.4) and PAP2 (0.7 - 11.1) activities were observed in the colon tumours. The 
activities of PAP1 and PAP2 were higher in the colon tumour tissue than in the 
adjacent normal mucosa in the majority of the 35 paired samples (Figure 4.4). The 
mean activity of PAP1 in the tumour tissue (1.6± 0.2 nmoles DRG formed /min /mg 
protein) was significantly higher (2.3 fold, p<0.0001) than that in the normal mucosa 
(0.7±0.1 nmoles DRG formed /min /mg protein). Likewise, the mean activity of PAP2 
in the tumour tissue (3.9±0.4 nmoles DRG formed /min /mg protein) was significantly 
higher (1.8 fold, p<0.0001) than that in the normal mucosa (2.2±0.2 nmoles DRG 
formed /min /mg protein). PAP activity was never lower in the tumour than in the 
normal colon. However, patients 15,18, 28, and 32 had similar activities of PAP2 in 
normal and tumour tissue and patients 15 and 24 had similar activities of PAP1 in 
normal and tumour tissues. There was no correlation between PAP1 and PAP2 
activities and either sex, age, Duke's Staging or location of tumour.
4.3.3 Phosphatidate and DRG Mass in Colon Samples
Mass levels of phosphatidate and DRG were measured in the majority of the 
patients. However, there was not sufficient tissue to measure phosphatidate mass in 
patient 12. There was a wide range of DRG mass in both normal colon (1.2 - 10.2) 
and in colon tumours (0.8 to 7.0) (Figure 4.5). A smaller range of levels of 
phosphatidate mass was observed in both normal colon (1.2 - 5.5) and in colon 
tumours (0.8 - 4.0) (Figure 4.6). In general, DRG mass was about twice that of 
phosphatidate mass.
Both second messengers were lower in the tumour tissue than in adjacent 
normal (Figures 4.5 and 4.6). The mean DRG mass in the tumour tissue (3.2±0.6 
pmoles DRG /nmole phospholipid) was significantly lower (1.6 fold, p<0.0005) than 
that in the normal colon (5.0+0.8 pmoles DRG/nmole phospholipid). Only 1 patient 
(27) had a higher DRG mass in the tumour than in the normal colon. Phosphatidate 
mass in colon tumour tissue (2.5±0.3 pmoles phosphatidate/nmole phospholipid) was
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Figure 4.5 Diradylglycerol mass in paired human colon and colon tumour
DRG mass was measured in paired colon tumour 03) and normal 03) colon from 
fourteen patients. Conversion of DRG to [32P]phosphatidate was measured in sample 
lipid extracts and the results compared to a standard curve of s/i-l-stearoyl-2- 
arachidonylglycerol. Determinatons were performed in triplicate and the values 
expressed as a mean ± SE per nmole phospholipid. Asterisks represent statistically 
significant differences (Student's nest; * p<0.02, ** p<0.01, ***p<0.001).
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Figure 4.6 Phosphatidate mass in paired human colon and colon tumour
Phosphatidate mass was measured using thin-layer chromatography in paired colon 
tumour (E3) and normal (□) tissue from thirteen patients. Determinatons were 
performed in triplicate and the values expressed as a mean ± SE per nmole total 
phospholipid. Asterisks represent statistically significant differences (Student's t test;
* p<0.02, ** p<0.01, ***p<0.001).
also significantly lower (1.5 fold, p<0.0001) than in adjacent normal mucosa (3.8+0.3 
pmoles phosphatidate/nmole phospholipid). The ratio of levels of the product of PAP 
activity (DRG mass) to that of the substrate (phosphatidate mass) was similar in the 
colon tumours and in the normal colon (Figure 4.7).
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Figure 4.7 Mass of DRG relative to phosphatidate in paired human colon 
and colon tumour
The mean DRG mass for each patient has been divided by the mean phosphatidate 
mass. The overall mean for the normal and tumour tissues is represented in each case 
by a small bar.
4.4 Discussion
PAP activity was determined in 35 human colon tumours and in the adjacent 
normal colonic mucosa. The activities of human PAP1 and PAP2 were characterised 
and shown to have similar properties to those of the rat liver enzymes. A wide range 
of activities of both PAP1 and PAP2 were observed in the normal colonic mucosa. 
Furthermore, activities of both forms of PAP were increased in the majority of the 
colon tumours. Levels of both the substrate and product of PAP activity, 
phosphatidate and DRG, were decreased in the majority of patients.
PAP activity has not previously been analysed in human tissue. Both an NEM 
sensitive and insensitive form were identified and these two activities showed similar 
sensitivities to Mg2+ (Figure 4.2) and Triton X-100 (Figure 4.3) as observed for the 
rat liver activities (Chapter 2, Figures 2.3 and 2.5). PAP1 and PAP2 activities have 
now been measured in human, rat and mouse tissues. These enzymes were active 
under the same assay conditions and displayed similar properties, such as in their 
sensitivity to NEM. This suggests that these enzymes are highly conserved in 
mammals and may play important roles in their tissues. There is limited information 
available regarding measurement of PAP activity in other species, however, two 
forms of PAP have been purified from the yeast, Saccharomyces cerevisiae (Lin & 
Carman, 1989). As the mammalian forms have not been purified it is not possible to 
compare the degree of homology between yeast and animal forms. However, the 
conditions used to measure PAP activity in animal and yeast are similar (Jamal et a l , 
1991; Morlock et a l, 1991). For example, as with mammalian PAP1 activity, the 
cytosolic form of PAP from yeast is dependent on Mg2+ (Lin & Carman, 1989).
A wide range of activities of both PAP1 and PAP2 were found in the normal 
colon (Figure 4.4). This was not unexpected for an enzyme that is involved in 
glycerolipid synthesis such as PAP1, since the fat content of the diet can vary 
markedly. Evidence from epidemiological studies has, in fact, suggested that high fat 
diets increase the risk of colon cancer (Reddy et a l , 1992). It has been proposed that
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specific bacteria in the lumen can metabolise dietary lipid to DRG. This may then 
enter the intestinal epithelium and activate PKC, thus stimulating proliferation 
(Morotomi et a l , 1990). In fact, Friedman and coworkers have shown that DRG can 
enhance proliferation of colonic adenoma and carcinoma derived cells in culture 
(Freidman et a l, 1989). It appears that DRG, produced both intracellularly and 
extracellularly, can act both as a mitogen and second messenger in the colon. If the 
diet is the cause of increased risk of cancer, for example, by increasing the rate of 
proliferation of colon cells, then this may also effect the normal tissue of these 
patients. This may explain why PAP1 activity is so varied amongst different patients 
in both their normal and tumour tissues. It would be of interest to determine if there is 
such a variation in PAP activity in the colon of individuals without cancer.
Activity of PAP2 also varied markedly between patients. This form of the 
enzyme is commonly thought to be involved in signal transduction and the 
interpatient variability was, therefore, rather surprising. It is not known if such 
variability in activity would be observed in the normal colon since it is possible that 
the so-called normal mucosa of the cancer patients is abnormal. It has already been 
reported that PKC activity is decreased in the histologically normal colon of patients 
with colon cancer (Guillem et a l, 1987b). On the other hand, DRG levels were 
similar in the colon of patients without cancer and the normal colon of patients with 
cancer (Kopp et a l , 1991).
Both PKC activity and DRG levels have been reported to be decreased in 
colon tumours (Guillem et a l, 1987a; Phan et a l, 1991; Sauter et a l, 1990). Since 
PAP is involved in the formation of DRG from PC, it was proposed that the decrease 
in DRG mass could be due to a decreased activity of PAP. However, both PAP1 and 
PAP2 activities were significantly increased in colon tumours when compared with 
activities in adjacent normal colon (Figure 4.4). This was an unexpected finding and 
difficult to interpret. Not all signalling pathways lead to mitogenesis. It is possible 
that the PLD/PAP pathway is involved in other cellular functions such as motility or 
membrane trafficking. The observed increase in PAP activities may be due to an
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increase in synthesis of lipid membranes (PAP1) and membrane proteins (PAP2) 
which are processed through the golgi. For example, the function of the GTP binding 
protein, ARF, as a regulator of organelle structure and membrane traffick has recently 
been elucidated, although it is unknown how this protein is regulated (Donaldson & 
Klausner, 1994). ARF has been shown to activate PLD which suggests that this 
enzyme may be involved in membrane trafficking (Kahn et al, 1993).
Mutations in Ki-ras have been identified in a high proportion of colon 
tumours and this mutation has been implicated in the progression of the tumour 
(Fearon & Jones, 1992). However, PAP activity was shown to be decreased in 
fibroblasts transfected with a mutant Ki-ras oncogene (Chapter 3, Figure 3.3). 
Furthermore, the fibroblasts expressed increased levels of DRG whereas the levels of 
this lipid were decreased in colon tumours. There is an apparent discrepancy between 
the cell models of increased proliferation and the tumour tissues. This can be 
accounted for by one of several reasons. It is possible, for instance, that when cells are 
removed from their tissue environment and placed in culture conditions, that 
regulation of enymes and lipids in the cells is altered. This could mean that 
measurements made in the tissue is more representative of the physiological 
biochemical events. However, analysis of signalling in cell models represents a 
homogenous population of cells whereas observed changes in tissue samples is a 
measurement in a variety of cell types. If there is a decrease in enzyme activity within 
the epithelial cells of the tissue, this could be masked by the changes present in the 
tissue as a whole. It could also be argued that any changes in PAP activity or second 
messengers in tumours are nothing to do with the ras oncogene. Other genetic events, 
such as mutations in src, could also effect these.
The increased activity of PAP was very consistent in that only 4 of the 35 
patients had no significant increase in PAP2 activity in their tumours and only 2 of 
the 35 had no significant increase in PAP1 activity. Since PAP has not yet been 
purified it is not possible to quantify expression of PAP at the level of either 
transcription or translation. Clearly, increased activity could be the result of increased
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levels of the protein but it is also possible that the increase is due to the presence of a 
mutant form of PAP. PAP catalyses the conversion of phosphatidate to DRG and a 
change in PAP activity could alter the levels of these two lipids. Both phosphatidate 
and DRG have been shown to be mitogenic in vitro (Freidman et a l, 1989; van 
Corven et a l ,  1992). Total phosphatidate and DRG mass was estimated in a 
representative sample of the colon tumours. DRG mass was significantly decreased in 
13 of the 14 tumours studied (Figure 4.5) and this confirms previous reports (Phan et 
a l,  1991; Sauter et a l, 1990). In addition, phosphatidate mass was also shown to be 
decreased in 11 of the 13 tumours studied (Figure 4.6). Thus, the levels of these two 
lipids, which are thought to play a key role in mitogenic signal transduction (Billah & 
Anthes, 1990; Moolenaar et a l , 1986; van Corven et a l, 1992), are decreased in this 
rapidly proliferating tumour.
Measurement of the total mass of phosphatidate and DRG is potentially 
misleading. Both lipids are important components of cell membranes and are 
composed of a number of distinct molecular species (Divecha et a l, 1991; Pessin et 
al , 1990; Pettitt & Wakelam, 1993). The specificity of PAP for particular molecular 
species of phosphatidate is not known. It is possible that this enzyme is specific for a 
limited number of phosphatidate species and its activation may generate specific 
forms of DRG. These could be involved in, for example, activation of particular 
isoforms of PKC. Although phosphatidate could have been converted to another 
second messenger, lysophosphatidate, by phospholipase A activity (Moolenaar, 
1994), increased activities of both PAP1 and PAP2 could explain, at least in part, the 
decrease in phosphatidate mass. The decrease in DRG mass suggests that there is an 
increase in the metabolism of this lipid, probably by metabolising enzymes such as 
DRG lipase and kinase.
The observation of increased activity of PAP in colon tumours is novel but the 
importance of this change is unclear. Clearly, it does not explain the decreased levels 
of DRG but does indicates that signalling pathways are disrupted in this tumour type. 
Results are not consistent with effects of mutant ras on lipid signalling in fibroblasts
64
or with the human colon cancer cell lines. Whilst ras mutations are common in colon 
cancer, clearly this factor alone does not appear to account for the observed changes 
in cell signalling pathways.
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CHAPTER FIVE
COMPARISON OF PHOSPHATIDATE PHOSPHOHYDROLASE ACTIVITY 
AND Ki-ras MUTATIONS IN HUMAN COLORECTAL TUMOURS
5.1 Introduction
In Chapter 3, a clear increase in DRG and phosphatidate mass levels was
observed in ras transformed cells in culture. There was also a consistent decrease in
-   ' "
PAP2 activity which suggests that.a mutation in the ras oncogene may cause-down-
regulation of this enzyme. A decrease in PAP2 activity could account for the elevated
levels of phosphatidate, a lipid which may have an important role in the regulation of
proliferation in cells. Although similar changes were observed in colon tumour cell
lines that contain a mutant ras oncogene, this was not the case when colon tumour
tissue was compared with normal colon. In the tumour samples DRG and
phosphatidate were decreased and PAP1 and PAP2 activities were increased. This
could be explained by differences in regulation of the lipids and enzymes under cell
culture conditions when compared to the more physiological environment of the
tumour sample. However, it is also possible that the ras oncogene is not the only
important oncogene mutation present in colon cancer and that some other oncogene,
such as src, may be responsible for changes in PAP activities and lipid levels.
A previous study attempted to correlate changes in DRG mass levels in colon 
tumours with presence of a mutated ras oncogene (Phan et a l , 1991). They showed 
that DRG mass was decreased in tumour tissue compared to normal, regardless of the 
ras mutation status. However, these workers limited their study to mutations in codon 
12. Four out of 15 tumours contained a mutation which is a lower frequency than had 
previously been reported for colon tumours (Bos et al., 1987a; Vogelstein et a l, 
1988). Furthermore, the presence of a mutation was associated with some of the 
biggest changes in DRG levels (Phan et a l , 1991). It is possible, therefore, that if they
66
had also identified mutations at codon 13, they may have been able to relate changes 
in DRG to the presence of mutant ras. Clearly, this is not the same relationship as that 
observed in colon cancer cells in culture, but it is nonetheless of interest. Since there 
was a marked variation in the magnitude of the changes in PAP activity and levels of 
DRG and phosphatidate, an attempt was made to relate these changes to the presence 
of a ras mutation.
Different methods have been used in the past to detect point mutations in the 
ras genes. Originally, activation of the ras oncogene was detected by transfection of 
genomic DNA into NIH 3T3 mouse fibroblasts. These cells undergo malignant 
transformation when a mutated ras gene is incorporated into their genome. This 
method is too laborious for large scale screening. Furthermore, false negative results 
can arise due to the DNA from human tumours being degraded, either because of 
necrosis or due to degradation which can occur during surgery and subsequent 
handling of the samples.
Several highly sensitive methods are now available for measuring Ki-ras 
mutations. These include analysis of single stranded conformation polymorphism 
(Orita et al., 1989) or large deletions/insertions that disrupt or create recognition 
sequences of restriction enzymes can be detected by Southern blotting following 
digestion with appropriate enzymes (restriction fragment length polymorphism) 
(Sugimura et al., 1990). However, these methods cannot identify specific point 
mutations. An alternative method which was used in this study was developed by Bos 
and co-workers using direct hybridisation of oligonucleotides to amplified regions of 
DNA (Bos et a l , 1987b). Polymerase chain reaction (PCR) (Mullis & Faloona, 1987) 
was used for DNA amplification so that enough DNA can be generated to enhance 
greatly the signals obtained with these oligonucleotide hybridisations (Verlaan de 
Vries et a l , 1986). For this procedure, DNA is isolated from frozen or fresh tissue 
samples, and ras-specific sequences amplified by PCR are dotted onto hybridisation 
membranes. The hybridisation procedure involved hybridising a collection of 
oligonucleotides complementary to possible mutations in codons 12, 13 or 61 of the
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Ki-ras oncogene. Stringent washing along with strict temperature control were used 
to obtain fully matched hybrids. After stringent washing, only the completely 
matching oligonucleotides remain hybridized and give a signal on autoradiographs.
The structure of the human Ki-ras gene from a lung cell line has been 
determined (Shimizu et a l , 1983) and the regions containing codons 12, 13 and 61 
can be amplified (Figure 5.1) by choosing amplimers complementary to sequences at 
the 5' and (in opposite orientation) 3' ends of the region of interest. Codons 12 and 13 
are located on exon 1, whilst codon 61 is found in exon 2 and the !KA' and 'KB* 
amplimers flank these regions (Verlaan de Vries et a l , 1986). Identification of point 
mutations by this method is very sensitive since amplification of mutant alleles can be 
detected from a small number of cells (Ehlen & Dubeau, 1989). Therefore this 
method is perfectly suited for the analysis of mutational events in solid tumour 
samples which will contain both neoplastic and normal cells. The knowledge and 
expertise for use of these techniques are also available in the department.
PCR and hybridisation techniques have been employed in the present study 
for detection of Ki-ras mutations in codons 12,13 or 61 of colon tumour and normal 
tissue. Fourteen paired samples were chosen as these had been used in previous 
studies to measure PAP activity and second messenger levels. In this way, direct 
comparisons could be made between these and the presence of a mutation in ras.
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5.2 Methods
5.2.1 Chemicals and Reagents
DNA was extracted from tissue samples using the Nucleon I extraction kit 
from Scotlab (Paisley, Scotland). PCR was carried out using the Gene Amp PCR 
Reagent kit from Perkin Elmer (Buckinghamshire, England) which contained 
ArwpMTaq DNA polymerase. Synthetic amplimers were produced at the Beatson 
Institute, Glasgow using reagents from Cruachem (West of Scotland Science Park, 
Glasgow) and then deprotected at 55°C overnight and purified on an OPC cartridge 
(Cruachem) according to the manufacturers' instructions. Oligonucleotides used for 
hybridisation were from Clontech Laboratories Inc. (Palo Alto, California). Other 
purchases included: tetramethylammonium chloride (TMAC) (Sigma), G-50 
sephadex Nick columns (Pharmacia LKB, St.Albans, Hertfordshire), T4 
polynucleotide kinase and 123bp DNA ladder were from Life Technologies (Paisley, 
Scotland).
5.2.2 Tissue Preparation and DNA Extraction
Solutions:
Tris/HCl Buffer: Tris/HCl 400mM (2M, pH 8)
EDTA 60mM
NaCl 150mM
SDS 1%, v/v
TBE Buffer: Tris/Borate 89mM, pH8.0
EDTA 2mM
Frozen colon tissue was ground to a fine powder as described in Section 4.2.1 
and approximately lOOmg of this tissue was used for DNA extraction. Samples of
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tissue for analysis were suspended in 340pil sterile Tris/HCl Buffer in 1.5ml 
microtubes. The suspension was vortexed briefly, 100pi sodium perchlorate (5M) 
added and the solution was continually agitated using a rotary mixer (Matbum 
Surgical Equipment, Portsmouth, England) at 37°C for 20min. These tubes were then 
incubated in a shaking waterbath at 65°C for 20min to deproteinise the tissue. DNA 
was extracted according to the method described in the DNA extraction kit. Briefly, 
580pl chloroform was added which had been stored at -20°C and this was mixed with 
constant agitation as before at room temperature for 20min. The contents of each tube 
were transferred to a nucleon eppendorf tube which is included in the kit. This has 
been specially designed with an insert at the upper end, through which the contents of 
the tubes flow. These were then centrifuged in a microcentrifuge (Microcentaur 
model, Scotlab) at 1300 x g for lmin. Nucleon silica suspension (45pi) was added to 
each tube which goes into the insert and after further centrifugaton for 4min at 1300 x 
g, the DNA phase becomes separated. Without disturbing the silica, the DNA phase 
above the insert was poured off into another clean test-tube. DNA was precipitated by 
addition of 880pl ethanol and samples were left at -20°C for 1-2 hours. DNA was 
pelleted by centrifugation at 4000 x g for 5min and the supematent discarded. The 
pellet was washed using 1ml of 70% ethanol at 4°C. This was removed and the pellet 
allowed to air dry before addition of between 100 and 200pl sterile water, depending 
on the size of the pellet. DNA extracted samples were stored at 4°C until used.
The quality of the extracted DNA was analysed by agarose gel electrophoresis 
using approximately 2pl extract on agarose gel (0.8%) prepared in TBE buffer and 
ethidium bromide (0.5pg/ml). A Hybaid Electro-4Gel Tank was used to run the gel in 
TBE buffer at lOOv for 2 hours and the ethidium bromide staining visualised by 
ultraviolet trans-illumination. One pi of the DNA extract was sufficient for 
amplification by PCR.
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5.2.3 Amplification of Ki-ras Specific Sequences by PCR
Amplification was carried out in a volume of lOOpl PCR reaction mix with the 
following final concentrations: Tris/HCl (lOmM, pH 8.3), KC1 (50mM), MgCl2 
(1.5mM), gelatin (0.001%, w/v), deoxynucleoside-triphosphates (dNTPs; dATP, 
dTTP, dCTP, dGTP; lOmM each), amplimers (0.5pg each), Taq polymerase (5U/ml) 
and DNA extract (lpg; lp l of sample extraction). Two different sets of amplimers 
were used to amplify the Ki -ras oncogene, each set amplifying regions around codons 
12 and 13 (KA12 and KB12, Table 5.1) and codon 61 (KA61 and KB61, Table 5.1). 
Before amplification, paraffin oil (50 pi) was overlaid on the amplification mix in 
each tube to prevent the samples drying. A negative control containing no DNA was 
included in the reactions to check for contamination.
Amplification was carried out for 35 cycles as previously described (Breivite 
al , 1994) at the following temperatures: 94°C for lmin, 58°C for lmin and 72°C for 
lmin, in a Dri-block device (LEP scientific, Linford Wood, Milton Keynes). A final 
incubation was carried out following the 35 cycles for lOmin at 72°C. Presence of a 
PCR amplified product was detected as before on a 2% agarose gel using lOpl of 
amplified sample. One pg of a 123bp DNA ladder was also placed in each gel to 
check the size of the PCR product. The amplified DNA was stored at -20°C.
5.2.4 Preparation of Oligonucleotide Probes
Radioactive oligonucleotide probes were prepared for each possible point 
mutation in the Ki -ras gene. The exact nucleotide sequences of each probe for point 
muations in codons 12,13 and 61 are given in Table 5.2.
A modification of the method described by Berent (Berente^ al , 1985) was 
used to 5’ label each probe as follows: in a reaction volume of 30pl was added 
Tris/HCl (60mM, pH 7.8), 2-mercaptoethanol (15mM), MgCl2 (lOmM), ATP 
(0.35pM), oligonucleotide (50ng), 50pCi [y-32P]ATP and T4 nucleotide kinase (5U).
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Amplimer Sequence Target Fragment 1 
Amplified 
(bp)
KA12 G ACT GAA TAT AAA CTT GTG G Ki-ras 108
KB 12 C TAT TGT TGG ATC ATA TCC G 12/13
KA61 T TCC TAC AGG AAG CAA GTA G 128
KB61 C ACA AAG AAA GCC CTC CCC A Ki-ras 61
Table 5.1 Amplimers used for Ki-ras codons 12/13 and codon 61
The first letter of the target sequence represents the 5' end and the last letter the 3' 
end. All amplimers are 20 nucleotides long. The fragment length includes the 
amplimer sequences.
Gene/Codon Mutation Amino Add Hybridisation
Pools
Ki-ras 12 GGA GCT GGT GGC GTA GGC AA gly (w.t)
AGT ser Pool 12A
GTT val
GAT asp
TGT cys Pool 12B
GCT ala
CGT arg
Ki-ras 13 GGA GCT GGT GGC GTA GGC AA gly (w.t.)
AGC ser Pool 13A
GTC val
GAC asp
TGC cys Pool 13B
CGC arg
GCC ala
Ki-ras 61 ACC GCA GGT CAA GAG GAG TA gin (w.t.)
GAA glu Pool 61A
AAA lys
CAT his-1
CTA leu Pool 61B
CCA pro
1
CGA arg
CAC his-2
Table 5.2 Primer oligonucleotides used for detection of point mutations 
in the Ki-ras gene
The incubation was carried out at 37°C for 60min. Labelled oligonucleotide was 
separated from the unincorporated nucleotides using Nick columns containing G-50 
DNA grade sephadex. The top and bottom caps were removed from the columns and 
the storage buffer allowed to drain off. The column was then washed with 400pl TE 
buffer (Tris/HCl (lOmM, pH 7.8), and EDTA (ImM)). The labelled product from the 
above reaction (30pl) was placed on the column which was flushed with a further 
400pl TE buffer. The column was placed over a microtube and 400pl of the same 
buffer was drained through the column into the tube, with unincorporated nucleotides 
remaining in the column. The purified labelled probe was stored at -20°C and used 
within 48h of preparation.
5.2.5 Selective Hybridisation of Mutation-Specific Oligonucleotides
Solutions:
lx  SSC Buffer: NaCl 150mM
Sodium citrate 15mM, pH7.6
IxSSPE Buffer: NaCl 180mM
NaH2P04 8mM
EDTA ImM
5x Denhardt's Solution: Ficoll 0.1%
BSA 0.1%
polyvinylpyrrolidine 0.1%
TMAC Wash Solution: TMAC 3M
Tris/HCl 50mM, pH8.8
EDTA 2mM
SDS 0.1%
Amplified DNA samples were spotted onto Hybond N transfer membranes 
(Amersham Int.) using a Dot blot manifold (BRL Hybridot, BRL Life Technologies,
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Paisley, Scotland). To do this the membrane was first washed with 2 x SSC solution 
before being placed into the manifold apparatus. To prepare the amplified DNA for 
application to the membrane, 5pi of amplified DNA per replicate (2 replicates per 
membrane) was diluted with one-fifth volume of NaOH and left at room temperature 
for 30min. Each replicate was diluted with lOOpl 10 x SSC and 100pi was added to 
the manifold which was attached to a vacuum unit. Following application of the 
DNA, the membrane was washed twice with 20 x SSC and the membrane then air- 
dried, wrapped in cling-film and, with DNA side down, placed on a pre-callibrated uv 
trans-illuminator for 5min to cross-link the DNA to the membrane.
For this study it was not necessary to study specific point mutations, only 
presence or absence of Ki-ras was of interest and, hence, up to four of the radioactive 
probes were pooled for the hybridisation procedure. The membranes were 
prehybridised for 2h at 37°C on a shaking waterbath in 25ml hybridisation mix per 
membrane (5 x SSPE, 5 x Denhardt's solution, sodium dodecyl sulphate (0.5%) and 
sodium pyrophosphate (0.1M)). Pools of the labelled probes as indicated in Table 5.2 
(the wild type probe was used on its own) were added to each membrane at a final 
concentration of 5 x 106 CPM/25ml hybridisation mix and this was hybridised for 2h 
at 37°C in a shaking waterbath. The hybridisation mix was removed and the filter 
washed with 100ml 6 x SSC for 15min at room temperature followed by 100ml of 
TMAC (3M) wash solution at 61°C for 30min with constant shaking. Finally, each 
filter was washed in 6 x SSC at room temperature. Autoradiography was carried out 
on the filters at -70°C for 1-4 hours. Sometimes longer exposure times were required, 
depending on the level of radioactivity retained on the membranes. The dot blot 
results are presented in a table indicating the wild type result and that after 
hybridising with pools of the labelled oligonucleotides.
The hybridisation procedures described above were those recommended by 
the manufacturer of the oligonucleotide probes (Clontech). The dissociation 
temperature (Tm) is used to determine the hybridisation temperature. The Tm depends
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on the base composition of the oligonucleotides and increasing the G-C content 
stabilises the duplex formed. Tm can be estimated by:
Tm(°0  = 2°C per A-T + 4°C per G-C (Suggs et a l ,1981).
The Tm of the oligonucleotides was approximately 63°C. Hybridisation to amplified 
regions of genomic DNA was carried out at 37°C which was about 25°C below the 
Tm of a fully matched hybrid. This results in hybridisation of oligonucleotides to both 
wild type and mutant sequences and, hence, mismatch pairing of oligonucleotides and 
target DNA. Washing of membranes was carried out in the presence of 3M TMAC 
(Wood et a l , 1985) so that different oligonucleotides can be used at the same time. 
At this concentration the G-C and A-T base pairs have similar stabilities, so that 
oligonucleotides of the same length have the same Tm, regardless of the base 
composition. Washing in TMAC was carried out at a temperature (61°C) which 
allows only fully matched hybrids to remain.
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5.3 Results
5.3.1 DNA Amplification
Detection of ras involved amplification of regions of DNA containing codons 
12/13 and 61. Figure 5.2 shows the PCR product obtained following amplification of 
codon 61 in tumour and normal tissue from two patients. The size of the amplified 
region for codon 61 was 128bp as determined by comparison with a 123bp ladder. 
The control lane indicates no amplified DNA as expected.
5.3.2 Ki-ras Mutations
In order to minimise the number of hybridisation reactions necessary for the 
detection of each possible mutation, multiple pools of probes were used for detection 
of mutant Ki-ras and the pools used are indicated in Table 5.2. Mix 12A, 12B, 13A 
and 13B each contained three possible point mutations in the first or second base of 
each codon. Mix 61A and 6IB contained 3 or 4 probes for detection of point 
mutations in either of the three bases. Figure 5.3 displays the results for Ki-ras 
mutation detection. None of the patients had a ras mutation within the normal tissue. 
However, 7 of the 14 tumours tested had a Ki -ras mutation. Mutant ras was detected 
in codon 12 of 4/7 patients and the rest were found in codon 13, with no mutations in 
codon 61. In 6 tumours, the point mutations were found in the pool of oligonucleotide 
probes which would detect a glycine to valine, serine or aspartate mutation. One 
patient had a point mutation in codon 12 which would result in a glycine to cystine, 
alanine or arginine alteration.
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Figure  5.2 K i-ras gene-specific am plification  of genom ic 
DNA from  tu m o u r and  norm al tissue
Lanel :123bp  DNA ladder.Lane 2:Control lane with no DNA, 
Lane3. 4. 5 & 6:PCR products from extracted DNA following 
amplification using KA61 and KB61 primers in normal (3,5) 
and tumour (4.6) colon tissue.
(A) Codon 12
atient Wild Mutations
No. type pool A
(Val.Ser.Asp)
N T N T
1 •  •
8 • •
10 • •
12 • •
15 • •
16 • •
17 •  •
18 • •
23 •  •
27 •  •
28 • •
29 • •
30 •  • #
33 •  •
Mutations 
pool B 
(Cys.Ala.Arg) 
N T
(B) Codon 13
atient W ild
No. type 
N T
1 •  •
8 •  •
10 ■
12 •  •1
15 •  • !
16 •  •
17 •  •
18 •  •
23 •  •
27 •  •
28 •  •
29 •  •
30 •  #
Mutations 
pool A 
(Val.Ser.Asp) 
N T
Mutations 
pool B 
(Cys.Ala,Arg) 
N T
(C) Codon 61
Patient Wild Mutations Mutations 
No. type pool A pool B 
(Glu.Lys,His-l) (Arg.Leu.Pro.
His-2)
N T  N T  N T
■ ■
30 •  •
33 #  •
Figure 5.3 Dot blot hybridisation of oligimer probes to amplified 
DNA in tumour and normal colon tissue
DNA from the indicated patients was amplified using the 
Ki-rc/.v amplimers in Table 5.1 for each of codons 12, 13 & 61. 
The DN A  was spotted onto Hybond N transfer membrane and 
hybridised to pools of oligimers as shown in the table. Each 
tissue sample was spotted in duplicate and one of the 
replicates is displayed. The hybridisation results for all patients 
are shown for codons 12 & 13, however, as all patients were 
negative for codon 61 only a representative sample is included.
5.3.3 Relationship Between Presence of ras Mutation and PAP Activity
The mutations found in the 7 tumours were distributed according to Duke's 
Staging as follows: 1 Duke's A, 1 Duke's B, 3 Duke's C and 2 Duke's D. There was no 
correlation between age, sex or location of the tumour and the presence of a Ki-ras 
mutation. Table 5.3 summarises the changes in PAP1 and PAP2 activities and DRG 
and phosphatidate levels in the 14 tumours. There was no clear relationship between 
any of these changes and the presence or absence of a mutation in the Ki-ras gene. 
However, when activated Ki-ras was present in the tumours, there was a tendancy 
towards a higher PAP2 activity but this did not reach statistical significance (p=0.06) 
(Table 5.4).
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1 Patient 
No.
PAP1 PAP2 Phosphat
idate
DRG Ki-nzs
Status
1 +3.5 +2.3 -2.0 -2.1 13
8 +1.9 +2.0 -1.8 -1.2 12
10 +2.8 +1.5 -1.5 -1.6 wt
12 +2.5 +2.4 ND -1.3 wt
15 +1.4 +1.3 -1.6 -1.3 wt
16 +2.4 +1.5 -1.5 -3.8 12
17 +1.3 +1.8 1.0 -3.0 12
18 +2.6 +1.1 +1.1 -1.5 wt
23 +2.3 +2.8 -2.4 -1.6 13
27 +2.2 +1.7 -1.3 +2.2 wt
28 +1.5 -1.1 -1.4 -3.0 wt
29 +4.0 +2.1 -3.8 -2.3 wt
30 +1.9 +2.0 -1.3 -1.5 12
33 +1.8 +2.3 -1.4 -1.4
Table 5.3 Summary of results for changes in PAP activity, second 
messenger levels and Ki-ros status in colon samples
The results have been summarised as the fold change in enzyme activity or second 
messenger levels calculated as that in the normal tissue divided by that in the tumour 
tissue. The presence of a ras mutation is indicated by identification of the codon 
containing the mutation.
Ki-ras
mutation
PAP1 PAP2 Phosphatidate DRG
+ 
n = 7
2.0 ± 0.5 3.8 ± 1.1 2.8 ±0.3 3.7 ± 0.9
n = 7
1.9 ± 0.5 1.6 ±0.3 2.2 ±0.3 2.7 ±0.6
Table 5.4 Summary of results for PAP activity, second messenger levels 
and presence or absence of Ki-ras mutation in colon tumours
Results of enzyme activity and mass levels of phosphatidate and DRG are presented 
as means ± SE from the tumours found to contain the Ki-ras oncogene and those 
without this mutation.
5.4 Discussion
Of the fourteen tumours analysed, half were found to contain a mutation in 
Ki-ras. In the majority of these a glycine at codon 12 or 13 was replaced by one of 
three amino acids; valine, serine or aspartate (Figure 5.3). The presence of activated 
ras did not correlate with the sex or age of the patient or with the location of the 
tumour. Changes in PAP activities and second messenger levels were independent of 
the presence of a Ki-ras mutation (Table 5.3). However, whilst PAP2 activity was 
increased in most tumours, the increase tended to be greater in those with a Ki-ras 
mutation (Table 5.4).
PCR and hybridisation techniques were utilised to make a qualitative analysis 
of 14 patient tumours for the presence of mutations in the Ki-ras gene. Mutations in 
Ha-ras have not been detected in colon tumours (Forrester et a l , 1987) and, therefore, 
this was not analysed in the present study. However, N -ras mutations could account 
for about 14% of all the ras mutations in colorectal cancer (Vogelstein et a l, 1988) 
and thus the present study could be a slight underestimate of the number of ras 
mutations in the 14 patient tumours. Mutations in YA-ras have been reported to occur 
in about 40-60% of colon carcinomas (Capella et a l, 1991) which reflects the 
frequency of 50% found in this study. Of the mutations occuring at codons 12 andl3, 
the G to A transitions resulting in the replacement of glycine by aspartate are the most 
common (Breivik et a l, 1994; Capella et a l, 1991; Farr et a l, 1988). Although the 
exact mutation was not identified in this study, the majority of mutations were 
detected by the oligonucleotide pool which included a change to an aspartate (Figure 
5.3). Mutations in the ras oncogene family are known to be early events in the tumour 
progression in animal models of chemical carcinogenesis (Balmain & Brown, 1988). 
Whilst individual carcinogens have been shown to induce specific mutations, the G to 
A transition at the second position of codon 12 of each of the three ras genes is the 
most common (Balmain & Brown, 1988; Zarbl et a l, 1985). This supports the 
suggestion that the mutations found, at least in some cancers, are caused by
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carcinogens. No mutations were found in the adjacent normal tissue from any of the 
patients (Figure 5.3). Since the method used was highly sensitive this suggests that 
the tissues did not contain any tumour cells.
In the preceeding chapters, decreased activity of PAP2 was shown to be 
associated with ras transformation of fibroblast cells and with presence of the Ki-ras 
mutations in colon cancer epithelial cell lines (Chapter 3, Tables 3.2). Furthermore, 
this decreased PAP2 activity accompanied a decrease in the ratio of DRG relative to 
phosphatidate (Chapter 3, Figures 3.7 and 3.8). The colon cell lines had a Kl-ras 
mutation of Gly to Asp in codons 12 and 13 and it has now been shown that this is 
likely to be the mutation present in these tumours. However, the majority of these 
tumours showed increased levels of PAP and decreased levels of DRG and 
phosphatidate when compared to adjacent normal tissue. Furthermore, it is now clear 
that these changes occured regardless of whether a Ki-ras gene mutation was present. 
This confirms the conclusion that the observed changes in enzyme activity and lipid 
second messengers in the colon were not a direct result of a mutation in the ras 
oncogene. This was not surprising since ras mutations are only one of many genetic 
changes that occur during tumour progression (Vogelstein et a l, 1988).
A previous report also found no correlation between the presence of YA-ras 
mutations and DRG levels in colon tumours (Phan et a l, 1991). Since these authors 
limited their study to mutations at codon 12, it was possible that they might have 
missed a relationship. In this study, mutations at codons 12, 13 and 61 were 
investigated. Although 50% of the tumours had a mutation at codon 12 or 13, all but 
one of the tumours had decreased levels of DRG compared to the normal colon and 
there was no relationship between the presence of a mutation and the level of DRG or 
the size of the decrease in DRG levels (Tables 5.3 and 5.4). Whilst PAP2 activity was 
increased in the majority of tumours, there was a tendancy for the activity to be 
highest in those tumours with a mutant ras oncogene (Table 5.4), although this did 
not reach statistical significance. Furthermore, it is not clear how to interpret this 
observation.
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Several reports have suggested that biochemical and molecular changes in 
colorectal tumours could be used as markers of tumour stage. For instance, PKC 
activity has been suggested as a possible marker for risk of developing colorectal 
cancer. A consistent lower PKC activity has been observed in cytosolic and 
particulate fractions in normal-appearing colon of tissue in patients with colon 
tumours compared to the normal colon of patients without cancer (Sakanoue et a l , 
1991). This suggests alterations in PKC activity may play a role in the early stages of 
malignant transformation (Guillem et al., 1987a). It is not possible to say whether 
PAP activity could be a marker of increased risk. Whilst this activity was increased in 
tumour compared to normal colon, it is not known if the activity in the normal colon 
is higher than patients without cancer. Determination of the Ki-ras point mutation has 
been suggested as a prediction for tumour aggression, with more aggressive tumours 
being classed as highly invasive and potentially metastatic (Finkelstein et a l, 1993). 
This report showed that tumours containing a gly to val mutation in codon 12 or a gly 
to asp mutation in codon 13 were associated with early stage tumours. However, other 
mutations such as a mutation in gly to arg in codon 12, accounted for the majority of 
more aggressive and invasive tumours. This group suggested that an understanding of 
the role played by specific point mutations may lead to prediction of the degree of 
tumour aggressiveness and, in addition, individualisation of treatment. Unfortunately, 
as the specific point mutations were not determined in the tumours in the present 
study, these could not be related to the tumour stage to corroborate the previous 
report.
In summary, Ki-ras mutations have now been measured in 50% of patients in 
which PAP activity and second messenger levels have already been measured. The 
observed changes in signalling were independent of the ras mutation status of the 
tumour. Although this study was more complete than previously reported correlations 
between signalling and ras mutations, nonetheless it confirms earlier conclusions.
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CHAPTER SIX
METABOLISM OF DIRADYLGLYCEROL IN HUMAN COLON TISSUE
6.1 Introduction
In Chapter 4, PAP1 and PAP2 enzyme activities were found to be increased 
and phosphatidate and DRG levels decreased in human colon tumour tissue compared 
to adjacent normal mucosa. Although the increased enzyme activity could account for 
the decreased level of phosphatidate, it does not explain the observed decrease in 
DRG mass.
DRG is an intermediate in the biosynthesis and degradation of glycerolipids in 
eukaryotic cells as well as functioning as an intracellular second messenger (Bishop 
& Bell, 1988). There may be discrete pools of this lipid in the various cell 
compartments which are highly regulated for these functions. It is not known if there 
is exchange of DRG between cell compartments or if the different enzyme isoforms, 
identified in various compartments, allow discrete pools of lipid to be maintained. 
During de novo glycerolipid synthesis DRG is generated by dephosphorylation of 
phosphatidate by PAP activity, probably the PAP1 form of the enzyme. DRG is 
known to be formed in the endoplasmic reticulum since this is where the enzymes 
involved in glycerolipid synthesis are located (Brindley, 1987). DRG is also formed 
in the plasma membrane where it is involved in activaton of PKC (Hannun et a l , 
1985). Evidence for this comes from agonist stimulation of cells. For example, in 
PDGF-stimulated Swiss 3T3 cells, DRG is produced within seconds of cell 
stimulation (Plevin et a l, 1991). The DRG is derived from both phosphatidylinositol 
and PC through receptor-linked responses in the plasma membrane, where the 
enzymes involved are found (Majerus et a l , 1990; Wakelam et a l , 1991).
DRG may play different roles depending on cell type. For example, activity of 
PAP1 is relatively high in the liver where it is controlled by hormonal and nutritional
80
factors (Brindley, 1985). Here it is involved in the generation of DRG as an 
immediate precursor of PC and triacylglycerols which are then utilised for the 
assembly of complex structures such as membrane bilayers, serum lipoproteins and 
for energy storage (Bishop & Bell, 1988; Brindley, 1987). DRG is also present in 
high levels in the brain (Farooqui & Hirashima, 1992) which may provide long-term 
activation of PKC (Farooqui et al., 1988). In particular, the PKCy isoform is found 
exclusively in the brain and spinal cord (Nishizuka, 1989). Although the precise 
function of this isoform is unknown, it may be involved in the control of neurone- 
specific physiological processes such as release of certain neurotransmitters. One 
source of this DRG may be from the PLD/PAP2 pathway, the latter enzyme of which 
was found to have high activity in this study in murine brain (Chapter 2, Figure 2.8). 
However, the phosphatidylinositol cycle is also active in the brain which involves 
recycling of both inositol trisphosphate and DRG, both of which can be generated 
from hydrolysis of phosphatidylinositol 4,5-trisphosphate (Berridge, 1987; Rana & 
Hokin, 1990). It is of interest to note that inositol trisphosphate recycling is inhibited 
by low levels of lithium ions which are widely used in the treatment of manic 
depressives (Rana & Hokin, 1990).
DRG is comprised of molecular species which are probably formed and 
catabolised at different rates due to the existence of complex enzyme systems which 
govern the fatty acid composition of the acylglycerols (Holub & Kuksis, 1978). There 
are three major classes of DRG, that is, sn 1,2-diacylglycerol (DAG), s/z-1-alky 1-2- 
acylglycerol (AAG) and STz-l-alkenyl-2-acylglycerol (ALG). These classes also have 
their component molecular species which can be analysed by reverse phase high 
performance liquid chromatography (HPLC) of the dinitrobenzoyl derivatives. In 
response to bombesin-stimulation of Swiss 3T3 cells, only certain species of the DAG 
class in the plasma membrane are altered (Pettitt & Wakelam, 1993). Of these, 1- 
stearoyl-2-arachidonyl-s/i-glycerol (SAG), generated from phosphatidylinositol 4,5- 
bisphosphate hydrolysis, was produced within the first few seconds following 
stimulation. Other changes in DAG species occured at later time points and these
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species appeared to be derived from PC (Pettitt & Wakelam, 1993). The exact 
function of the specific DAG species is not known but it is possible that they may 
activate specific PKC isoforms. Other DRG classes such as AAG are poor activators 
of PKC (Cabot & Jaken, 1984; Heymans et a l , 1987) and may perform other 
functions such as generation of triacylglycerols in the endoplasmic reticulum for 
energy storage.
DRG, generated in the cell from various pathways, is subsequently 
metabolised by a number of enzymes. There are two major pathways for the 
metabolism of DRG (Figure 6.1). It can be phosphorylated by DRG kinase leading to 
production of phosphatidate, the reverse reaction to that catalysed by PAP (Kanoh et 
a l , 1990). Alternatively, DRG may be metabolised to glycerol and free fatty acids by 
the sequential action of DRG and monoacylglycerol (MG) lipases (Bishop & Bell,
1988). Free fatty acids can be used for membrane formation or can activate PKC 
(McPhail et a l , 1984). It should be noted that previous reports have referred to these 
enzyme activities as 'diacylglycerol' kinase and lipase. However, as they are not 
specific for this particular class of DRG, they have been referred to as DRG kinase 
and lipase in this thesis. It is not known whether the DRG kinase or lipase pathway is 
the predominant route of metabolism in cells and it may be cell type dependent. For 
example, the metabolism of [3H]DRGs by kinase and lipase enzymes was 
investigated in human platelets. Although these cells could attenuate the DRG signal 
by the action of both enzymes, the primary metabolic fate of DRG was by conversion 
to phosphatidate by kinase activity (Bishop & Bell, 1986). In other cell types it 
appears that lipase action predominates over DRG kinase. For example, DRG 
metabolism was measured in vascular smooth muscle cells in which lipase activity 
was found to be 30-34 fold greater than that of DRG kinase (Severson & Hee- 
Cheong, 1989).
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Figure 6.1 Scheme for formation and metabolism of DRG second messenger
DRG is produced by hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) by phospho- 
inositide (PI)-specific PLC and by degradation of phosphatidylcholine either by a PC-specific 
PLC or by the concerted action of PLD and PAP. DRG can activate PKC. It is metabolised by 
DRG kinase to form phosphatidate. Metabolism by DRG lipase results in the release of fatty acid 
(FA) from sn-1 position followed by hydrolysis of 2-monoglyceride (MG) intermediate by 
monoacylglycerol lipase to produce glycerol (G) and another FA.
6 . 1.1 DRG Kinase
DRG kinase converts DRG to phosphatidate. It was first purified from porcine 
brain cytosol (Kanoh et a l, 1983) but the amino acid sequences have also been 
described for porcine thymus (Sakane et a l, 1990), human (Schaap et a l, 1990) and 
rat (Goto & Kondo, 1993) forms. These have molecular weights around 80kDa and 
are more than 80% identical. There may be a family of DRG kinase isoenzymes since 
a variety of activities have been described in animal tissues. For example, purification 
of DRG kinase from rat brain has identified two isoforms of size 80 and HOkDa in a 
soluble fraction (Kahn & Besterman, 1991; Kato & Takenawa, 1990) and a 150kDa 
form which is membrane-bound (Kato & Takenawa, 1990). More recently, a 58kDa 
membrane-bound DRG kinase has been purified from bovine testes (Walsh et al. , 
1994). It has been suggested that these DRG kinase isoforms have distinct 
enzymological properties. Evidence for this comes from the work of Lemaitre and 
coworkers who have recently identified a membrane-bound DRG kinase activity in 
baboon tissues that has a specificity for arachidonyl-containing DRGs as opposed to a 
soluble DRG kinase activity which has no apparent substrate specificity (Lemaitre et 
a l ,  1990). The 58kDa bovine DRG kinase also has specificity for arachidonyl- 
containing DRG species (Walsh et a l, 1994). A similar activity has also been 
detected in fibroblasts where an arachidonyl-specific DRG kinase was shown to 
phosphorylate DRG formed in the plasma membrane from phosphatidylinositols 
(MacDonald et a l,  1988a; MacDonald et a l,  1988b). Receptor-stimulated 
phosphorylation of DRG derived from phosphatidylinositol-specific PLC activity is 
thought to be important in the resynthesis of phosphoinositides (Berridge & Irvine,
1989). This involves generation of arachidonyl-rich DRG species such as SAG, which 
is phosphorylated by the specific DRG kinase enzyme to arachidonyl-phosphatidate 
and this is then converted back into phosphatidylinositol. This has been termed the 
phosphatidylinositol-phosphatidate cycle (MacDonald et a l, 1988b). The function of 
this cycle is not known but it may help to maintain the arachidonyl-rich lipid species
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which are found in the plasma membrane. The soluble DRG kinase has no substrate 
specificity and will probably metabolise DRG derived from any source. This form of 
the enzyme will metabolise DRG generated from PC hydrolysis (Kanoh et a l, 1990; 
Sakane et a l, 1990). This could theoretically occur in the plasma membrane upon 
translocation of the cytosolic form. It has already been shown that DRG and phorbol 
ester can induce translocation of DRG kinase activity from the cytosol to particulate 
fractions in rat brain and liver (Besterman et a l, 1986b) as well as in fibroblasts cells 
(Maroney & Macara, 1989). Huang and coworkers showed an accumulation of DRG 
in ras transformed rat fibroblasts without any significant change in PLC activity 
(Huang et a l, 1988). Although they found that total DRG kinase activity was not 
altered in these cells, membrane-bound DRG kinase was actually decreased. They 
suggest that this change in activity could have led to the observed increase in DRG 
(Huang et a l , 1988). This report showed the value of measuring the activity of DRG 
kinase in individual cellular compartments. However, the membrane-bound kinase 
activity measured was probably not the SAG-specific form as sn-1,2-dioleoylglycerol 
was used as the substrate (Huang et a l , 1988). As well as compartmentalisation of the 
activities, it would also have been of interest to study their substrate specificities.
It is not known how DRG kinase and PAP are regulated in the cell. Since they 
catalyse opposite reactions they may work together to control levels of phosphatidate 
and DRG. It is possible that different isoforms of each enzyme are specific for 
different phosphatidate and DRG species, such as was shown for arachidonyl-specific 
DRG kinase (MacDonald et a l, 1988a). In this way, different pools of each lipid 
could be maintained in each cell compartment. There have been several reports 
analysing the molecular species of phosphatidate and DRG (Divecha et a l, 1991; 
Pessin et a l, 1990; Pettitt & Wakelam, 1993). Additional characterisation of the 
molecular mechanisms of enzyme interaction with lipid substrates would help to 
elucidate the significance of different enzyme isoforms and lipid species.
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6.1.2 DRG Lipase
An alternative route for DRG metabolism is by breakdown to glycerol and 
free fatty acids as a result of the sequential action of DRG and monoacylglycerol 
(MG) lipases. DRG lipase catalyses the removal of fatty acids from the sn-1 position 
of the glycerol and the subsequent hydrolysis of the sn-2 acyl chain from the 
intermediate lipid. Studies with partially pure DRG lipase from a soluble subcellular 
fraction from bovine aorta have established that DRG is hydrolysed by a single lipase 
(Lee & Severson, 1994). Further purification, however, is required to determine 
unequivocally if DRG and MG lipase activities result from a single or separate 
enzymes. The exact subcellular localisation of DRG lipase activity is not known but 
there is evidence to suggest that it may be associated with the plasma membrane. 
Stimulation of human platelets by thrombin results in the rapid, within seconds, 
production of arachidonate from SAG by a DRG lipase activity located in particulate 
fractions of the cells (Bell et a l, 1979). This fatty acid has several functions within 
the cell including activation of protein kinase C (Price et a l , 1989) or regulation of 
ras through an inhibition of GAP (Yu et al, 1990). The isolation of DRG lipase 
and/or development of specific inhibitors will be necessary to clarify the role of this 
enzyme. As there is limited information available regarding different lipase isoforms, 
an alternative approach is to consider using different forms of DRG as substrate. The 
use of such species as SAG or DOG, which are derived from phosphatidylinositol and 
PC respectively, would indicate if the enzyme is specific for DRG derived from a 
particular source.
6.1.3 Measurement of Kinase and Lipase Activities
DRG kinase activity can be estimated as the amount of [32P]phosphatidate 
formed from DRG and [32P]ATP (MacDonald et a l ,  1988a). Subcellular 
fractionation of the colon tissue into soluble and membrane components would allow
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detection of DRG kinases within the different compartments of the cell (Lemaitre et 
al., 1990; MacDonald et a l,  1988a). This would indicate whether DRG 
phosphorylation occurs in the plasma membrane or endoplasmic reticulum. A limited 
amount of colon tissue was available at this stage of the study and, hence, subcellular 
fractionation could not be carried out. However, important information could still be 
gained by the use of different substrates to measure DRG kinase activity. Two 
activities of DRG kinase can be identified based on substrate specificity. The 
cytoplasmic form metabolises all species of DRG (Lin et a l , 1986), whereas the 
membrane-bound form shows specificity for arachidonyl-containing substrates, such 
as SAG (Lemaitre et a l, 1990; MacDonald et a l, 1988b). Different substrates have 
been used in the past to study the specificity of different isoforms for DRG species 
(Florin-Christensen et al. , 1992; MacDonald et al. , 1988a). A mixed micellar assay 
system based on that of MacDonald (MacDonald et a l, 1988b) was employed to 
study metabolism of different DRG species by DRG kinase activity present in 
homogenates from colon tissue. Molecular species analysis has shown that 1- 
palmitoyl-2-oleoyl-s«-glycerol (POG) and sn-1,2-di-oleoylglycerol (DOG) are the 
predominant DRG species generated as part of a sustained increase in DRG mass in 
fibroblast cells stimulated with a-thrombin, EGF and PDGF (Pessin et a l , 1990). One 
of these, DOG, was chosen as a substrate in this study to represent PC as a source of 
this lipid. SAG was also used as a substrate since it is derived from 
phosphatidylinositols which predominantly consist of sn -1 -stearoy 1-2- arachidony 1 
species. Therefore, DRG kinase activities measured in this study cannot be attributed 
to different isoforms, however, the source of DRG, from which metabolism occurs, 
should be indicated.
Activity of DRG lipase can be estimated by determining the release of 
radiolabelled fatty acid from DRG labelled in either the sn-1 or sn-2 position 
(Severson & Hee-Cheong, 1989). Again, as representatives of lipids derived from PC 
or phosphoinositides, POG and SAG were used. These have been used in the past as 
substrates for measuring DRG lipase activity (Chuang et al. , 1994; Lee & Severson,
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1994). Colon tissue itself will contain various DRG species but this contributes less 
than 2% of the total DRG in the assays.
Thus, substrate specific DRG kinase and lipase activities were determined in 
colon tumour and adjacent normal colon in 14 of the 35 samples described in Chapter 
4. These 14 were chosen as representatives of the changes observed in PAP activity 
and levels of phosphatidate and DRG.
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6 .2 Methods
6.2.1 Chemicals and Reagents
l- [14C]palmitoyl-2-oleoyl-sfl-glycerol (l-[14C]POG) was a kind gift fron 
Dr.D.L.Severson (University of Calgary, Alberta, Canada) and had been synthesised 
by them as previously reported (Hee-Cheong et a l ,  1985). n-Octyl-|3,D- 
glucopyronaside (OBG) was purchased from Boehringer Mannheim (Lewes, East 
Sussex), 1 -stearoy 1-2-[14C]-arachidony 1-saz-glycerol (2-[l4C]SAG) from Amersham 
(Little Chalfont, Buckinghamshire) and all unlabelled lipids from Sigma (Poole, 
Dorset).
6.2.2 Preparation of Human Colon Tissue for Analysis
Tumour and adjacent normal colon tissue from the 14 patients previously 
analysed for PAP activity and second messenger levels, were used to measure DRG 
kinase and lipase activities, although in the latter case there was only enough tissue 
from 12 of the paired samples.
Tissue samples were prepared for analysis as in section 4.2.1 by homogenising 
the powdered colon tissue in a Tris buffer. Aliquots were stored at -70°C and protein 
determined as in section 2.2.3.
6.2.3 Measurement of DRG Kinase Activity
The detergent, OBG and phosphatidylserine were used to form a mixed 
micelle with the DRG substrate. Phosphorylation of this substrate was then used as a 
measure of DRG kinase activity (MacDonald et a l, 1988b). Either DOG or SAG 
were used as substrates. A stock solution of OBG/phosphatidylserine was prepared by 
drying down 16.05mg of the lipid (purchased stock = 18mg/ml chloroform) under a
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stream of nitrogen in a 2ml glass vial. This was then solubilised in 2ml of a 4- 
morpholinepropanesulfonic acid (MOPS) buffer (112.5mM, adjusted to pH7.2 with 
NaOH) containing OBG (182.5mM), NaF (50mM) and DTT (2.5mM). This was 
vortexed and then sonicated (KS100 bath sonicator, Kerry Ultrasonics Ltd., Kent) for 
lOmin at 4°C. SAG or DOG (300pl), prepared as a lOmM stock in 1ml chloroform, 
was aliquoted into glass test tubes and dried down under a stream of nitrogen. 
OBG/phosphatidylserine solution (40pl), was added to each tube to solubilise the 
lipid followed by sonication for 30min at 4°C in a bath sonicator. Colon tissue 
homogenate (50^ig, 50ptl) was added and the reaction started by the addition of lOpl 
[y-32p]ATP (30mM; lO^Ci/pmol) prepared in a MOPS/NaOH buffer (50mM, pH7.2) 
containing MgCl2 (180mM). Control reactions contained no enzyme preparation. The 
final reaction mixture contained OBG (73mM), phosphatidylserine (4.48mM), lipid 
substrate (3mM), MOPS/NaOH (50mM, pH 7.2), MgCl2 (18mM), NaF (20mM), 
DTT (ImM) and ATP (3mM; lOpCi/pmol). The samples were incubated at 30°C for 
30min and the reaction terminated by addition of 1ml chloroform / methanol / 
conc.HCl (150:300:2, v/v/v). The test tubes were vortexed and lipids left to extract for 
15min at room temperature. Following addition of 300pl chloroform and 400pl water, 
the tubes were vortexed and centrifuged for lOmin at 250 x g in a benchtop centrifuge 
(model CR411, Deva Medical Electronics Ltd., Runcorn, Cheshire). The upper 
aqueous phase was discarded and the organic phase was washed in 1ml chloroform / 
methanol /  water (1:1:0.9, v/v/v) and then vortexed and centrifuged as before. The 
upper phase was again discarded and the final lower organic phase was dried under 
vacuum. Dried lipid was reconstituted in 50pl chloroform and applied to glass silica 
gel t.l.c. plates. Radiolabelled products were separated by developing in chloroform / 
methanol / acetic acid (39:9:4.5, v/v/v) and the [32P]phosphatidate identified by 
autoradiography and quantified by scintillation counting of scraped bands. All 
samples were assayed in triplicate and the results expressed as a specific activity 
(pmoles phosphatidate formed / min / mg protein). Statistically significant differences 
were determined by Student’s paired t-test.
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DRG kinase activity was characterised in colon tissue by varying both time 
and protein concentration. Also, optimum substrate concentration was determined 
with a range of lipid concentrations from 0.2 to lOmM SAG or DOG. This was 
carried out by drying down different volumes of a stock of lipid (lOmM/ml 
chloroform) and the reaction carried out as before. Optimum ATP was determined 
with a range of final ATP concentrations from 0.1 to lOmM (lOpCi/pmol).
6.2.4 Measurement of DRG Lipase Activity
DRG lipase activity was determined by measuring the release of radiolabelled 
fatty acid from labelled DRG substrates as described by Lee and coworkers (Lee & 
Severson, 1994). Co-sonicates of radiolabelled DRG and phosphatidylserine were 
used as the substrate with the radiolabel as l-[14C]POG or 2-[14C]SAG.
A stock solution was prepared consisting of 4 parts l-[14C]POG (4mM; 2500 
dpm/nmole in hexane) and 5 parts phosphatidylserine (4mM in chloroform), allowing 
18pl per assay. This was dried down in a glass vial and then reconstituted in the ratio 
of 80pl potassium phosphate buffer (0.25M, pH 7), 20pl water and lp l Triton X-100 
(10%, v/v) per 18pl original solution. This substrate solution was sonicated in a bath 
sonicator for lOmin at 4°C until optically clear. Colon tissue homogenate (50p,g; 
50pl) was added to each glass test tube of an experiment along with 250pl potassium 
phosphate buffer (0.25M, pH 7). The reaction was started by addition of lOOpl 
substrate solution. Final assay concentrations were: l-[14C]POG (80pM; specific 
activity 2500 dpm/nmole), phosphatidylserine (lOOpM), Triton X-100 (0.025%) and 
potassium phosphate buffer (50mM, pH 7). Samples were incubated for 30min at 
37°C and the reaction stopped by addition of 3ml of a fatty acid extraction solution 
consisting of methanol / chloroform / heptane (1.41:1.21:1, v/v/v) and O.lmM 
palmitate as carrier. NaOH (1M; lOOpl) was added to each tube and these were then 
vortexed vigourously for 30s and centrifuged at 250 x g for lOmin. A sample (0.5ml) 
was removed from the aqueous upper phase and added to scintillation vials. Samples
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were neutralised by addition of HC1 to avoid chemiluminesence. Scintillation fluid 
(80 volumes) was premixed with HC1 (2M; lvolume) and 3ml of this was added to 
each vial. Radioactivity was measured using a 1600TR scintillation counter (Canberra 
Packard, Berkshire, UK). Release of palmitate was used as a measure of lipase 
activity.
To measure DRG lipase activity with 2-[l4C]SAG as substrate, a stock of 
radiolabelled lipid (4mM; 2500dpm/nmole) was prepared by mixing SAG (5.54mg), 
400pl of 2-[14C]SAG (53 pCi/nmol) and 1800pl hexane. The was stored at -20°C. 
Substrate preparation and incubations were carried out as described above for POG. 
The reaction was terminated by addition of chloroform / methanol (2:1, v/v; 2ml) and 
HC1 (5M; 0.1ml) with arachidonate (lOpg) as carrier. After addition of NaCl (1M; 
0.3ml), the samples were centrifuged at 250 x g and the upper phase removed. The 
lower phase was dried under N2, resuspended in chloroform / methanol (2:1, v/v; 
50pl) and applied to glass t.l.c. plates. After development to 95% of the length of the 
t.l.c. plate in hexane / diethylether / acetic acid (70:30:1, v/v/v), the position of MG 
and [14C] arachidonate was determined by iodine staining. The radioactive band was 
scraped and 14C counted in scintillation fluid. Release of arachidonate was used as a 
measure of lipase activity.
Specific activities of all enzymes were routinely expressed as nmoles fatty 
acid (palmitate or arachidonate) formed / min / mg protein. Statistically significant 
differences were determined using Student's paired t-test.
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6.3 Results
6.3.1 Characterisation of the DRG Kinase Assay
Various experiments were carried out to characterise DRG kinase activity in 
human colon tissue using DOG or SAG as substrate for the enzyme. The reaction rate 
of the DRG kinase enzymes was proportional to protein concentration up to 50pg 
(Figure 6.2A) and time up to 30min (Figure 6.2B). For this reason, the majority of 
experiments were carried out using 50pg protein for a reaction time of 30min.
The effect of increasing substrate concentration on DRG kinase activity from 
colon tissue was measured at various SAG and DOG concentrations. Optimum 
activity for both lipids was achieved at a lipid concentration of about 3mM (Figure 
6.3). At concentrations above this, there was a slight decrease in enzyme activity. 
Hence, 3mM SAG and DOG was used in subsequent assays.
The effect of increasing ATP concentration on DRG kinase activity was also 
determined. Optimum activity was achieved at 3mM ATP (Figure 6.4). At higher 
concentrations of ATP, there was a slight decrease in enzyme activity and, hence, in 
subsequent assays, 3mM ATP was used.
6.3.2 DRG Kinase Activity in Human Colon Tumour and Adjacent Normal
Mucosa
The activity of DRG kinase determined with DOG as the substrate in 14 
paired tumour and normal colon tissues is shown in Figure 6.5A. There was a wide 
range of activities of DRG kinase in the normal colon (1.1 - 19.2) and in the tumour 
tissue (2.7 - 22.5). Activity was significantly different in tumour and adjacent normal 
tissue in 10 patients. Of these, activity was increased in the tumour in 6 patients and 
decreased in 4 patients. Overall, the mean activity of this non-specific form of the 
enzyme was not significantly different between normal mucosa (8.0 ±1.5 pmoles
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Figure 6.2 Effect of enzyme concentration and incubation time on DRG 
kinase activity in normal colon tissue
Phosphatidate production was measured with various concentrations of normal human 
colon tissue with either di-oleoyl-s/i-glycerol (P) or s/z-l-stearoyl-2-arachidonyl- 
glycerol (■) as the substrate (A). Phosphatidate production was also determined after 
incubation of samples (50pg) for various times (B). ATP and substrate concentration 
were 3mM. Each point is a mean ± SE from triplicate determinations and is 
representative of two observations showing similar results.
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Figure 6.3 Effect of increasing concentrations of lipid substrates on DRG 
kinase activity from human colon tissue
Phosphatidate production was measured with various concentrations of di-oleoyl-s/z- 
glycerol O  ors/i-l-stearoyl-2-arachidonylglycerol (■) with human colon tissue 
(50pg) as a source of the enzyme. ATP concentration was 3mM. Each point is a mean 
± SE from triplicate determinations and is representative of two observations showing 
similar results.
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Figure 6.4 Effect of increasing concentrations of ATP on DRG kinase activity 
from human colon tissue 
Phosphatidate production was measured with various concentrations of ATP with 
human colon tissue (50pg) as a source of the enzyme. Di-oleoyl-s/z - glycerol (p) or 
s/z-l-stearoyl-2-arachidonylglycerol (■) concentrations were 3mM. Each point is a 
mean ± SE from triplicate determinations and is representative of two independent 
observations showing similar results.
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Figure 6.5 Specific activity of DRG kinase in paired colon tumour and 
adjacent normal tissue
DRG kinase activity in paired normal (□) and tumour tissue (0) was determined with 
either (A) di-oleoyl-s/z-glycerol or (B) Sfl-l-stearoyl-2-arachidonylglycerol as substrate. 
Each assay contained 50pg protein. Results are the mean ± SE of triplicate 
determinations. Asterisks represent statistically significant differences (Student's t test; *
p<0.02, ** p<0.01, ***p<0.001).
phosphatidate formed / min/ mg protein) compared to tumour tissue (9.3 ±1.4 pmoles 
phosphatidate formed / min/ mg protein).
DRG kinase activity also showed a marked variation between patients in both 
normal (4.4 - 24.0) and tumour tissue (5.5 - 39.0) when measured with SAG as the 
substrate (Figure 6.5B). Activity was significantly higher in the tumour when 
compared with the normal colon in 8 patients and significantly lower in the tumour in 
2 patients (Figure 6.5B). Overall, the SAG-specific enzyme had a significantly higher 
activity (1.7 fold; p<0.017) in colon tumours (21.8 ± 3 .1  pmoles phosphatidate 
formed / min/ mg protein) compared to normal colon tissue (13.0 ± 1.6 pmoles 
phosphatidate formed / min/  mg protein).
6.3.3 DRG Lipase Activity in Human Colon Tumour and Adjacent Normal
Mucosa
Due to the small amount of the radiolabelled lipids and tissue samples 
available for this part of the study, enzyme activity for both substrates used was not as 
well characterised in colon tissue as would ideally have been carried out. However, 
the incubation conditions previously well-characterised for other cells and tissues 
(Lee & Severson, 1994; Severson & Hee-Cheong, 1989) were used and a limited 
characterisation of the enzyme was carried out for the colon tissue samples.
The reaction rate for DRG lipase utilising 2-[14C]SAG as substrate was 
proportional to protein concentration up to 80pg and time up to 30min (Figure 6.6). 
Measurement of DRG lipase activity was, therefore, carried out using protein 
concentration from the linear portion of the curve for an incubation time of 30min.
In contrast to DRG kinase, both lipase activities showed only a small variation 
between patients. DRG lipase activity measured with l-[l4C]POG as the substrate 
was significantly higher (2 fold; p<0.0018) in tumour tissue (12.2 ± 0.7 nmoles 
palmitate formed / min /  mg protein; range 4.9 - 24.7) compared to normal mucosa 
(6.1 ± 0.4 nmoles palmitate formed / min/ mg protein; range 2.8 - 10.6). Overall,
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Figure 6.6 Effect of enzyme concentration and incubation time on DRG lipase 
activity in normal colon tissue
Arachidonate production was measured with various concentrations of normal human 
colon tissue with s/z-1 -stearoyl-2-arachidonylglycerol as substrate(A). Arachidonate 
production was also determined after incubation of samples (50pg) for various times 
(B). Each point is a mean ± SE of triplicate determinations and is representative of 
two independent observations showing similar results.
DRG lipase activity measured with 2-[14C]SAG as substrate was not significantly 
different in normal mucosa (2.1 ± 0.2 nmoles arachidonate formed / min/  mg protein; 
range 1.5 - 3.3) and tumour tissue (1.8 ± 0.2 nmoles arachidonate formed / min/ mg 
protein; range 0.8 - 3.5) (Figure 6.7B). However, activity of this enzyme was 
significantly decreased in the tumour tissue in 8 patients and significantly increased in 
3 patients.
6.3.4 Relative Changes in PAP, DRG Kinase, DRG Lipase and DRG Mass
The fold change in DRG mass, PAP, kinase and lipase activities in tumour 
compared to normal mucosa are summarised in Table 6.1. There was no clear 
correlation between the magnitude of the decrease in total cellular DRG and the 
changes in activity of the synthesising and metabolising enzymes.
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Figure 6.7 Specific activity of DRG lipase in paired colon tumour and adjacent 
normal tissue
DRG lipase activity in paired normal (□) and tumour tissue ([3) was determined with 
either (A) palmitoyl-2-oleoyl-s/i-glycerol or (B) sn-1 -stearoyl-2-arachidonylglycerol as 
substrate. Each assay contained 50pg protein. Results are the mean ± SE of triplicate 
determinations. There was inadequate tissue sample to measure activity in all patients. 
Asterisks represent statistically significant differences (Student's t test; * p<0.02, **
p<0.01, ***p<0.001).
I Patient 
I No.
DRG PAP1 PAP2 SAG
kinase
DOG
kinase
SAG
lipase
POG
lipase
1 -2.1 +3.5 +2.3 +1.6 +1.2 ND ND
8 -1.2 +1.9 +2.0 +2.3 +2.8 -1.4 +1.1
10 -1.6 +2.8 +1.5 +1.7 +1.2 -1.3 1.0
12 -1.3 +2.5 +2.4 +7.1 -1.6 ND ND
15 -1.3 +1.4 +1.3 +2.5 +5.2 -1.7 ND
16 -3.8 +2.4 +1.5 -3.7 +1.3 +1.7 +2.1
17 -3.0 +1.3 +1.8 1.0 +1.1 -1.3 +4.5
18 -1.5 +2.6 +1.1 +2.6 +2.1 +1.4 +1.1
23 -1.6 +2.3 +2.8 +1.2 -1.4 -1.4 +1.4
27 +2.2 +2.2 +1.7 +1.1 +1.1 -1.9 +2.6
28 -3.0 +1.5 -1.1 -1.4 -1.3 -1.8 +2.8 1
29 -2.3 +4.0 +2.1 +4.1 +3.1 +1.3 +2.8
30 -1.5 +1.9 +2.0 +1.2 -1.4 -1.9 +3.5
I 33 -1.4 +1.8 +2.3 +2.1 +1.4 -1.1 +2.0
Table 6.1 Summary of results for changes in DRG mass, PAP, DRG lipase
and DRG kinase activities in colon tumour
The results have been summarised as the fold change in enzyme activity or second 
messenger levels calculated as that in the normal tissue divided by that in the tumour 
tissue. SAG kinase represents the membrane bound form of the enzyme whereas 
DOG kinase is the non-specific enzyme which will phosphorylate all forms of DRG. 
The two lipase activities were measured using SAG and POG which represent 
substrates derived from phosphoinositides and PC respectively.
6.4 Discussion
DRG kinase and DRG lipase activities in the normal colon varied markedly 
between patients. In general, DRG kinase activity was increased in the tumour tissue 
and this increase was most consistent when SAG was used as the substrate. In 
contrast, DRG lipase activity was increased in the tumour when POG was used as the 
substrate but no consistent change in SAG-specific activity was observed.
A clear decrease in DRG mass in human colon tumour tissue has been shown 
in this and other work (Phan et a l , 1991). Previously, this was proposed to be the 
result of a decrease in the generaton of DRG from phosphoinositides or PC. However, 
the results presented in Chapter 4 indicated a significant increase in PAP2 activity 
(Figure 4.4) which could have accounted for the observed decrease in phosphatidate 
mass (Figure 4.6), but not the decrease in DRG. The lower DRG mass in the colon 
tumour tissue was, therefore, not indicative of decreased production but more a rapid 
clearance of this second messenger. DRG kinase and lipase activities each play 
predominant metabolising roles in different cell systems (Florin-Christensen et a l , 
1993; Florin-Christensen et a l, 1992; Hee-Cheong & Severson, 1989), and it was 
these enzymes that were considered in the present study. It is difficult to make direct 
comparisons between the kinase and lipase activities measured in this study and those 
in previous reports. Other workers have utilised subcellular fractions as a source of 
enzyme activity such that membrane-associated and cytosolic activities could be 
distinguished. In this study, a colon tissue homogenate was used as a source of kinase 
and lipase activity and different DRG substrates were used as an indication of the 
specificity of these activities. Observed differences in enzyme activities based on 
those substrate specificities may not necessarily indicate different enzyme isoforms 
and the metabolism cannot be assigned to particular subcellular compartments.
In signalling, DRG is derived from phosphoinositides or PC (Wakelam et a l ,
1991). If PC is a major source, as proposed (Cook & Wakelam, 1991a; Lassegue et 
a l , 1993), then the observed increase in PAP2 activity in colon tumour suggests an
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increase in PC derived DRG metabolism is occurring. In this study, DOG was used as 
a substrate for kinase activity to represent DRG derived from PC. No overall 
significant increase or decrease in the activity of DRG kinase was observed using this 
substrate (Figure 6.5). This suggests that this enzyme is not a major route of 
metabolism of PC derived DRG. A similar result was found in another study using 
NIH 3T3 cells to examine the metabolic fate of [l4C]DOG. This was found to be 
preferentially converted, not to phosphatidate indicative of kinase activity, but to 
other lipids such as monoacylglycerol and fatty acid (Florin-Christensen et a l , 1992). 
This may be the case within colon tumour tissue, where DOG could be preferentially 
metabolised by other enzymes.
One of the predominant DRG species, POG, is probably generated from PC 
(Pessin et a l , 1990) as an intermediate within either signal transduction pathways or 
glycerolipid synthesis. Metabolism by lipase appeared to be a major route for removal 
of this DRG species in nearly all patient tumour samples as indicated by the increased 
activity in lipase using POG as the substrate (Figure 6.7). It is unclear from this study 
whether this occurs in the plasma membrane or endoplasmic reticulum. DRG 
metabolism by lipase is unlikely to occur in the plasma membrane, however, as the 
products from this route are not known to recycle and the membrane would 
eventually run out of PC. It probably occurs in the endoplasmic reticulum where PC 
can be produced by the action of choline phosphotransferase (Brindley, 1987). 
Complete metabolism of POG results in the release of oleate. This fatty acid has been 
shown to have several effects in the cell, for example, in isolated hepatocytes and 
perfused rat liver, translocation of PKC from cytosol to membranes was observed at 
physiological oleate concentrations, in particular, the PKC(3 isoform. Oleate and 
related unsaturated fatty acids can also stimulate PKC activity in colonic epithelial 
cells (Craven & DeRubertis, 1988).
If phosphatidylinositol is the major source of DRG in signalling, an increase 
in phosphatidylinositol 4,5-bisphosphate derived DRG would be expected. This may 
be the case as a recent report showed an increased expression of PLCy in human
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colon tumours (Noh et a l , 1994; Park et a l , 1994a). It is not known if this increased 
expression is associated with increased activity of the enzyme, however, there is a 
possibility that there is an increase in DRG derived from this source. In addition, 
other work has shown that a decrease in membrane-associated DRG kinase activity in 
ras transformed fibroblast cells may have resulted in an observed increase in DRG 
mass (Huang et a l , 1988). This suggests a change in the activity of this enzyme can 
effect DRG levels. SAG was used as a substrate to measure both kinase and lipase 
activities and represents a phosphatidylinositol derived lipid (MacDonald et a l , 
1988b). The activity of DRG lipase was not uniformly increased in colon tumour and, 
therefore, could not account for the overall decrease in DRG mass in this tissue 
(Figure 6.7). However, when DRG kinase activity was measured using SAG as 
substrate, this enzyme was found to have significantly higher activity in the tumour 
(Figure 6.5). Hence, a decrease in phosphatidylinositol derived DRG may be 
explained by the increased DRG kinase activity. This is a similar finding to NIH 3T3 
fibroblasts in which [14C]SAG was mainly converted to phosphatidate, indicating 
kinase activity (Florin-Christensen et a l, 1992). This activity in colon tissue may 
represent the membrane-bound form of DRG kinase which has been found in other 
tissues (Lemaitre et a l, 1990). The membrane-bound enzyme is specific for 
arachidonyl-containing DRG species (MacDonald et a l, 1988b) which may be active 
in a cycle within the plasma membrane. The phosphatidate formed by this enzyme 
can be subsequently converted back to phosphatidylinositol (MacDonald et a l , 
1988a; MacDonald et a l , 1988b), and this raises the possibility that membrane-bound 
DRG kinase contributes to the unique fatty acid composition of phosphatidylinositols 
observed in animal cells (Berridge & Irvine, 1989). Not only would this maintain 
levels of arachidonyl-phosphatidylinositols for use in signalling (Rana & Hokin, 
1990) but also other products are generated in the cycle. For example, arachidonyl- 
phosphatidate produced by the action of DRG kinase which may itself be metabolised 
by phospholipase A2 activity to arachidonate. This can have several functions within 
the cell including activation of specific PKC isoforms (Asaoka et a l , 1992).
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There are other routes for conversion of DRG which have not been considered 
in this study. For example, DRG can be converted to triacylglycerols by the action of 
DRG acyl transferase. This could occur in both the plasma membrane or endoplasmic 
reticulum. For instance, when [14C]DOG was incorporated into fibroblast plasma 
membranes by a liposomal fusion technique, 23% of total cellular radioactivity was 
recovered in triacylglycerols (Florin-Christensen et al., 1992) and use of kinase and 
lipase inhibitors did not influence this conversion. The increase in activities, 
therefore, of kinase and lipase enzymes in colon tumour tissue may not solely account 
for the observed decrease in total DRG mass.
There was a large interpatient variation in the activity of both the kinase and 
lipase enzymes. This does not reflect variation between assays since one patient 
sample was included in every experiment as a quality control. Even within the normal 
tissue there was a wide range in activity. For example, when DRG kinase activity was 
measured with DOG as substrate there was a 6-fold range in activities observed in the 
normal colon tissue. It is not clear why there is such a range in activity but it could be 
related to the diet of each patient. For instance, a high fat diet in some patients could 
be correlated to requirement for higher levels and activity of metabolising enzymes. It 
is not known if kinase and lipase activities are controlled by nutritional factors as has 
been shown for PAP1 activity (Brindley, 1985).
Using SAG as a substrate should represent a total kinase activity since both 
the SAG-specific and non-specific forms will utilise this lipid. Subsequently, kinase 
measurements with DOG as substrate represent only the non-specific form of the 
enzyme and activity in this case is expected to be lower than using SAG. This was not 
always the case, for example, in the normal colon tissue of patient 12 there was a 
much higher activity with DOG as substrate. It is possible, however, that the non­
specific form in colon cannot utilise SAG to any great extent and that the two specific 
and non-specific activities should be regarded as separate entities. Overall, kinase 
activity was found to be higher than lipase in the colon tissues. This has also been 
observed in human platelets (Bishop & Bell, 1986). However, as these enzymes were
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measured under optimal conditions in the test tube, it is difficult to be certain that the 
difference in activity between kinase and lipase enzymes would be physiological. An 
alternative method to measure these would have been to assay for both enzymes at the 
same time. This could have been carried out by determining release of [14C]palmitate 
and formation of [l4C]phosphatidate in the presence of [14C]POG and ATP/Mg2+. In 
this way, the two enzymes would have to compete for substrate, which may have 
been a more physiological reflection of their activity. Using a similar technique, 
lipase activity had much higher activity in rabbit aortic smooth muscle cells 
(Severson & Hee-Cheong, 1989). This method may not be valid, however, as each 
enzyme cannot be measured under optimal conditions in the one assay.
It is not possible to correlate DRG mass results directly to enzyme activity. 
For example, a 2 fold increase in enzyme activity will not necessarily equate with a 2 
fold increase in DRG mass. It is possible, however, to relate a change in enzyme 
activity to alterations in DRG. For example, the significant increase in some of the 
metabolising enzymes such as lipase, which was found to hydrolyse a predominant 
DRG species (POG), may account for at least some of the observed decrease in DRG 
mass. In contrast, as SAG is a fairly minor component of total DRG species (Pessin et 
al., 1990), then increased metabolism by DRG kinase specific for SAG would 
probably account for only a minor part of the total DRG decrease.
In summary, the present data suggest that a DRG kinase activity may be 
eliminating DRG derived from phosphatidylinositols in the membrane and that lipase 
activity might be an important method for metabolising DRG from PC, probably in 
the endoplasmic reticulum. This appears to reflect changes in both signalling and 
glycerolipid synthesis and can, at least in part, explain the decrease in DRG mass in 
colon tumour tissue. The role of PAP in DRG production is far from clear at the 
moment because of the difficulty in understanding the relative contributions of 
several other pathways that generate or utilise DRG. When a clearer, unambiguous 
understanding of the sources and functions of DRG species is available, the role 
played by both PAP1 and PAP2 will hopefully be a lot easier to define. In addition,
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colon tumours will have multiple changes as a result of several genetic alterations 
which occur during the progression of the colon tumour (Fearon & Vogelstein, 1990). 
It is unlikely that only one of these changes, such as a mutation in ras, is driving 
signalling abnormalities. This study has provided an insight into signalling in colon 
tumours, however, it is still unclear how important the observed changes are to the 
progression of the tumour. Other second messengers, such as cAMP, and signalling 
enzymes, such as the MAP kinase cascade, have not been considered here but these 
may well play important roles in colon tumour development.
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CHAPTER SEVEN
MODULATION OF PAP ACTIVITY BY CATIONIC AMPHIPHILIC
AGENTS
7.1 Introduction
One of the underlying aims of this thesis is to determine whether PAP is a 
suitable target for anticancer drug development. The studies described in the previous 
chapters attempted to elucidate the role, if any, of PAP in the control of signal 
transduction in transformed cells. In both ras transformed fibroblasts and in human 
colon cancer epithelial cells which have a ras mutation, a decrease in PAP2 activity 
was observed. In contrast, when compared with the normal colon, PAP2 activity was 
increased in colon tumours. Neither system is ideal for the study of PAP activity but 
both show that PAP activity can be perturbed. A much cleaner approach would be to 
alter, directly, the activity of PAP in the cell. Since PAP has not yet been purified, it 
is not possible to overexpress the enzyme nor is it possible to reduce expression either 
by antisense oligonucleotides (Calabretta et al. , 1992) or by gene knockout 
(Capecchi, 1994). These approaches are all currently in use to study the role of 
various PKC isoforms (Dekker & Parker, 1994). However, cellular enzyme activities 
can be modulated by the use of specific activators or inhibitors. For example, the 
fungal metabolite, Wortmannin, has been used in cells to irreversibly inhibit 
phosphatidylinositol 3-kinase activity in mammalian cells. When added at nanomolar 
concentrations, this compound does not effect other kinases (Okada et al., 1994). 
Wortmannin has been used in several studies such as inhibition of neutrophil 
activation by chemotactic-peptide (Okada et a l, 1994) and for both G protein and 
tyrosine kinase regulated phosphatidylinositol 3-kinase activities (Stephens et a l , 
1994). The PKC inhibitor, Ro 31-8220, has been used by several workers to study the 
dependency of signalling pathways on PKC. For example, the activation of PLD
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catalysed PC breakdown in EGF stimulated Swiss 3T3 cells was found to be 
independent of PKC activition. However, EGF induced PLD induction was shown to 
be coupled to tyrosine phosphorylation since the tyrosine kinase inhibitor, AG 18, 
selectively inhibited the reaction (Cook & Wakelam, 1992).
In the past, a number of cationic amphiphilic agents (CAAs) have been used 
to inhibit PAP. These compounds are characterised by having a hydrophobic domain 
and an ionizable nitrogen atom which is positively charged (Figure 7.1). One of these, 
propranolol, is used clinically as a p-adrenergic receptor anatgonist (Stiles et al., 
1984) but has also been shown to inhibit PAP activity (Jamal et a l, 1991). Efforts to 
study the role of this enzyme in biochemical pathways have often used synthetic 
CAAs such as propranolol to interfere with the PLD pathway at the level of PAP. For 
example, Perry and coworkers studied second messengers involved in activation of 
the respiratory burst in formyl methionyl leucyl phenylalanine (FMLP)-stimulated 
human neutrophils (Perry et a l, 1992). They used the CAAs propranolol and 
chlorpromazine to inhibit PAP in order to study the importance of DRG generation 
from the PAP/PLD pathway. Use of these agents resulted in an increase in 
phosphatidate and a decrease in DRG levels and a reduction in oxygen consumption. 
They suggested that DRG, derived from the PAP/PLD pathway, was essential for the 
respiratory burst in neutrophils. However, propranolol, and probably other CAAs, 
also effect other enzymes such as PKC (Sozzani et al., 1992) and 
phosphatidylinositol-specific PLC activity (Das, 1988). It is not clear how the effects 
of the compounds on these enzymes would influence DRG levels. Furthermore, 
propranolol is not specific for PAP1 or PAP2, and hence de novo synthesis of DRG 
could also be effected in these cells. Although Perry and co-workers were aware of 
these problems, no attempt was made to asses if the CAAs effected any of these 
enzymes in vitro. Using a similar approach, comparable conclusions were made in a 
study of chemotactic-peptide stimulation of the same cells (Billah et al., 1989).
There is a group of natural CAAs known as the sphingoid bases (Lavie et al. , 
1990). These form the backbone of sphingolipids, such as sphingomyelin, which are
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Figure 7.1 Structures of the synthetic and natural cationic amphiphilic 
agents (CAAs)
important membrane constituents and are particularly concentrated in brain and nerve 
tissue. The sphingoid bases have a typical 2-amino 1,3-diol hydrophilic head structure 
and a long hydrophobic alkyl chain (Figure 7.1). They are regarded as a new class of 
bioregulatory molecules (Hannun & Bell, 1989; Merrill et a l, 1989) and endogenous 
sphingolipids are known to play a role in the regulation of cell growth, differentiation 
and neoplastic transformation (Liscovitch & Lavie, 1990; Merrill & Stevens, 1989; 
Michell & Wakelam, 1994). Sphingosine has been shown to inhibit both PAP1 and 
PAP2 activity when included in the same cell free assay system described in Chapter 
2 (Gomez-Munoz et a l , 1992; Jamal et a l , 1991) and has been used to inhibit PAP in 
whole cells (Lavie et a l , 1990; Mullmann et a l, 1991). However, these compounds, 
like the other CAAs, are not specific for PAP. DRG was shown to be decreased 
following treatment of NG108-15 neural-derived cells with sphingosine (Lavie & 
Liscovitch, 1990). Since PKC activity is also decreased in these cells it was proposed 
that inhibition of PAP reduced the level of DRG and this in turn resulted in down- 
regulation of PKC activity. However, as this compound can also activate an 80kDa 
DRG kinase enzyme in the same cells (Sakane et a l, 1989), sphingosine may also 
decrease DRG levels by a concomitant stimulation of DRG metabolism. In addition, 
sphingosine can inhibit PKC activity directly through interference with the binding of 
PKC to the ternary complex formed at the plasma membrane between calcium, 
phosphatidylserine and DRG (Hannun & Bell, 1987). Thus, sphingosine could reduce 
DRG levels both by inhibition of PAP activity and by stimulated DRG kinase and 
inhibit PKC activity by both direct and indirect mechanisms.
Work on the CAAs carried out some time ago showed that the mechanism of 
PAP inhibition is related to the interaction of the amine with the anionic substrate, 
rather than a direct interaction with the enzyme (Bowley et a l, 1977). This was 
concluded from enzyme kinetic studies that used chlorpromazine to inhibit PAP 
activity. The inhibition was found to be of a competitive type in which 
chlorpromazine interacted with phosphatidate, such that it was a poor substrate for 
PAP. If this is the mechanism of action, then it would explain why these compounds
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effect the metabolism of a wide range of acidic lipids and modify the activity of 
enzymes that are regulated by acidic lipids. For example, propranolol effects PKC 
activity by modifying the ability of phosphatidylserine to activate the kinase (Sozzani 
et a l, 1992).
It may be possible to produce analogues of lead compounds which have 
increased selectivity for the target enzyme. This can be through the simple use of a 
single isomer of a particular compound. For example, the L-isomer of propranolol is 
much more active as a (3-blocker than the D-isomer (McEvoy et a l, 1990). A more 
complicated approach has been to alter the chemical structure of the parent 
compound. Modification of the PKC inhibitor, staurosporine, which itself is not 
selective for PKC, has resulted in the production of agents which are more specific 
for this enzyme. One derivative of staurosporine produced by Ciba Ceigy, CGP 41 
251, shows a high degree of selectivity towards PKC and, in addition, antitumour 
activity both in vitro and in vivo (Meyer et al , 1989). In fact, this compound is about 
to enter clinical trial in Glasgow as an anticancer agent in 1995. A number of 
staurosporine analogues have been developed by Roche and these are widely used as 
tools to study the involvement of PKC in various signalling pathways (Uings et a l,
1992). A similar approach can be envisaged for PAP inhibitors. Compounds such as 
propranolol or sphingosine, which are already used as PAP inhibitors, might be 
potential lead compounds for the development of more specific analogues. These 
compounds would not only provide useful laboratory tools for studying the function 
and importance of PAP in cells, but might also be potential anticancer agents.
The CAAs were therefore investigated as potential inhibitors of PAP. A range 
of synthetic and naturally occuring CAAs (Merrill & Stevens, 1989) were examined 
for their ability to inhibit PAP activity in vitro. Whilst this approach should identify 
compounds that are potent inhibitors of PAP, it takes no account of the potency of the 
compound in the whole cell. Clearly, this will also be determined by the stability of 
the agent and its ability to enter the cell and to gain access to the enzyme within the 
cell. The CAAs were, therefore, tested for their ability to inhibit cell proliferation in
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vitro. Two assays in routine use in the Department of Medical Oncology were chosen. 
A tetrazolium-dye based microtitration assay, modified from that used by the USA 
National Cancer Institute to screen for potential antitumour agents, was used (Plumb 
et al. , 1989). This assay includes a fixed drug exposure time and a regrowth period in 
drug free medium. The regrowth period allows cells to recover from any short-term 
non-lethal damage. However, since inhibitors of signal transduction pathways may 
cause cytostasis rather than cell death, the assay may not detect their activity. Thus a 
short term assay, [3H]thymidine incorporation, was also used. The cell lines used 
were the NIH 3T3 fibroblasts and one of the ras transformed variants shown to 
express increased activity of PAP1 but decreased activity of PAP2 (Chapter 3, Table 
3.2).
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7.2 Materials and Methods
7.2.1 Chemicals and Reagents
Cis-diammine-dichloroplatinum II (cisplatin), tamoxifen, bis- 
chloroethylnitrosourea (BCNU), etoposide (VP-16), psychosine, sphingosine, 
dihydro-sphingosine, propranolol, chlorpromazine, imipramine and 3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from 
Sigma (Poole, Dorset). N,N,N-trimethyl-sphingosine was a gift from Professor 
Igarashi (University of Washington, Washington D.C., U.S.A). [3H]Thymidine was 
from Amersham (Little Chalfont, Buckinghamshire).
7.2.2 Cell Lines
The cell lines used were the mouse fibroblast cell line, NIH 3T3 I, and the 
sub-line transformed with v-Ha-ras (HT3 I). Details of these cell lines and their 
routine maintenance is described in section 3.2.3.
7.2.3 Drugs
Chlorpromazine, propranolol, imipramine, sphingosine and the anticancer 
agents were all prepared as 30mM stock solutions in dimethylsulphoxide (DMSO). 
The other sphingoid bases were also prepared in DMSO at a stock concentration of 
lOmM. In the viability assays, propranolol, imipramine, psychosine and BCNU were 
used at a range of concentrations between 0 and 200pM by diluting the stock solution
in culture medium. The other compounds were diluted in the same way and used at a
concentration range between 0.1 and lOOpM. A solvent control was used in the 
assays.
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7.2.4 Cytotoxicity Assay
Cytotoxicity was determined using a tetrazolium-based microtitration assay 
(Plumbet aL, 1989). Cells were seeded (103 cells/well) into 96 well microtitration 
plates (Linbro, Flow Laboratories, Irvine, Scotland) in 200pl of medium (DMEM + 
DCS, 10%). The first and last row of 8 wells contained medium only. Plates were 
incubated for 48h at 37°C in an atmosphere of 2% CO2 in air to allow the cells to 
attach and grow. Medium from the wells was then replaced with medium containing a 
range of drug concentrations. Eight concentrations were used for each drug and four 
wells per concentration. After a 24h incubation period, drugs were removed and cells 
fed daily for a further three days. At the end of the growth period the cells were fed 
with fresh medium and MTT (50pl; 5mg/ml PBS) was added to each well. Plates 
were wrapped in aluminium foil and incubated for a further 4h. Medium and MTT 
were removed from the wells and the formazan crystals dissolved in 200pl DMSO 
added from a dispenser (Welltech Wellfill 3: Denley, Sussex, England). Sorenson's 
glycine buffer (25pl; glycine (0.1M) plus NaCl (0.1M), adjusted to pH 10.5 with 
NaOH (1M)) was added to adjust the final pH and the absorbance recorded at a 
wavelength of 570nm in a plate reader (Model 3550 ELISA plate reader, Bio-Rad 
Laboratories Ltd., Watford, England). The first and last rows of 8 wells which 
contained medium and MTT only were used to blank the plate reader. Results were 
expressed as the IC50 concentration which was determined as the drug concentration 
required to reduce the absorbance to half that of control untreated cells.
7.2.5 [3H]Thymidine Incorporation
Cells were seeded at a density of 103 cells/well into 96 well plates in 200pl 
medium. The cells were allowed to attach and grow for three days. Drugs were added 
to triplicate wells at a range of concentrations in fresh medium. Control wells 
contained medium only. [3H]Thymidine (O.lpCi/well) was added immediately after
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drug addition. After a 24h incubation period, drug and radiolabel were removed, the 
cells washed twice in ice-cold PBS and 50pl of trypsin solution (0.2% in PBS) was 
added to each well. The cells were incubated for 30min at 37°C and an LKB cell 
harvester (1295-001 cell harvester, Pharmacia LKB, St.Albans, Hertfordshire) was 
used to transfer the contents of each well to filter paper. Each filter contained the 
contents from one 96 well plate and was mixed with 10ml scintillation fluid in a 
sealed plastic bag. Radioactivity was determined with a Beckman 1205 Betaplate 
scintillation counter. Results are expressed as the IC50 concentration which was 
calculated as the amount of drug required to reduce the counts per minute (CPM) to 
half that of the control untreated cells.
7.2.6 Effect of Modulators on PAP Activity
Cytosolic and plasma membrane fractions from rat liver were used as a source 
of PAP1 and PAP2 enzymes. Preparation of the fractions has already been described 
in Section 2.2.3. The drugs were used at a range of concentrations between 0 and 
1.5mM. The DMSO concentration was always less than 5% in the assay and a solvent 
control was used. PAP1 and PAP2 enzyme activities were measured as described in 
section 2.2.4. The drug to be tested was included in the reaction mixture and 
following addition of the enzyme preparation, samples were preincubated as 
described for lOmin at 37°C. The reaction was then started by addition of the 
substrate. Enzyme kinetic analysis was carried out on PAP2 using four concentrations 
of substrate (0.02, 0.06, 0.2, 0.6 mM) and various concentrations of sphingosine (0, 
0.1, 0.3, 0.8,1.2 and 1.5 mM).
Samples were assayed in triplicate and the inhibition values expressed as a % 
of the rate measured in the absence of drug. Enzyme kinetic data was analysed by the 
"Enzyme Kinetics" package as described in Chapter 2.
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7.3 Results
7.3.1 Effect of the CAAs on Cell Proliferation
The cytotoxicity of various CAAs towards NIH 3T3 I and ras transformed 
fibroblast cells (HT3I) is shown in Table 7.1. Toxicity of a range of established 
anticancer agents was included for comparison. The CAAs were all toxic to cells with 
IC50 values in the micromolar range which were comparable to those of the 
anticancer agents. Sphingosine and dihydro-sphingosine were the most active of the 
CAAs in both types of assay whilst psychosine showed least activity. The two cell 
lines were equally sensitive to the majority of CAAs when sensitivity was determined 
by MTT reduction. However, differences were apparent when sensitivity was 
determined by [3H]thymidine incorporation. For example, HT3I was less sensitive to 
sphingosine and dihydro-sphingosine (p<0.0026 and p<0.0054, respectively) than 
NIH 3T3I. The opposite was true of N,N,N-trimethyl-sphingosine where the IC50 was 
lower in the transformed cells (p<0.021). Otherwise, the MTT assay and 
[3H]thymidine incorporation assay gave similar results except for N,N,N-trimethyl- 
sphingosine where both lines appeared more sensitive when assessed by 
[3H]thymidine incorporation (p<0.0032).
7.3.2 Effect of CAAs and Anticancer Drugs on PAP Activity
The effects of propranolol, imipramine and chlorpromazine on PAP1 and 
PAP2 activities are shown in Figure 7.2. Partial inhibition of these enzymes was 
observed with the synthetic CAAs but at the concentrations used in this study, 
complete inhibition was not achieved. The sphingoid bases were all strong inhibitors 
of the PAP1 enzyme activity (Figure 7.3A). Psychosine and N,N,N-trimethyl- 
sphingosine were the most potent with IC50S of 75pM and 80pM respectively. At 
similar concentrations, these drugs had no affect on PAP2 activity (Figure 7.3B).
109
ID50 <HM)
MTT pH] Thymidine
DRUG NIH 3T3 I HT3 I NIH 3T3 I HT3 I
Cisplatin 8.6 ±0.7 10.1 ±0.7 7.2 ± 1.3 3.0 ± 0.7
Tamoxifen 23.1 ±0.5 29.8 ±0.9 10.5 ± 1.5 25.5 ± 1.6
BCNU 19.8 ±1.4 41.5 ± 1.4 87.3 ±4.3 31.2 ±2.1
VP-16 8.5 ± 0.7 10.7 ± 0.9 6.0 ± 1.3 3.1 ± 0.5
Psychosine 96.0 ± 2.5 102.4 ±2.8 79.2 ± 8.7 70.4 ±5.8
Sphingosine 3.3 ± 1.0 4.7 ± 0.4 9.1 ± 0.9 27.6 ± 2.2
Dihydro-sphingosine 7.1 ± 0.7 5.3 ±0.5 4.1 ± 0.5 15.8 ±1.5
Trimethyl-sphingosine 56.5 ±4.5 45.3 ± 2.7 27.6 ± 2.5 11.5 ±1.8
Propranolol 45.6 ± 2.8 63.3 ± 2.3 40.5 ± 2.3 120.2 ± 3.1
Chlorpromazine / / 17.5 ± 2.1 24.1 ±2.1
Imipramine 34.1 ±2.4 49.3 ±2.9 21.2 ±1.5 60.8± 6.6
Table 7.1 Sensitivity of untransformed (NIH 3T3 I) and ras transformed
(HT3 I) fibroblast cells to various cationic amphiphilic agents and 
anticancer drugs
Cells were exposed to the indicated agents for 24h and cytotoxicity was determined 
either by MTT dye reduction or by pHjthymidine incorporation. Results are the mean 
ID50 ± SE of triplicate experiments.
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Figure 7.2 Effect of synthetic cationic amphiphilic agents on PAP1 and PAP2
enzyme activities
PAP activity was measured in the presence of increasing concentrations of 
propranolol (□), chlorpromazine (A) and imipramine (O) as indicated. Rat liver 
cytosol (PAP1) (A) and plasma membrane (PAP2) (B) fractions were used as sources 
of the enzymes using 20pg protein in the assay. Each experimental determination is 
the mean ± SE of triplicate measurements and is representative of two independent 
observations showing similar results. Results are expressed as % of control.
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Figure 7.3 Effect of sphingoid bases on PAP1 and PAP2 enzyme activities
PAP activity was measured in the presence of increasing concentrations of 
sphingosine (□), dihydro-sphingosine (A), psychosine (O) and trimethyl-sphingosine 
(•) as indicated. Rat liver cytosol (PAP1) (A) and plasma membrane (PAP2) (B) 
fractions were used as sources of the enzymes using 20pg protein in the assay. Each 
experimental determination is the mean ± SE of triplicate measurements and is 
representative of two independent observations showing similar results. Results are 
expressed as % of control.
Sphingosine and analogues of sphingosine only partially inhibited PAP2 activity, by 
about 40%, at concentrations which inhibited almost totally PAP1 activity. Overall, 
this group of compounds were stronger inhibitors of both PAP1 and PAP2 than the 
synthetic CAAs. None of the established anticancer agents significantly inhibited 
PAP2 activity, however, tamoxifen and VP-16 partially inhibited PAP1 enzyme 
activity and cisplatin completely inhibited this enzyme at a concentration of ImM 
(Figure 7.4).
Addition of sphingosine reduced the rate of the reaction of PAP2 at all 
substrate concentrations used (Figures 7.5A). Furthermore, the magnitude of the 
inhibition increases with increasing concentrations of sphingosine. From this limited 
study, it appears that sphingosine does not reduce the Vmax of the reaction. This 
observation is supported by the Lineweaver-Burk plot (Figure 7.5B), although it 
should be noted that at high concentrations of sphingosine the data does not transform 
to a linear plot. This is further demonstrated in the Eadie-Hofstee plot (Figure 7.5C). 
At the lowest concentrations of the inhibitor used (0.1 and 0.3mM) the slope (Km) is 
unchanged but the Vmax (y intercept) is decreased. This contrasts with the 
interpretation of the double reciprocal plot. However, at higher concentrations of 
sphingosine, the Eadie-Hofstee plot is non-linear and cannot be interpreted.
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Figure 7.4 Effect of various anticancer agents on PAP1 and PAP2 enzyme 
activities
PAP activity was measured in the presence of increasing concentrations of 
cisplatinum (□), VP-16 (A), BCNU (O) and tamoxifen (•) as indicated. Rat liver 
cytosol (PAP1) (A) and plasma membrane (PAP2) (B) fractions were used as sources 
of the enzymes using 20 pg protein in the assay. Each experimental determination is 
the mean ± SE of triplicate measurements and is representative of two independent 
observations showing similar results. Results are expressed as % of control.
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Figure 7.5 Effect of increasing concentrations of sphingosine on the rate of
reaction of PAP2
PAP2 activity was measured at a range of substrate concentrations in the presence of increasing 
concentrations of sphingosine (mM): 0 (A), 0.1 (O), 0.3 (A), 0.8 (•), 1.2 (O) and 1.5 (■). In A, 
rate of reaction, v (nmoles DRG formed / min / mg protein), is plotted against substrate, s 
(mM), whereas B represents a Lineweaver-Burk plot (1/v against 1/s) and C is an Eadie- 
Hoftsee plot (v against v/s). This graph shows triplicate determinations from one of two 
independent observations showing similar results.
7.4 Discussion
The CAAs have been used in the past to inhibit PAP activity in whole cells. 
All the CAAs were shown to be cytotoxic at concentrations comparable to standard 
anticancer agents. The sphingoid bases were the most potent inhibitors of cell growth 
and were also shown to be potent inhibitors of both PAP1 and PAP2 enzyme 
activities.
The cytotoxic properties of the CAAs were determined in an attempt to 
establish whether inhibition of PAP effects cell growth. MTT and [3H]thymidine 
incorporation assays were used to screen the compounds and the CAAs showed 
activity in the two assays at concentrations of between 3 and lOOpM (Table 7.1). 
Although neither assay indicates whether the compounds were cytostatic or cytotoxic, 
it does show that they are somehow affecting fibroblast cell growth.
On the whole, the two assays gave similar results but there were some 
inconsistencies. N,N,N-trimethyl-sphingosine was apparently more active when 
cytotoxicity was determined by the [3H]thymidine incorporation assay (Table 7.1). 
This could be explained if the drug was causing a cell cycle block at G0/G1 thus 
preventing cells from entering S phase and incorporating [3H]thymidine into their 
DNA. In the MTT assay there is a three day regrowth period during which the cells 
can recover from the initial effect of the drug. This observation suggests that N,N,N- 
trimethyl-sphingosine is perhaps antiproliferative rather than cytotoxic. It might be 
expected that drugs which act by inhibiting signal transduction pathways would have 
a cytostatic rather than a cytotoxic effect. That is, they block proliferation but do not 
necessarily kill tumour cells in the same way that is associated with classic anticancer 
drugs. If the drug had been cytotoxic this would result in a terminal reaction and no 
recovery would occur in the MTT assay. Compounds such as cisplatin or 
dihydrosphingosine were probably cytotoxic and there was no significant difference 
between short term and long term assays.
I l l
It has been suggested that C AA compounds act by competing with the enzyme 
for a binding site on the substrate (Bowley et al., 1977). If the reaction involves either 
a direct or indirect interaction with PAP in whole cells, the observed difference 
between enzyme activity and phosphatidate levels in the NIH 3T3I and HT3I lines 
might be reflected by differences in the growth inhibitory effects of the compounds. 
In this case, the CAAs would be expected to have more effect in the cell line with the 
highest PAP activity and phosphatidate levels (HT3I). The majority of the CAAs 
were actually less active in the transformed cells (Table 7.1). This could be explained 
if the inhibition of cell growth by these compounds is through mechanisms other than 
PAP. Alternatively, the main inhibitory effect may be through PAP2 activity which is 
lower in HT3I cells than in the NIH 3T3I cells (Chapter 3, Table 3.2). One of the 
CAAs, N,N,N-trimethyl-sphingosine, was more active in the ras transformed cell 
lines in both assays. This indicated that at least one of the mechanisms of action of 
this compound could be through PAP1.
Sphingosine and psychosine are structurally very similar compounds differing 
only in that psychosine has a galactose group on the positively charged amphiphilic 
head group. This made a significant difference in activities since psychosine was 
much less effective than sphingosine in terms of growth inhibition (Table 7.1). 
Psychosine was, however, the more potent in terms of PAP1 inhibition. This activity 
may not have been observed in the whole cells due to poor uptake of the drug by the 
fibroblasts. Endo and co-workers showed a stronger inhibitory effect of N,N,N- 
trimethyl-sphingosine compared to sphingosine in the in vitro [3H]thymidine 
incorporation assay (Endo et al., 1991). This was seen for HT3 I cells in this study but 
not for the NIH 3T3 I cells. These investigators used different cell lines in their study 
but they also presented the drugs to the cells in a different manner. In this study, the 
drug was dissolved in DMSO and subsequently diluted in medium for application to 
cells and this is a common practice (Franson et al , 1992; Hannun et al. , 1986; Jamal 
et al., 1991; Mullmann et a l, 1991). However, other groups have prepared the 
sphingoid bases in a complex with BSA (Aridor-Piterman et al., 1992; Endo et al.,
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1991; Merrill & Stevens, 1989). This keeps the drug in suspension and is thought to 
aid in uptake into cells. Hence, a difference in drug presentation or cell lines may 
account for the observed differences between this study in which N,N,N,-trimethyl- 
sphingosine was found to be less potent than sphingosine and another study in which 
the opposite was observed (Endo et a l , 1991).
In addition to screening the activity of these compounds in whole cells, the 
specificity of the drugs for PAP1 and PAP2 was also investigated by incorporating 
them into the enzyme activity assays. In the cell free PAP assay, there are no 
problems of access in which a drug has to penetrate the plasma membrane to reach 
the enzyme. In addition there would not be the same problems with competition for 
other binding sites as in whole cells. For example, in whole cells the CAAs may also 
inhibit PKC by a direct interaction with this enzyme (Sozzani et a l , 1992). One might 
expect, therefore, that an enzyme measured in isolation of cells would be inhibited at 
even lower concentrations than in whole cells if that compound was acting through 
PAP. However, milli molar concentrations of the majority of the compounds were 
required to inhibit the enzymes in the PAP assay (Figures 7.2 and 7.3). This is 
probably due to the fact that concomitantly high concentrations of drug, substrate and 
enzyme are required to optimise conditions for measuring PAP activity in the cell free 
assay. This makes relating the results to whole cells difficult. However, the enzyme 
assay does indicate whether the compounds directly effect PAP, and if so, how 
specific they are for PAP1 or PAP2. For instance, N,N,N-trimethylsphingosine and 
sphingosine inhibit both forms of the enzymes in the PAP assay with IC50S of 80 and 
200[uM for PAP1 respectively (Figure 7.3), which is a similar result to those 
previously reported for sphingosine (Jamal et a l, 1991; Lavie et a l, 1990). The 
concentrations required for inhibition of cell growth in vitro are much lower as shown 
in this and other work (Endo et a l , 1991; Park et a l , 1994b). It is not known whether 
the observed inhibitory affect in the PAP assay would occur in whole cells. These 
compounds probably produce their effects through a variety of antisignalling events. 
One of the mechanisms of action of these drugs was proposed to be through
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modulation of PKC activity (Igarashi et a l , 1989). Thus, the effects of the 
compounds on cell proliferation support the proposed lack of specificity of these lead 
compounds.
Anticancer agents with known mechanisms of action were incorporated into 
the assay for PAP activity as controls. For example, cisplatin causes cell damage 
through production of inter-strand and intra-strand DNA adducts at micro molar 
concentrations. Surprisingly, this drug was also found to inhibit PAP1 activity with an 
even lower IC50 value than propranolol (Figure 7.4). This mechanism of interaction 
with PAP or its substrate is unknown, although it may involve the platinum 
integrating into the substrate, perhaps displacing Mg2+. This inhibition is unlikely to 
occur in cells. HT3I has a much higher PAP1 activity compared to NIH 3T3I but is 
not any more sensitive to cisplatin which indicates that this drug does not inhibit 
PAP1 in intact cells (Table 7.1).
Enzyme kinetic studies have shown that chlorpromazine is competitive with 
PAP for the binding site on the substrate and it was suggested that other synthetic 
CAAs may act in the same way. The reaction is thought to involve a direct interaction 
between the positively charged head group and the negatively charged phosphatidate 
substrate (Koul & Hauser, 1987; Pappu & Hauser, 1983) thus preventing the enzyme- 
substrate complex forming. Since sphingosine was one of the few compounds that 
inhibited PAP2 activity, this sphingoid base was used in enzyme kinetic studies in an 
attempt to determine if the mechanism of inhibition of this enzyme is the same as the 
other CAAs. Sphingosine shares important structural features with propranolol, such 
as a positively charged amine group and a hydrophobic domain and thus its 
mechanism of PAP inhibition could be similar. It has already been shown that the 
PAP1 enzyme does not follow Michaelis-Menton kinetics (Chapter 2, Figure 2.6) and 
further inhibition studies were not carried out on this enzyme. One of the most 
commonly reported methods for estimating Km and Vmax is the double-reciprocal 
Lineweaver-Burk plot (1/v against 1/s) as described previouly (Chapter 2), however, 
this is not the only graphical method. The Eadie-Hofstee (Eadie, 1942; Hofstee, 1952)
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(v against v/s) plot is another common method for linearising the data. Inhibition of 
PAP2 activity by sphingosine resulted in kinetic profiles which were difficult to 
interpret. It appeared that at high drug concentrations the best fit line became non­
linear (Figure 7.5). Like PAP1, there may be factors in the assay which interfere with 
the kinetics of PAP2. It is unknown, for instance, how Triton X-100 effects the 
kinetics of PAP2 and it should be noted that the method of substrate presentation to 
the enzyme is far from ideal when compared with the close association of enzyme and 
substrate in the whole cells. The observed conflicting competitive and noncompetitive 
interpretation of the interaction may be accounted for by different forms of interaction 
between sphingosine and phosphatidate. A detailed kinetic analysis of the PAP 
enzymes will clearly require purification of these enzymes.
Sphingosine has been shown to inhibit both PAP1 and PAP2 in vitro and to 
inhibit cell proliferation. This compound was therefore chosen as the lead compound 
in a synthesis programme to develop more specific inhibitors of PAP activity. This is 
a joint project between the Departments of Medical Oncology and Chemistry at 
Glasgow University. Sphingosine is recognised as a potent inhibitor of PKC (Aridor- 
Piterman et al. , 1992; Endo et a l, 1991; Merrill & Stevens, 1989) and the initial 
screen of the compounds will therefore concentrate on selection between PKC and 
PAP inhibition. However, a number of other related enzymes will also be included. 
Development of a specific inhibitor of PAP will clearly aid in the study of the role of 
PAP, if any, in the control of cell proliferation. There is also the possibility that such a 
compound may possess antitumour activity.
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CHAPTER EIGHT
GENERAL DISCUSSION
The aims of this thesis have essentially been achieved. The aims were:
(i) to establish an assay for measuring PAP1 and PAP2 enzyme activities and 
determine their tissue distribution.
(ii) to determine whether PAP activity is altered in ras transformed fibroblasts.
(iii) to measure PAP activity in colorectal cancer and in adjacent normal tissue and 
to relate changes in PAP to levels of the second messengers phosphatidate and DRG.
(iv) to determine the effects of known PAP inhibitors on enzyme activity and cell 
proliferation.
(v) to establish whether PAP is a potential target for anticancer drug development.
An assay was established for measurement of PAP activity. Two activities can 
be distinguished mainly based on their sensitivity to NEM. PAP1, thought to be 
involved in glycerolipid synthesis in the endoplasmic reticulum, is sensitive to NEM 
whereas PAP2, the signalling form located in the plasma membrane, is insensitive to 
this compound. It is unclear whether PAP is one enzyme with different properties in 
the different subcellular compartments, or if PAP1 and PAP2 represent two separate 
enzymes. Purification and cloning of these enzymes from both the plasma membrane 
and endoplasmic reticulum will determine this. Partially pure preparations obtained 
by fractionation of rat liver were used as a source of the enzymes to characterise the 
different activities. However, the differential sensitivity to NEM allows measurement 
of the two activities in a cell or tissue homogenate without the need for fractionation.
PAP2 displayed Michaelis-Menton kinetics where activity increased with 
substrate concentration until a maximum velocity was obtained. However, the 
kinetics were not so clear for the PAP1 form. This enzyme did not display typical 
Michaelis-Menton kinetics but showed a sigmoid dependence on substrate. This can
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be indicative of an allosteric enzyme and is often associated with the activity of a 
regulatory enzyme. It has been suggested that PAP is a regulatory enzyme in the 
pathway for synthesis of glycerolipids (Bell & Coleman, 1980). Although it is not 
known how this enzyme is regulated, it could involve feedback inhibition by the 
product, DRG.
The activities of PAP1 and PAP2 were measured in a variety of murine 
tissues. The wide range in activities observed in the tissues suggests a difference in 
the relative importance in the function of the enzymes. The highest activity was found 
in the brain which is also known to show high rates of inositol phospholipid turnover 
(Farooqui & Hirashima, 1992). Although it was not shown which particular cell type 
contained this high activity, it would be interesting to study these enzymes in diseases 
associated with the brain, such as glioma. Other pathological conditions such as 
spinal cord injury and Alzheimer’s disease are associated with massive increases in 
DRG levels which may in turn cause neuronal cell damage (Farooqui & Horrocks, 
1991). The exact source of this DRG has not been determined but may involve 
changes in some of the enzymes involved in generating this second messenger, 
including PAP activity.
The role of PAP activity in proliferation was studied in ras transformed 
fibroblasts. This was chosen as a well established model of disrupted cell signalling. 
These transformed cells have already been shown to express increased DRG levels 
(Lacal et a l , 1987; Price et a l , 1989; Wakelam et a l , 1986) and PKC activity (Morris 
et a l, 1989). Hence, it was disappointing to find that PAP2 activity was decreased in 
the ras transformed cells. This would suggest that it is not involved in the effects of 
ras on cell growth and that other signalling pathways may be associated with 
activated ras. Recent evidence suggests that ras is involved in the activation of 
phosphatidylinositol 3-kinase (PI 3-kinase) (Kaplan e ta l, 1990; Kodaki et a l , 1994). 
One of the effects of this is to substantially increase the levels of the 
phosphatidylinositols. Hence, DRG production in ras transformed cells may be 
derived, not from the PLD/PAP pathway but from other sources such as increased
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hydrolysis of phosphatidylinositol 4,5-bisphosphate. This does not rule out PC 
hydrolysis as an important pathway in signalling. It is possible that the PLD/PAP 
pathway is generating increased levels of phosphatidate, another important second 
messenger which was also increased in the transformed fibroblasts. The ras oncogene 
could be involved in down-regulation of PAP2 which would disrupt this pathway, 
allowing phosphatidate to accumulate. It is unclear whether DRG or phosphatidate is 
the most important second messenger in cell proliferation and until this has been 
established the function and importance of PAP2 will remain unclear.
Since signalling in fibroblasts may not be representative of all cell types, these 
enzyme activities were also measured in epithelial cells. A study of this cell type was 
particularly useful to this study as the majority of solid tumours are derived from 
epithelial cells. Normal epithelial cells, however, are difficult to grow in culture and, 
therefore, a cell model was chosen which allowed a comparison of the effects of 
mutant ras in colon cancer epithelial cells. Although the choice of colon tumour cell 
lines was based on the presence or absence of a ras mutation, there was probably a 
number of other oncogenic differences between the lines. It was therefore somewhat 
surprising to obtain results that closely reflected those observed in the transfected cell 
lines. The main difference between the two cell models was in the activity of PAP1 
which was increased in the ras transformed fibroblasts but was decreased in the colon 
cancer cells with the ras mutation. The role of PAP1 in these is unclear but 
differential regulation of this enzyme may allow production of different lipids in the 
endoplasmic reticulum which may be involved in different processes in the two cell 
types. The effects of ras on PAP2 and second messengers were fairly consistent 
between the fibroblasts and epithelial models, in that there was a decrease in the 
activity of this enzyme accompanying increased levels of DRG and phosphatidate. As 
for the fibroblasts, ras may have a similar role in these cancer lines in the constitutive 
activation of other enzymes such as PI 3-kinase.
One of the most exciting results came from the study of PAP2 activity in 
human colon tumours. Both PAP1 and PAP2 activities were increased in the majority
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of tumours when compared with activities in adjacent normal colon. Since the 
underlying aim of this thesis was to determine whether PAP activity is a suitable 
target for anticancer drug development, this was a promising result. In addition to 
altered PAP activity, levels of two second messengers, phosphatidate and DRG, were 
decreased in the tumour tissue. These changes are clearly very different from those 
induced by ras transformations in the fibroblasts cell lines. Although mutations in the 
ras gene are common in colon tumours (Rodenhuis, 1992), only 50% of the tumours 
used in this study had this mutation. A number of genetic changes have been 
identified in colon tumours and the relative importance of these changes in the 
development of the tumour is not known (Fearon & Vogelstein, 1990). Clearly, it 
would be important to know whether the changes in PAP activity are an early event 
that can be detected at the adenoma stage.
PAP catalyses the conversion of phosphatidate to DRG. Both phosphatidate 
and DRG are important second messengers and a change in PAP activity might be 
expected to alter the balance between these two lipids. The observed decrease in 
phosphatidate levels is consistent with the increased activities of PAP. However, 
levels of DRG were also decreased in the tumours but this could be explained in part 
by an increase in activity of specific isoforms of the metabolising enzymes, DRG 
lipase and DRG kinase. Clearly, mass measurements of lipids could be misleading 
since phosphatidate and DRG both consist of a family of molecular species, not all of 
which are involved in signalling pathways (Pessin et al, 1990; Pettitt & Wakelam, 
1993).
There was a surprising variability between patients in both enzyme activities 
and lipid levels in the normal colon. The significance of this observation is not 
known. There is a strong association between a high fat diet and the incidence of 
colon cancer (Reddy et a l, 1992). It may be that dietary fibre influences lipid 
metabolism in the colon. Whether this variability is a true reflection of a range of 
activities present in normal colon or whether it is indicative of pre-malignant changes 
is an interesting area for further study.
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In view of the increased activity of PAP in colon tumours, an attempt was 
made to identify a lead compound for the development of a specific enzyme inhibitor. 
The sphingoid bases were the most potent inhibitors of both PAP1 and PAP2 enzyme 
activities and in particular, sphingosine, was also shown to be a potent inhibitor of 
cell growth. However, the inhibitory effect of this compound on cell growth was 
probably not just through PAP, for example, sphingosine has been shown to inhibit 
PKC activity and stimulate PLD (Franson et a l, 1992; Merrill & Stevens, 1989). It 
may be possible to produce analogues of potential lead compounds which have 
increased selectivity for the target enzyme. Indeed, this project has led to the 
development of a synthesis programme in which analogues of sphingosine are being 
tested for their specificity for PAP. A specific PAP2 inhibitor would be provide a 
useful tool with which to study the importance of this enzyme and the second 
messengers, phosphatidate and DRG, in signalling in whole cells. For example, 
inhibition of this enzyme in growth factor-stimulated cells would identify its 
importance in mitogenesis in the PLD/PAP pathway and if phosphatidate, which 
would be expected to accumulate, is the important second messenger. Analogues of 
sphingosine might also be potential antitumour agents. It is possible that these lipid 
compounds may be poorly absorbed or could pass through the blood-brain barrier to 
cause neuronal disorders, in which case long-term treatment could not be envisaged. 
To overcome this, antibody-drug conjugates may be used in which the drug is 
attached to an antibody directed against a tumour-specific antigen which will bind 
selectively to those tumour cells. In addition, it should be possible to package the 
compounds into liposomes which may aid in drug uptake. It has already been shown 
that liposomal trimethyl-sphingosine reduces toxicity and enhances drug efficacy 
when compared to free trimethyl-sphingosine in vivo (Park et a l, 1994). Having 
obtained evidence of specific drug-target interaction in both in vitro and in vivo 
preclinical models, it is also important to screen the drugs in patients for their ability 
to inhibit PAP activity. Obviously, this is a more difficult task but it may be possible,
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for instance, to measure PAP activity in white blood cells before and after treatment. 
This may determine the specificity of the drug for PAP in patients.
PAP has been an interesting enzyme to study due to its altered activity in both 
cell and tissue models used in the study. Clearly, purification of both PAP1 and PAP2 
are required to study these enzymes in more detail. Pure enzymes would lead to the 
development of specific inhibitors and a more detailed kinetic analysis could be 
carried out. In addition, the exact function of this enzyme could be established by 
cloning a cDNA encoding the PAP enzymes. This could then be transfected into cells 
to produce cell lines which stably overexpress the enzymes. In this way the role of 
PAP1 and PAP2 in modulating the expression of genes related to cellular growth 
could be investigated and the importance of the enzymes in cell proliferation 
established. The function of PAP2 in cell signalling is not clear at the moment but 
further work is well worth attempting to establish its importance in the PLD/PAP 
pathway in generating two second messengers. Although a pure enzyme is required 
for further studies of PAP, this may be available in the near future since David 
Brindley's group in Canada is very close to producing a homogenous enzyme 
(personal communication).
PAP has proved to be a potential target for anticancer agents. One of the main 
reasons for the development of tyrosine kinase inhibitors is based on the evidence of 
increased expression of the EGF receptor in various cancers (Arteaga et a l , 1991), yet 
there is no evidence to suggest that growth of the tumours is dependent on this 
pathway. The fact that the increase in PAP activity occured in almost every patient 
tumour sample is certainly a more consistent change than has been observed for many 
other novel targets.
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